NO327129B1 - CDK-inhiberende pyrimider, farmasoytiske preparater,og deres anvendelse for fremstilling av legemidler - Google Patents
CDK-inhiberende pyrimider, farmasoytiske preparater,og deres anvendelse for fremstilling av legemidler Download PDFInfo
- Publication number
- NO327129B1 NO327129B1 NO20035298A NO20035298A NO327129B1 NO 327129 B1 NO327129 B1 NO 327129B1 NO 20035298 A NO20035298 A NO 20035298A NO 20035298 A NO20035298 A NO 20035298A NO 327129 B1 NO327129 B1 NO 327129B1
- Authority
- NO
- Norway
- Prior art keywords
- ylamino
- bromo
- pyrimidin
- benzenesulfonamide
- methyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title description 8
- 238000004519 manufacturing process Methods 0.000 title description 7
- 230000002401 inhibitory effect Effects 0.000 title description 5
- 239000000825 pharmaceutical preparation Substances 0.000 title description 4
- 229940079593 drug Drugs 0.000 title description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 66
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- -1 phenyloxy Chemical group 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- BWOHFZMMQXOIOB-UHFFFAOYSA-N 4-[[5-bromo-4-[[4-(cyclopropylamino)cyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(CC2)NC2CC2)=N1 BWOHFZMMQXOIOB-UHFFFAOYSA-N 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 150000003230 pyrimidines Chemical class 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- XSPDIJHMXIOAAM-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2s)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@H](CO)C(C)C)=NC(NC=2C=C(C=CC=2)S(F)(=O)=O)=N1 XSPDIJHMXIOAAM-CYBMUJFWSA-N 0.000 claims description 4
- SEKKALNTFPTFSU-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-morpholin-4-ylcyclohexyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(CC2)N2CCOCC2)=N1 SEKKALNTFPTFSU-UHFFFAOYSA-N 0.000 claims description 4
- FGHMZQKPPMDGPL-HNNXBMFYSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCO)=N1 FGHMZQKPPMDGPL-HNNXBMFYSA-N 0.000 claims description 4
- CAEOUNLFYKBMQK-UHFFFAOYSA-N 4-[[5-bromo-4-[[4-(1,3-dihydroxypropan-2-ylamino)cyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(CC2)NC(CO)CO)=N1 CAEOUNLFYKBMQK-UHFFFAOYSA-N 0.000 claims description 4
- OBAVLVDITDFXPY-UHFFFAOYSA-N 4-[[5-bromo-4-[[4-(3-hydroxypyrrolidin-1-yl)cyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(CC2)N2CC(O)CC2)=N1 OBAVLVDITDFXPY-UHFFFAOYSA-N 0.000 claims description 4
- YQCBGLUENDIFKW-UHFFFAOYSA-N 4-[[5-bromo-4-[[4-(dimethylamino)cyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1CC(N(C)C)CCC1NC1=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C1Br YQCBGLUENDIFKW-UHFFFAOYSA-N 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 231100000360 alopecia Toxicity 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- ZJBFNXOTWBYPTB-UHFFFAOYSA-N 4-[(5-bromo-4-morpholin-4-ylpyrimidin-2-yl)amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N2CCOCC2)=N1 ZJBFNXOTWBYPTB-UHFFFAOYSA-N 0.000 claims description 3
- BUWBYOIMHIIOAZ-UHFFFAOYSA-N 4-[[5-bromo-4-[(2-methylcyclohexyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CC1CCCCC1NC1=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C1Br BUWBYOIMHIIOAZ-UHFFFAOYSA-N 0.000 claims description 3
- MJIALGDLOLWBRQ-MRVPVSSYSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 MJIALGDLOLWBRQ-MRVPVSSYSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 3
- 201000010927 Mucositis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- FKWGXFQRNHMIPY-UHFFFAOYSA-N methyl 6-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]hexanoate Chemical compound C1=C(Br)C(NCCCCCC(=O)OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 FKWGXFQRNHMIPY-UHFFFAOYSA-N 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- NENICYIQLCYNII-AWEZNQCLSA-N (2r)-2-[[5-bromo-2-(3-methylsulfonylanilino)pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=C(C=CC=2)S(C)(=O)=O)=N1 NENICYIQLCYNII-AWEZNQCLSA-N 0.000 claims description 2
- OAOMNZDRBMUIIJ-AWEZNQCLSA-N (2r)-2-[[5-bromo-2-(4-methylsulfonylanilino)pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 OAOMNZDRBMUIIJ-AWEZNQCLSA-N 0.000 claims description 2
- PDDGNHRDVDSZHX-KRWDZBQOSA-N (2r)-2-[[5-bromo-2-(4-morpholin-4-ylsulfonylanilino)pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=N1 PDDGNHRDVDSZHX-KRWDZBQOSA-N 0.000 claims description 2
- AFQIRVPDWCOXNF-GFCCVEGCSA-N (2r)-2-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]-3-methylbutanoic acid Chemical compound C1=C(Br)C(N[C@H](C(C)C)C(O)=O)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 AFQIRVPDWCOXNF-GFCCVEGCSA-N 0.000 claims description 2
- NPVIKAVSNCQXGM-SECBINFHSA-N (2r)-2-[[5-bromo-2-[(1,1-dioxo-3,4-dihydro-2h-1$l^{6},2-benzothiazin-7-yl)amino]pyrimidin-4-yl]amino]propan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C3S(=O)(=O)NCCC3=CC=2)=N1 NPVIKAVSNCQXGM-SECBINFHSA-N 0.000 claims description 2
- DMPLZVOZGQRKFY-HNNXBMFYSA-N (2r)-2-[[5-bromo-2-[3-(2-hydroxyethylsulfonyl)anilino]pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)CCO)=N1 DMPLZVOZGQRKFY-HNNXBMFYSA-N 0.000 claims description 2
- BNJGHFMCPWJPNT-CQSZACIVSA-N (2r)-2-[[5-bromo-2-[4-(2-hydroxyethylsulfamoyl)anilino]pyrimidin-4-yl]amino]-3-methylbutanoic acid Chemical compound C1=C(Br)C(N[C@H](C(C)C)C(O)=O)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCO)=N1 BNJGHFMCPWJPNT-CQSZACIVSA-N 0.000 claims description 2
- WDAQHQPSZNIQMH-ZDUSSCGKSA-N (2r)-2-[[5-bromo-2-[4-(trifluoromethylsulfonyl)anilino]pyrimidin-4-yl]amino]-3-methylbutan-1-ol Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)C(F)(F)F)=N1 WDAQHQPSZNIQMH-ZDUSSCGKSA-N 0.000 claims description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- HFISRXLKZTXXKP-AUEPDCJTSA-N 2-[(e)-3-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]butan-2-ylideneamino]oxyacetic acid Chemical compound C1=C(Br)C(NC(C)C(\C)=N\OCC(O)=O)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 HFISRXLKZTXXKP-AUEPDCJTSA-N 0.000 claims description 2
- GUUYSULIBQOZIQ-UHFFFAOYSA-N 2-[3-[[5-bromo-4-(2-morpholin-4-ylethylamino)pyrimidin-2-yl]amino]phenyl]sulfonylethanol Chemical compound OCCS(=O)(=O)C1=CC=CC(NC=2N=C(NCCN3CCOCC3)C(Br)=CN=2)=C1 GUUYSULIBQOZIQ-UHFFFAOYSA-N 0.000 claims description 2
- RJVHJGWKLQVDCX-UHFFFAOYSA-N 2-[3-[[5-bromo-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]phenyl]sulfonylethanol Chemical compound OCCS(=O)(=O)C1=CC=CC(NC=2N=C(NCC#C)C(Br)=CN=2)=C1 RJVHJGWKLQVDCX-UHFFFAOYSA-N 0.000 claims description 2
- CITDQBCZOBOFHG-NSHDSACASA-N 2-[3-[[5-bromo-4-[[(2s)-1-methoxypropan-2-yl]amino]pyrimidin-2-yl]amino]phenyl]sulfonylethanol Chemical compound C1=C(Br)C(N[C@@H](C)COC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)CCO)=N1 CITDQBCZOBOFHG-NSHDSACASA-N 0.000 claims description 2
- MGLNAHDYUZYRJP-UHFFFAOYSA-N 2-[[5-bromo-2-[3-(2-hydroxyethylsulfonyl)anilino]pyrimidin-4-yl]amino]propane-1,3-diol Chemical compound OCCS(=O)(=O)C1=CC=CC(NC=2N=C(NC(CO)CO)C(Br)=CN=2)=C1 MGLNAHDYUZYRJP-UHFFFAOYSA-N 0.000 claims description 2
- FETWCXOAWZUZBR-UHFFFAOYSA-N 2-n-[3-(benzenesulfonyl)phenyl]-5-bromo-4-n-prop-2-ynylpyrimidine-2,4-diamine Chemical compound N1=C(NCC#C)C(Br)=CN=C1NC1=CC=CC(S(=O)(=O)C=2C=CC=CC=2)=C1 FETWCXOAWZUZBR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- KTJVQPLZQWUAQY-UHFFFAOYSA-N 3-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]propanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCC(O)=O)=N1 KTJVQPLZQWUAQY-UHFFFAOYSA-N 0.000 claims description 2
- AFKUTJOFCAOYQP-UHFFFAOYSA-N 3-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]propylphosphonic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCCP(O)(O)=O)=N1 AFKUTJOFCAOYQP-UHFFFAOYSA-N 0.000 claims description 2
- DOEGEYSAKWHDSP-UHFFFAOYSA-N 3-[[5-bromo-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]-n-butylbenzenesulfonamide Chemical compound CCCCNS(=O)(=O)C1=CC=CC(NC=2N=C(NCC#C)C(Br)=CN=2)=C1 DOEGEYSAKWHDSP-UHFFFAOYSA-N 0.000 claims description 2
- AHTSLHIJXZTEIU-UHFFFAOYSA-N 3-[[5-bromo-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(NC=2N=C(NCC#C)C(Br)=CN=2)=C1 AHTSLHIJXZTEIU-UHFFFAOYSA-N 0.000 claims description 2
- DLAUIGAWBXLWFR-INIZCTEOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-hydroxypropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCO)=N1 DLAUIGAWBXLWFR-INIZCTEOSA-N 0.000 claims description 2
- ALOBCOOXNZFQRZ-SFHVURJKSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(5-hydroxypentyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCCCO)=N1 ALOBCOOXNZFQRZ-SFHVURJKSA-N 0.000 claims description 2
- FCNGRYGECNKENN-HNNXBMFYSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-ethoxybenzenesulfonamide Chemical compound CCONS(=O)(=O)C1=CC=CC(NC=2N=C(N[C@@H](CO)C(C)C)C(Br)=CN=2)=C1 FCNGRYGECNKENN-HNNXBMFYSA-N 0.000 claims description 2
- DQOCEAXNGWJYOV-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCOC=2C=CC=CC=2)=N1 DQOCEAXNGWJYOV-MRXNPFEDSA-N 0.000 claims description 2
- WEFXZBPQJHRJGU-QGZVFWFLSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)=N1 WEFXZBPQJHRJGU-QGZVFWFLSA-N 0.000 claims description 2
- PYJUMANJGQJYCC-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylbutyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCC(C)C)=N1 PYJUMANJGQJYCC-CQSZACIVSA-N 0.000 claims description 2
- KZAIMJMQCPUPST-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-3-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=NC=CC=2)=N1 KZAIMJMQCPUPST-OAHLLOKOSA-N 0.000 claims description 2
- IBIBVRHCWCQJNH-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(2-methoxyphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C(=CC=CC=2)OC)=N1 IBIBVRHCWCQJNH-MRXNPFEDSA-N 0.000 claims description 2
- DAIDXAJCTQALAF-OFLPRAFFSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-cyanocyclohexyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC2CCC(CC2)C#N)=N1 DAIDXAJCTQALAF-OFLPRAFFSA-N 0.000 claims description 2
- SNTLJCJGTVYKFQ-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CC(F)=CC=2)=N1 SNTLJCJGTVYKFQ-MRXNPFEDSA-N 0.000 claims description 2
- SVAIQKVFEZHILC-QGZVFWFLSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-methylphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CC(C)=CC=2)=N1 SVAIQKVFEZHILC-QGZVFWFLSA-N 0.000 claims description 2
- OYPQNXKADMGHLP-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(dimethylamino)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCN(C)C)=N1 OYPQNXKADMGHLP-CQSZACIVSA-N 0.000 claims description 2
- ADGWKXKIHZBHAX-SECBINFHSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(F)(=O)=O)=N1 ADGWKXKIHZBHAX-SECBINFHSA-N 0.000 claims description 2
- UFHQGGDEMRSHDQ-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCN2CCOCC2)=N1 UFHQGGDEMRSHDQ-CQSZACIVSA-N 0.000 claims description 2
- WPOHQHLIZSRXQU-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCOC=2C=CC=CC=2)=N1 WPOHQHLIZSRXQU-OAHLLOKOSA-N 0.000 claims description 2
- RVGJRAWSYHAMFA-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)=N1 RVGJRAWSYHAMFA-OAHLLOKOSA-N 0.000 claims description 2
- WVRXIMVPTKLEPX-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-piperidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCN2CCCCC2)=N1 WVRXIMVPTKLEPX-OAHLLOKOSA-N 0.000 claims description 2
- KHHGKANJWHUIAX-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-pyrrolidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCN2CCCC2)=N1 KHHGKANJWHUIAX-CQSZACIVSA-N 0.000 claims description 2
- MTBKYKFYNKWNGJ-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-imidazol-1-ylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCN2C=NC=C2)=N1 MTBKYKFYNKWNGJ-CQSZACIVSA-N 0.000 claims description 2
- PJBORUXSXCOIQM-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylbutyl)benzenesulfonamide Chemical compound CC(C)CCNS(=O)(=O)C1=CC=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 PJBORUXSXCOIQM-CYBMUJFWSA-N 0.000 claims description 2
- XPXZIODJTRYGEE-SECBINFHSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylsulfanyl-1h-1,2,4-triazol-5-yl)benzenesulfonamide Chemical compound CSC1=NNC(NS(=O)(=O)C=2C=C(NC=3N=C(N[C@H](C)CO)C(Br)=CN=3)C=CC=2)=N1 XPXZIODJTRYGEE-SECBINFHSA-N 0.000 claims description 2
- KIWXNRCTXOKRJR-GFCCVEGCSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(furan-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2OC=CC=2)=N1 KIWXNRCTXOKRJR-GFCCVEGCSA-N 0.000 claims description 2
- AULKUOWQTVHRKB-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-3-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=NC=CC=2)=N1 AULKUOWQTVHRKB-CYBMUJFWSA-N 0.000 claims description 2
- NLYBAGOFTTYOKJ-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-4-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CN=CC=2)=N1 NLYBAGOFTTYOKJ-CYBMUJFWSA-N 0.000 claims description 2
- SAJCHQYDWJCRSK-GFCCVEGCSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2SC=CC=2)=N1 SAJCHQYDWJCRSK-GFCCVEGCSA-N 0.000 claims description 2
- MNKUNFVGHBROAO-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(2-methoxyphenyl)methyl]benzenesulfonamide Chemical compound COC1=CC=CC=C1CNS(=O)(=O)C1=CC=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 MNKUNFVGHBROAO-CQSZACIVSA-N 0.000 claims description 2
- NNYSAPFTRZPKQP-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(3-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=C(F)C=CC=2)=N1 NNYSAPFTRZPKQP-CYBMUJFWSA-N 0.000 claims description 2
- YVQWALIASCAKJZ-QQFBHYJXSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-cyanocyclohexyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC2CCC(CC2)C#N)=N1 YVQWALIASCAKJZ-QQFBHYJXSA-N 0.000 claims description 2
- VUVPZBWLWVJAAQ-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CC(F)=CC=2)=N1 VUVPZBWLWVJAAQ-CYBMUJFWSA-N 0.000 claims description 2
- QQKJAUQFSDWVDD-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-methylphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CC(C)=CC=2)=N1 QQKJAUQFSDWVDD-OAHLLOKOSA-N 0.000 claims description 2
- NSDKWIAIQYRORA-GFCCVEGCSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(5-methylfuran-2-yl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2OC(C)=CC=2)=N1 NSDKWIAIQYRORA-GFCCVEGCSA-N 0.000 claims description 2
- WBAQCFNNCJEJOD-IURRXHLWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCC2N(CCC2)C)=N1 WBAQCFNNCJEJOD-IURRXHLWSA-N 0.000 claims description 2
- YAVSDGHOUMLLGF-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-chlorophenyl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCC=2C=CC(Cl)=CC=2)=N1 YAVSDGHOUMLLGF-CQSZACIVSA-N 0.000 claims description 2
- AYWKQVYUIOQCJD-GFCCVEGCSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCN(C)C)=N1 AYWKQVYUIOQCJD-GFCCVEGCSA-N 0.000 claims description 2
- XNEVTOKXOOQLRB-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(2-oxopyrrolidin-1-yl)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCN2C(CCC2)=O)=N1 XNEVTOKXOOQLRB-CQSZACIVSA-N 0.000 claims description 2
- SUSZGWOOWBEOCO-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(dimethylamino)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCN(C)C)=N1 SUSZGWOOWBEOCO-CYBMUJFWSA-N 0.000 claims description 2
- GSLCIMBHXOOWFC-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[3-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=C(C=CC=2)C(F)(F)F)=N1 GSLCIMBHXOOWFC-CYBMUJFWSA-N 0.000 claims description 2
- PXFVJBMLSGTTBX-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[4-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=N1 PXFVJBMLSGTTBX-CYBMUJFWSA-N 0.000 claims description 2
- YYUAOKYOMBAEIV-MRVPVSSYSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C=CC=2)S(F)(=O)=O)=N1 YYUAOKYOMBAEIV-MRVPVSSYSA-N 0.000 claims description 2
- OROWGIVHKDNXBO-UHFFFAOYSA-N 4-[(5-bromo-4-piperidin-4-yloxypyrimidin-2-yl)amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(OC2CCNCC2)=N1 OROWGIVHKDNXBO-UHFFFAOYSA-N 0.000 claims description 2
- VDBWWJBJRVAGQB-UHFFFAOYSA-N 4-[[4-(1-adamantylmethylamino)-5-bromopyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC23CC4CC(CC(C4)C2)C3)=N1 VDBWWJBJRVAGQB-UHFFFAOYSA-N 0.000 claims description 2
- GCGSXQZTUFHHCZ-UHFFFAOYSA-N 4-[[4-(3-bicyclo[2.2.1]heptanylamino)-5-bromopyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2C3CCC(C3)C2)=N1 GCGSXQZTUFHHCZ-UHFFFAOYSA-N 0.000 claims description 2
- JTRVZRICDWQIPA-ZDUSSCGKSA-N 4-[[4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]-5-iodopyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(I)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 JTRVZRICDWQIPA-ZDUSSCGKSA-N 0.000 claims description 2
- JYUVZGOTLRBBIS-UHFFFAOYSA-N 4-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]butanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCCC(O)=O)=N1 JYUVZGOTLRBBIS-UHFFFAOYSA-N 0.000 claims description 2
- NPOBEUCLSYVDCY-UHFFFAOYSA-N 4-[[5-bromo-4-(1,3-diethoxypropan-2-yloxy)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(OC(COCC)COCC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 NPOBEUCLSYVDCY-UHFFFAOYSA-N 0.000 claims description 2
- RSSOAJYESBJIOK-UHFFFAOYSA-N 4-[[5-bromo-4-(1,3-dihydroxypropan-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC(CO)CO)=N1 RSSOAJYESBJIOK-UHFFFAOYSA-N 0.000 claims description 2
- LCSODXGZHNCVHW-UHFFFAOYSA-N 4-[[5-bromo-4-(1,3-dihydroxypropan-2-yloxy)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(OC(CO)CO)=N1 LCSODXGZHNCVHW-UHFFFAOYSA-N 0.000 claims description 2
- QPEQBYJEVPXQJZ-UHFFFAOYSA-N 4-[[5-bromo-4-(1-phenylethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C=1C=CC=CC=1C(C)NC(C(=CN=1)Br)=NC=1NC1=CC=C(S(N)(=O)=O)C=C1 QPEQBYJEVPXQJZ-UHFFFAOYSA-N 0.000 claims description 2
- WELQEQDZCUWKQM-UHFFFAOYSA-N 4-[[5-bromo-4-(2,2,3,3,3-pentafluoropropoxy)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(OCC(F)(F)C(F)(F)F)=N1 WELQEQDZCUWKQM-UHFFFAOYSA-N 0.000 claims description 2
- VMFCDYLTPGHBNJ-UHFFFAOYSA-N 4-[[5-bromo-4-(2,2,3,3,3-pentafluoropropylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC(F)(F)C(F)(F)F)=N1 VMFCDYLTPGHBNJ-UHFFFAOYSA-N 0.000 claims description 2
- HNGISIDHOUFLCO-UHFFFAOYSA-N 4-[[5-bromo-4-(2,2,3,3,4,4,4-heptafluorobutylamino)pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCO)=CC=C1NC1=NC=C(Br)C(NCC(F)(F)C(F)(F)C(F)(F)F)=N1 HNGISIDHOUFLCO-UHFFFAOYSA-N 0.000 claims description 2
- CJGXSBQAYYVPRL-UHFFFAOYSA-N 4-[[5-bromo-4-(2-hydroxybutylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NCC(O)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 CJGXSBQAYYVPRL-UHFFFAOYSA-N 0.000 claims description 2
- XZHUQRVSRNNCNT-UHFFFAOYSA-N 4-[[5-bromo-4-(2-hydroxyethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCO)=N1 XZHUQRVSRNNCNT-UHFFFAOYSA-N 0.000 claims description 2
- KWQAFWXOCINKEE-UHFFFAOYSA-N 4-[[5-bromo-4-(2-hydroxypentan-3-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(CC)C(C)O)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 KWQAFWXOCINKEE-UHFFFAOYSA-N 0.000 claims description 2
- STGDSBMMLJUBLC-UHFFFAOYSA-N 4-[[5-bromo-4-(2-hydroxypropylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NCC(O)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 STGDSBMMLJUBLC-UHFFFAOYSA-N 0.000 claims description 2
- XSDPUAAWRKOPAY-UHFFFAOYSA-N 4-[[5-bromo-4-(2-morpholin-4-ylethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCN2CCOCC2)=N1 XSDPUAAWRKOPAY-UHFFFAOYSA-N 0.000 claims description 2
- KTTXFMUXETXSAW-UHFFFAOYSA-N 4-[[5-bromo-4-(3-diethoxyphosphorylpropylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NCCCP(=O)(OCC)OCC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 KTTXFMUXETXSAW-UHFFFAOYSA-N 0.000 claims description 2
- RTESXBYJBNNKBT-UHFFFAOYSA-N 4-[[5-bromo-4-(3-hydroxyhex-5-en-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(O)CC=C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 RTESXBYJBNNKBT-UHFFFAOYSA-N 0.000 claims description 2
- ZOBMWTCOGJLMCJ-UHFFFAOYSA-N 4-[[5-bromo-4-(3-hydroxyhexan-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(O)CCC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 ZOBMWTCOGJLMCJ-UHFFFAOYSA-N 0.000 claims description 2
- YTTHJGBSJSAALC-UHFFFAOYSA-N 4-[[5-bromo-4-(3-hydroxyiminobutan-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(C)=NO)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 YTTHJGBSJSAALC-UHFFFAOYSA-N 0.000 claims description 2
- XJOGWEVFKQFVRV-UHFFFAOYSA-N 4-[[5-bromo-4-(3-hydroxypentan-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(O)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 XJOGWEVFKQFVRV-UHFFFAOYSA-N 0.000 claims description 2
- DEUNZRZNKLIPOL-UHFFFAOYSA-N 4-[[5-bromo-4-(3-oxobutan-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(C)=O)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 DEUNZRZNKLIPOL-UHFFFAOYSA-N 0.000 claims description 2
- GYQQYCSCAZNEIH-UHFFFAOYSA-N 4-[[5-bromo-4-(4,4,4-trifluorobutoxy)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(OCCCC(F)(F)F)=N1 GYQQYCSCAZNEIH-UHFFFAOYSA-N 0.000 claims description 2
- UTWKYJCAWVQKLQ-UHFFFAOYSA-N 4-[[5-bromo-4-(4-hydroxybutylamino)pyrimidin-2-yl]amino]-n-methylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1NC1=NC=C(Br)C(NCCCCO)=N1 UTWKYJCAWVQKLQ-UHFFFAOYSA-N 0.000 claims description 2
- XCGNELJEIMQENC-UHFFFAOYSA-N 4-[[5-bromo-4-(4-hydroxybutylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCCCO)=N1 XCGNELJEIMQENC-UHFFFAOYSA-N 0.000 claims description 2
- BBVZCQPITGEOJG-UHFFFAOYSA-N 4-[[5-bromo-4-(4-hydroxyhexan-3-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(CC)C(O)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 BBVZCQPITGEOJG-UHFFFAOYSA-N 0.000 claims description 2
- ZKORCOAXYCRUCN-UHFFFAOYSA-N 4-[[5-bromo-4-(butan-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 ZKORCOAXYCRUCN-UHFFFAOYSA-N 0.000 claims description 2
- BKNFOZHRQQKWNM-UHFFFAOYSA-N 4-[[5-bromo-4-(cycloheptylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCCCCC2)=N1 BKNFOZHRQQKWNM-UHFFFAOYSA-N 0.000 claims description 2
- VPWWFLLPZUCGAG-UHFFFAOYSA-N 4-[[5-bromo-4-(cyclohexylamino)pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCO)=CC=C1NC1=NC=C(Br)C(NC2CCCCC2)=N1 VPWWFLLPZUCGAG-UHFFFAOYSA-N 0.000 claims description 2
- XGXLQYXQHKKNBW-UHFFFAOYSA-N 4-[[5-bromo-4-(cyclohexylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCCCC2)=N1 XGXLQYXQHKKNBW-UHFFFAOYSA-N 0.000 claims description 2
- HVLFLNWNVOHNGC-UHFFFAOYSA-N 4-[[5-bromo-4-(cyclopropylmethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC2CC2)=N1 HVLFLNWNVOHNGC-UHFFFAOYSA-N 0.000 claims description 2
- BKQWRIPYUSWLIX-UHFFFAOYSA-N 4-[[5-bromo-4-(dimethoxyphosphorylmethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NCP(=O)(OC)OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 BKQWRIPYUSWLIX-UHFFFAOYSA-N 0.000 claims description 2
- WOKLXKLQILMIOI-UHFFFAOYSA-N 4-[[5-bromo-4-(oxan-4-yloxy)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(OC2CCOCC2)=N1 WOKLXKLQILMIOI-UHFFFAOYSA-N 0.000 claims description 2
- HVGPOHZHMRGTBL-UHFFFAOYSA-N 4-[[5-bromo-4-(phenacylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC(=O)C=2C=CC=CC=2)=N1 HVGPOHZHMRGTBL-UHFFFAOYSA-N 0.000 claims description 2
- HBITXFFJRLBCBB-UHFFFAOYSA-N 4-[[5-bromo-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC#C)=N1 HBITXFFJRLBCBB-UHFFFAOYSA-N 0.000 claims description 2
- MXYTWRWCLAIKPZ-UHFFFAOYSA-N 4-[[5-bromo-4-(pyridin-2-ylmethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC=2N=CC=CC=2)=N1 MXYTWRWCLAIKPZ-UHFFFAOYSA-N 0.000 claims description 2
- HEVZYWBHZIVJCG-UHFFFAOYSA-N 4-[[5-bromo-4-(thiolan-3-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CSCC2)=N1 HEVZYWBHZIVJCG-UHFFFAOYSA-N 0.000 claims description 2
- MAKPVOMTPFBUDR-UHFFFAOYSA-N 4-[[5-bromo-4-[(1-ethynylcyclohexyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2(CCCCC2)C#C)=N1 MAKPVOMTPFBUDR-UHFFFAOYSA-N 0.000 claims description 2
- UFOQEUPOIVSAKO-UHFFFAOYSA-N 4-[[5-bromo-4-[(1-hydroxy-2,3-dimethylbutan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)(CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 UFOQEUPOIVSAKO-UHFFFAOYSA-N 0.000 claims description 2
- TVHFYTNZZQSQQP-UHFFFAOYSA-N 4-[[5-bromo-4-[(1-hydroxy-2-methylpropan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)(CO)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 TVHFYTNZZQSQQP-UHFFFAOYSA-N 0.000 claims description 2
- MQOXDWNBNCQLAV-UHFFFAOYSA-N 4-[[5-bromo-4-[(1-hydroxy-3-methoxypropan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(CO)COC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 MQOXDWNBNCQLAV-UHFFFAOYSA-N 0.000 claims description 2
- WYVLZIBRAMTJBR-UHFFFAOYSA-N 4-[[5-bromo-4-[(2-hydroxy-2-phenylethyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC(O)C=2C=CC=CC=2)=N1 WYVLZIBRAMTJBR-UHFFFAOYSA-N 0.000 claims description 2
- QUSJIZGWTJJURZ-UHFFFAOYSA-N 4-[[5-bromo-4-[(2-hydroxy-2-phenylpropyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C=1C=CC=CC=1C(O)(C)CNC(C(=CN=1)Br)=NC=1NC1=CC=C(S(N)(=O)=O)C=C1 QUSJIZGWTJJURZ-UHFFFAOYSA-N 0.000 claims description 2
- AUGYGCJBVAWRFY-UHFFFAOYSA-N 4-[[5-bromo-4-[(2-hydroxy-3,3-dimethylbutyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NCC(O)C(C)(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 AUGYGCJBVAWRFY-UHFFFAOYSA-N 0.000 claims description 2
- OZTBYNUUGKQRDE-UHFFFAOYSA-N 4-[[5-bromo-4-[(3,3-dimethyl-2-oxobutyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NCC(=O)C(C)(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 OZTBYNUUGKQRDE-UHFFFAOYSA-N 0.000 claims description 2
- QCVJAROPMVVQQM-UHFFFAOYSA-N 4-[[5-bromo-4-[(3-hydroxy-1-methoxybutan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(COC)C(C)O)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 QCVJAROPMVVQQM-UHFFFAOYSA-N 0.000 claims description 2
- ISUNAZHSSOIYRS-UHFFFAOYSA-N 4-[[5-bromo-4-[(3-hydroxy-1-phenylpropyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC(CCO)C=2C=CC=CC=2)=N1 ISUNAZHSSOIYRS-UHFFFAOYSA-N 0.000 claims description 2
- VPYOPYDJTQEJRA-UHFFFAOYSA-N 4-[[5-bromo-4-[(3-hydroxy-3-methylbutan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(C)(C)O)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 VPYOPYDJTQEJRA-UHFFFAOYSA-N 0.000 claims description 2
- GCKYLPIHRIXFNW-UHFFFAOYSA-N 4-[[5-bromo-4-[(3-hydroxy-3-methylpentan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(C)(O)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 GCKYLPIHRIXFNW-UHFFFAOYSA-N 0.000 claims description 2
- INSKTYQYOKTRST-UHFFFAOYSA-N 4-[[5-bromo-4-[(3-hydroxy-4-methylpentan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(O)C(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 INSKTYQYOKTRST-UHFFFAOYSA-N 0.000 claims description 2
- ZNDGZGFDXHELDB-UHFFFAOYSA-N 4-[[5-bromo-4-[(3-hydroxy-4-phenylbutan-2-yl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C=1C=CC=CC=1CC(O)C(C)NC(C(=CN=1)Br)=NC=1NC1=CC=C(S(N)(=O)=O)C=C1 ZNDGZGFDXHELDB-UHFFFAOYSA-N 0.000 claims description 2
- VDDHXEFQMMPYFB-UHFFFAOYSA-N 4-[[5-bromo-4-[(3-pyridin-3-yl-1,2-oxazol-4-yl)methylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC=2C(=NOC=2)C=2C=NC=CC=2)=N1 VDDHXEFQMMPYFB-UHFFFAOYSA-N 0.000 claims description 2
- ACZDAHXHLOAGRC-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-fluorophenyl)methylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC=2C=CC(F)=CC=2)=N1 ACZDAHXHLOAGRC-UHFFFAOYSA-N 0.000 claims description 2
- PADQQENOHOLKJI-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-hydroxycyclohexyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(O)CC2)=N1 PADQQENOHOLKJI-UHFFFAOYSA-N 0.000 claims description 2
- YZNKBOPXCBPXQL-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-methoxyphenyl)methylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C1Br YZNKBOPXCBPXQL-UHFFFAOYSA-N 0.000 claims description 2
- PJPWWTSDKINYAU-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-methylcyclohexyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1CC(C)CCC1NC1=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C1Br PJPWWTSDKINYAU-UHFFFAOYSA-N 0.000 claims description 2
- QQNKPKIIVDTBII-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-oxocyclohexyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(=O)CC2)=N1 QQNKPKIIVDTBII-UHFFFAOYSA-N 0.000 claims description 2
- ZWCNPJSGCZIBRJ-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-piperidin-1-ylcyclohexyl)amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(CC2)N2CCCCC2)=N1 ZWCNPJSGCZIBRJ-UHFFFAOYSA-N 0.000 claims description 2
- XVBYOJUJGBQWPE-UHFFFAOYSA-N 4-[[5-bromo-4-[2-(1-methylpyrrolidin-2-yl)ethylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1CCCC1CCNC1=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C1Br XVBYOJUJGBQWPE-UHFFFAOYSA-N 0.000 claims description 2
- KNLYXFXSEDFZHB-UHFFFAOYSA-N 4-[[5-bromo-4-[2-(1h-imidazol-5-yl)ethylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCC=2NC=NC=2)=N1 KNLYXFXSEDFZHB-UHFFFAOYSA-N 0.000 claims description 2
- PMJHAXGVXBMMHX-UHFFFAOYSA-N 4-[[5-bromo-4-[2-(2-ethoxyethoxy)ethoxy]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(OCCOCCOCC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 PMJHAXGVXBMMHX-UHFFFAOYSA-N 0.000 claims description 2
- PFXMRXGKDQGXSN-UHFFFAOYSA-N 4-[[5-bromo-4-[3-(cyclopropylamino)butan-2-ylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound N=1C(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C(Br)C=1NC(C)C(C)NC1CC1 PFXMRXGKDQGXSN-UHFFFAOYSA-N 0.000 claims description 2
- WCKYTBXMLZSLSM-UHFFFAOYSA-N 4-[[5-bromo-4-[3-(dimethylamino)propylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NCCCN(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 WCKYTBXMLZSLSM-UHFFFAOYSA-N 0.000 claims description 2
- WRXMGEYGNHUEPI-UHFFFAOYSA-N 4-[[5-bromo-4-[3-(hydroxymethyl)pentan-3-ylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(CC)(CO)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 WRXMGEYGNHUEPI-UHFFFAOYSA-N 0.000 claims description 2
- ABDYUBZPBBQKTD-INIZCTEOSA-N 4-[[5-bromo-4-[[(1r)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@@H](CO)C=2C=CC=CC=2)=N1 ABDYUBZPBBQKTD-INIZCTEOSA-N 0.000 claims description 2
- SBACLTGMCWRKCJ-WOJBJXKFSA-N 4-[[5-bromo-4-[[(1r,2r)-2-phenylmethoxycyclopentyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@H]2[C@@H](CCC2)OCC=2C=CC=CC=2)=N1 SBACLTGMCWRKCJ-WOJBJXKFSA-N 0.000 claims description 2
- UKLQIRIXWVHJCZ-IRXDYDNUSA-N 4-[[5-bromo-4-[[(1s,2s)-1,3-dihydroxy-1-phenylpropan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@@H](CO)[C@@H](O)C=2C=CC=CC=2)=N1 UKLQIRIXWVHJCZ-IRXDYDNUSA-N 0.000 claims description 2
- KCTZDKZTFSBZEX-KBPBESRZSA-N 4-[[5-bromo-4-[[(1s,2s)-2-hydroxycyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@@H]2[C@H](CCCC2)O)=N1 KCTZDKZTFSBZEX-KBPBESRZSA-N 0.000 claims description 2
- SBACLTGMCWRKCJ-PMACEKPBSA-N 4-[[5-bromo-4-[[(1s,2s)-2-phenylmethoxycyclopentyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@@H]2[C@H](CCC2)OCC=2C=CC=CC=2)=N1 SBACLTGMCWRKCJ-PMACEKPBSA-N 0.000 claims description 2
- REFWQLGSUZABCN-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-cyclohexyl-3-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@@H](CO)CC2CCCCC2)=N1 REFWQLGSUZABCN-OAHLLOKOSA-N 0.000 claims description 2
- CQLAJLGSSXZYMT-ZDUSSCGKSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3,3-dimethylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 CQLAJLGSSXZYMT-ZDUSSCGKSA-N 0.000 claims description 2
- WJPZGCKNPYXRFI-LBPRGKRZSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-3-hydroxybenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C(=CC(=CC=2)S(N)(=O)=O)O)=N1 WJPZGCKNPYXRFI-LBPRGKRZSA-N 0.000 claims description 2
- GOKHZGQBLPFGPX-INIZCTEOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(1,3-dihydroxypropan-2-yl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC(CO)CO)=N1 GOKHZGQBLPFGPX-INIZCTEOSA-N 0.000 claims description 2
- SQEBTISVTWEPAY-HNNXBMFYSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC=2SC=CN=2)=N1 SQEBTISVTWEPAY-HNNXBMFYSA-N 0.000 claims description 2
- NWRRAJNEOKIKSV-JRZJBTRGSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-hydroxybutyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCC(O)CC)=CC=C1NC1=NC=C(Br)C(N[C@@H](CO)C(C)C)=N1 NWRRAJNEOKIKSV-JRZJBTRGSA-N 0.000 claims description 2
- QNTPIUDNXRXINQ-INIZCTEOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-hydroxypropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCO)=N1 QNTPIUDNXRXINQ-INIZCTEOSA-N 0.000 claims description 2
- QYTFTGGLPZXRQR-SFHVURJKSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(5-hydroxypentyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCCCO)=N1 QYTFTGGLPZXRQR-SFHVURJKSA-N 0.000 claims description 2
- MSWSAELIPUGNJB-KRWDZBQOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(cyclopropylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CC2)=N1 MSWSAELIPUGNJB-KRWDZBQOSA-N 0.000 claims description 2
- UCAZDSIXDRHHKJ-PKHIMPSTSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(oxolan-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2OCCC2)=N1 UCAZDSIXDRHHKJ-PKHIMPSTSA-N 0.000 claims description 2
- HEOQKVPIQAJIAD-BPZDKFOGSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-cyanocyclohexyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CCC(CC2)C#N)=N1 HEOQKVPIQAJIAD-BPZDKFOGSA-N 0.000 claims description 2
- GITZPQVLXGQOFC-ZDUSSCGKSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-hydroxybenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NO)=N1 GITZPQVLXGQOFC-ZDUSSCGKSA-N 0.000 claims description 2
- JRCIPBPLMCNNAZ-AWEZNQCLSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-methylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1NC1=NC=C(Br)C(N[C@@H](CO)C(C)C)=N1 JRCIPBPLMCNNAZ-AWEZNQCLSA-N 0.000 claims description 2
- SURDDRPIORWROJ-FQEVSTJZSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-phenylmethoxybenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NOCC=2C=CC=CC=2)=N1 SURDDRPIORWROJ-FQEVSTJZSA-N 0.000 claims description 2
- DBRARTVFVQICAR-INIZCTEOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-pyrimidin-2-ylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CN=2)=N1 DBRARTVFVQICAR-INIZCTEOSA-N 0.000 claims description 2
- HKKPMWUXYNOAMH-ZDUSSCGKSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 HKKPMWUXYNOAMH-ZDUSSCGKSA-N 0.000 claims description 2
- JYHIAVNXXAOMOP-GFCCVEGCSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCOC)=N1 JYHIAVNXXAOMOP-GFCCVEGCSA-N 0.000 claims description 2
- MOQOQWYFSLCRAF-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN2CCOCC2)=N1 MOQOQWYFSLCRAF-OAHLLOKOSA-N 0.000 claims description 2
- CGGQTGLIIRJICO-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCOC=2C=CC=CC=2)=N1 CGGQTGLIIRJICO-MRXNPFEDSA-N 0.000 claims description 2
- CJCFZRXZAIMSEF-QGZVFWFLSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)=N1 CJCFZRXZAIMSEF-QGZVFWFLSA-N 0.000 claims description 2
- NBYSQJLMKWONFD-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-piperidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN2CCCCC2)=N1 NBYSQJLMKWONFD-MRXNPFEDSA-N 0.000 claims description 2
- YDJPJQPQTWFPDG-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-pyrrolidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN2CCCC2)=N1 YDJPJQPQTWFPDG-OAHLLOKOSA-N 0.000 claims description 2
- OIDQEZVDBXFHIZ-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-imidazol-1-ylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCN2C=NC=C2)=N1 OIDQEZVDBXFHIZ-OAHLLOKOSA-N 0.000 claims description 2
- TYLJSCDFQRNRPP-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylbutyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC(C)C)=N1 TYLJSCDFQRNRPP-CQSZACIVSA-N 0.000 claims description 2
- JBYAKKJCFOWWBR-SNVBAGLBSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylsulfanyl-1h-1,2,4-triazol-5-yl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC=2NN=C(SC)N=2)=N1 JBYAKKJCFOWWBR-SNVBAGLBSA-N 0.000 claims description 2
- CPNHYHNOBMDVOF-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(cyclohexylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CCCCC2)=N1 CPNHYHNOBMDVOF-MRXNPFEDSA-N 0.000 claims description 2
- CYCCZYUADXNPOZ-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-3-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=NC=CC=2)=N1 CYCCZYUADXNPOZ-OAHLLOKOSA-N 0.000 claims description 2
- OXYBJLCZAKJBLV-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-4-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CN=CC=2)=N1 OXYBJLCZAKJBLV-OAHLLOKOSA-N 0.000 claims description 2
- CTSAAFVAKMBXOE-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2SC=CC=2)=N1 CTSAAFVAKMBXOE-CYBMUJFWSA-N 0.000 claims description 2
- ZREICNPHXIRKFS-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(2-methoxyphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C(=CC=CC=2)OC)=N1 ZREICNPHXIRKFS-MRXNPFEDSA-N 0.000 claims description 2
- XKQPZMWHAHLRFF-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(3,4-dimethoxyphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=C(OC)C(OC)=CC=2)=N1 XKQPZMWHAHLRFF-MRXNPFEDSA-N 0.000 claims description 2
- JALQCMUJHPYDDR-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(3-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=C(F)C=CC=2)=N1 JALQCMUJHPYDDR-MRXNPFEDSA-N 0.000 claims description 2
- CONRSYAAHSEZNE-OFLPRAFFSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-cyanocyclohexyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CCC(CC2)C#N)=N1 CONRSYAAHSEZNE-OFLPRAFFSA-N 0.000 claims description 2
- HWXKWOWZXBIKQE-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(F)=CC=2)=N1 HWXKWOWZXBIKQE-MRXNPFEDSA-N 0.000 claims description 2
- OTXZJRWIKYDAFG-QGZVFWFLSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-methylphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(C)=CC=2)=N1 OTXZJRWIKYDAFG-QGZVFWFLSA-N 0.000 claims description 2
- DUGZLAZIQIAHNA-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(5-methylfuran-2-yl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2OC(C)=CC=2)=N1 DUGZLAZIQIAHNA-CQSZACIVSA-N 0.000 claims description 2
- PVCLSBRNZFMIIL-LDCVWXEPSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC2N(CCC2)C)=N1 PVCLSBRNZFMIIL-LDCVWXEPSA-N 0.000 claims description 2
- NXMZNKRQBUGKFU-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN(C)C)=N1 NXMZNKRQBUGKFU-CYBMUJFWSA-N 0.000 claims description 2
- FADZTHFNEKILEE-QGZVFWFLSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-[di(propan-2-yl)amino]ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN(C(C)C)C(C)C)=N1 FADZTHFNEKILEE-QGZVFWFLSA-N 0.000 claims description 2
- ZCNLIKVHFSZRMA-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(2-oxopyrrolidin-1-yl)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCN2C(CCC2)=O)=N1 ZCNLIKVHFSZRMA-OAHLLOKOSA-N 0.000 claims description 2
- IQZPISAYENKKPK-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(dimethylamino)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCN(C)C)=N1 IQZPISAYENKKPK-CQSZACIVSA-N 0.000 claims description 2
- QOXHCBQLRMGDND-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[3-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=C(C=CC=2)C(F)(F)F)=N1 QOXHCBQLRMGDND-MRXNPFEDSA-N 0.000 claims description 2
- NGKJZKMAMLIWOF-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[4-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=N1 NGKJZKMAMLIWOF-MRXNPFEDSA-N 0.000 claims description 2
- JKAGJQIISTWTSJ-LLVKDONJSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-cyclopropylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC2CC2)=N1 JKAGJQIISTWTSJ-LLVKDONJSA-N 0.000 claims description 2
- XRGNODWUWZWICO-SECBINFHSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 XRGNODWUWZWICO-SECBINFHSA-N 0.000 claims description 2
- SOIDQVUTNSQPIE-SECBINFHSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(F)(=O)=O)=N1 SOIDQVUTNSQPIE-SECBINFHSA-N 0.000 claims description 2
- OPOIKZSKCNYCGG-LLVKDONJSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCOC)=CC=C1NC1=NC=C(Br)C(N[C@H](C)CO)=N1 OPOIKZSKCNYCGG-LLVKDONJSA-N 0.000 claims description 2
- AXGKHKXXCZWGDR-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN2CCOCC2)=N1 AXGKHKXXCZWGDR-CQSZACIVSA-N 0.000 claims description 2
- GRLTVHLTFXVCDS-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCOC=2C=CC=CC=2)=N1 GRLTVHLTFXVCDS-OAHLLOKOSA-N 0.000 claims description 2
- KYKYMCDWQJIZJJ-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-phenylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)=N1 KYKYMCDWQJIZJJ-OAHLLOKOSA-N 0.000 claims description 2
- CZFUEQDFLHSZDI-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-imidazol-1-ylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCN2C=NC=C2)=N1 CZFUEQDFLHSZDI-CQSZACIVSA-N 0.000 claims description 2
- PJUUERIEVHJDSL-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylbutyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCC(C)C)=CC=C1NC1=NC=C(Br)C(N[C@H](C)CO)=N1 PJUUERIEVHJDSL-CYBMUJFWSA-N 0.000 claims description 2
- SNKRUHDRJOWIGC-SECBINFHSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylsulfanyl-1h-1,2,4-triazol-5-yl)benzenesulfonamide Chemical compound CSC1=NNC(NS(=O)(=O)C=2C=CC(NC=3N=C(N[C@H](C)CO)C(Br)=CN=3)=CC=2)=N1 SNKRUHDRJOWIGC-SECBINFHSA-N 0.000 claims description 2
- BEBSFANBTSGFFQ-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-phenylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCC=2C=CC=CC=2)=N1 BEBSFANBTSGFFQ-MRXNPFEDSA-N 0.000 claims description 2
- JIQCPHSHJJKNLU-QGZVFWFLSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(4-phenylbutyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCCC=2C=CC=CC=2)=N1 JIQCPHSHJJKNLU-QGZVFWFLSA-N 0.000 claims description 2
- NVZSOJQMXPPCHS-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(cyclohexylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CCCCC2)=N1 NVZSOJQMXPPCHS-CQSZACIVSA-N 0.000 claims description 2
- WHARBMGFJSUXET-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-3-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=NC=CC=2)=N1 WHARBMGFJSUXET-CYBMUJFWSA-N 0.000 claims description 2
- CQISQCHYUDUYKD-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-4-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CN=CC=2)=N1 CQISQCHYUDUYKD-CYBMUJFWSA-N 0.000 claims description 2
- CVVPAUWBCXQHIB-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(2-methoxyphenyl)methyl]benzenesulfonamide Chemical compound COC1=CC=CC=C1CNS(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(Br)C(N[C@H](C)CO)=N1 CVVPAUWBCXQHIB-CQSZACIVSA-N 0.000 claims description 2
- GKWZVHMMHGRNCC-QQFBHYJXSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-cyanocyclohexyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CCC(CC2)C#N)=N1 GKWZVHMMHGRNCC-QQFBHYJXSA-N 0.000 claims description 2
- RKOXJQRKXRDDLL-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(F)=CC=2)=N1 RKOXJQRKXRDDLL-CYBMUJFWSA-N 0.000 claims description 2
- GVZCJBSKTSUYNK-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-methylphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(C)=CC=2)=N1 GVZCJBSKTSUYNK-OAHLLOKOSA-N 0.000 claims description 2
- VAXNDIJVKXZTEP-GFCCVEGCSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(5-methylfuran-2-yl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2OC(C)=CC=2)=N1 VAXNDIJVKXZTEP-GFCCVEGCSA-N 0.000 claims description 2
- NJMQSCXETRCMLD-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-chlorophenyl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC=2C=CC(Cl)=CC=2)=N1 NJMQSCXETRCMLD-CQSZACIVSA-N 0.000 claims description 2
- AWZKKEKCRDKYIN-GFCCVEGCSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN(C)C)=N1 AWZKKEKCRDKYIN-GFCCVEGCSA-N 0.000 claims description 2
- AEXPTWWTZXNJTN-MRXNPFEDSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-[di(propan-2-yl)amino]ethyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCN(C(C)C)C(C)C)=CC=C1NC1=NC=C(Br)C(N[C@H](C)CO)=N1 AEXPTWWTZXNJTN-MRXNPFEDSA-N 0.000 claims description 2
- CKAJKOCHOVOSEQ-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(2-oxopyrrolidin-1-yl)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCN2C(CCC2)=O)=N1 CKAJKOCHOVOSEQ-CQSZACIVSA-N 0.000 claims description 2
- AULZJRFGVAEASE-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[3-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=C(C=CC=2)C(F)(F)F)=N1 AULZJRFGVAEASE-CYBMUJFWSA-N 0.000 claims description 2
- NOTZBHHJZRWHNU-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[4-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=N1 NOTZBHHJZRWHNU-CYBMUJFWSA-N 0.000 claims description 2
- YJSHWXLAAXZPHF-SNVBAGLBSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-cyclopropylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC2CC2)=N1 YJSHWXLAAXZPHF-SNVBAGLBSA-N 0.000 claims description 2
- VQASKXHBWAXJBZ-MRVPVSSYSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(F)(=O)=O)=N1 VQASKXHBWAXJBZ-MRVPVSSYSA-N 0.000 claims description 2
- NAKHVYGRJPQMKS-VXGBXAGGSA-N 4-[[5-bromo-4-[[(2r,3s)-1,3,4-trihydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@H](CO)[C@H](O)CO)=N1 NAKHVYGRJPQMKS-VXGBXAGGSA-N 0.000 claims description 2
- CQLAJLGSSXZYMT-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2s)-1-hydroxy-3,3-dimethylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@H](CO)C(C)(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 CQLAJLGSSXZYMT-CYBMUJFWSA-N 0.000 claims description 2
- GITZPQVLXGQOFC-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2s)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-hydroxybenzenesulfonamide Chemical compound C1=C(Br)C(N[C@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NO)=N1 GITZPQVLXGQOFC-CYBMUJFWSA-N 0.000 claims description 2
- HKKPMWUXYNOAMH-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2s)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 HKKPMWUXYNOAMH-CYBMUJFWSA-N 0.000 claims description 2
- XXRVXBGHUKJSIE-LBPRGKRZSA-N 4-[[5-bromo-4-[[(2s)-1-hydroxy-4-methylpentan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@H](CO)CC(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 XXRVXBGHUKJSIE-LBPRGKRZSA-N 0.000 claims description 2
- XRGNODWUWZWICO-VIFPVBQESA-N 4-[[5-bromo-4-[[(2s)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 XRGNODWUWZWICO-VIFPVBQESA-N 0.000 claims description 2
- MJIALGDLOLWBRQ-QMMMGPOBSA-N 4-[[5-bromo-4-[[(2s)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@H](CO)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 MJIALGDLOLWBRQ-QMMMGPOBSA-N 0.000 claims description 2
- YWHGNLJQAAZUSQ-NSHDSACASA-N 4-[[5-bromo-4-[[(2s)-1-methoxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](C)COC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)N(C)C)=N1 YWHGNLJQAAZUSQ-NSHDSACASA-N 0.000 claims description 2
- XAYLGTIEKZYYHR-NSHDSACASA-N 4-[[5-bromo-4-[[(2s)-1-methoxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](C)COC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCO)=N1 XAYLGTIEKZYYHR-NSHDSACASA-N 0.000 claims description 2
- YRDQBAKMPBVDID-JTQLQIEISA-N 4-[[5-bromo-4-[[(2s)-1-methoxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-methylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1NC1=NC=C(Br)C(N[C@@H](C)COC)=N1 YRDQBAKMPBVDID-JTQLQIEISA-N 0.000 claims description 2
- NMCCJSJOKZFDIW-VIFPVBQESA-N 4-[[5-bromo-4-[[(2s)-1-methoxypropan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](C)COC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 NMCCJSJOKZFDIW-VIFPVBQESA-N 0.000 claims description 2
- HQGQQBSYKPJVMW-BRJLIKDPSA-N 4-[[5-bromo-4-[[(3e)-3-[(2-methylpropan-2-yl)oxyimino]butan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(\C)=N\OC(C)(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 HQGQQBSYKPJVMW-BRJLIKDPSA-N 0.000 claims description 2
- GROTZQKRUBGFKS-LSHDLFTRSA-N 4-[[5-bromo-4-[[(3e)-3-methoxyiminobutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(/C)=N/OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 GROTZQKRUBGFKS-LSHDLFTRSA-N 0.000 claims description 2
- PNZLCZKYHUQWKQ-LLVKDONJSA-N 4-[[5-bromo-4-[[(3r)-2-oxooxolan-3-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@H]2C(OCC2)=O)=N1 PNZLCZKYHUQWKQ-LLVKDONJSA-N 0.000 claims description 2
- BVQPZAIXEHOTTK-JTQLQIEISA-N 4-[[5-bromo-4-[[(3s)-oxolan-3-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(N[C@@H]2COCC2)=N1 BVQPZAIXEHOTTK-JTQLQIEISA-N 0.000 claims description 2
- VJSXBIHTEMQPKF-UHFFFAOYSA-N 4-[[5-bromo-4-[[1-(hydroxymethyl)cyclopentyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2(CO)CCCC2)=N1 VJSXBIHTEMQPKF-UHFFFAOYSA-N 0.000 claims description 2
- ZLNJYIARGUQBMB-UHFFFAOYSA-N 4-[[5-bromo-4-[[4-(2-pyrrolidin-1-ylethylamino)cyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(CC2)NCCN2CCCC2)=N1 ZLNJYIARGUQBMB-UHFFFAOYSA-N 0.000 claims description 2
- KXFBOVVIXHEMBB-UHFFFAOYSA-N 4-[[5-bromo-4-[[4-(4-hydroxypiperidin-1-yl)cyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NC2CCC(CC2)N2CCC(O)CC2)=N1 KXFBOVVIXHEMBB-UHFFFAOYSA-N 0.000 claims description 2
- OQLMHCXDDKLEGP-UHFFFAOYSA-N 4-[[5-chloro-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCO)=CC=C1NC1=NC=C(Cl)C(NCC#C)=N1 OQLMHCXDDKLEGP-UHFFFAOYSA-N 0.000 claims description 2
- YHVZUEKIFDIKTE-UHFFFAOYSA-N 4-[[5-chloro-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Cl)C(NCC#C)=N1 YHVZUEKIFDIKTE-UHFFFAOYSA-N 0.000 claims description 2
- GGWXJVRSLQRCJA-UHFFFAOYSA-N 4-[[5-fluoro-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(F)C(NCC#C)=N1 GGWXJVRSLQRCJA-UHFFFAOYSA-N 0.000 claims description 2
- TWMVRLBMEKNBNI-ZDUSSCGKSA-N 4-[[5-fluoro-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(F)C(N[C@@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 TWMVRLBMEKNBNI-ZDUSSCGKSA-N 0.000 claims description 2
- JEBBDHYFCKGZOA-ZDUSSCGKSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=C(C(C)=CC=2)S(N)(=O)=O)=N1 JEBBDHYFCKGZOA-ZDUSSCGKSA-N 0.000 claims description 2
- WCWUWLWSXQKLBN-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-morpholin-4-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN2CCOCC2)=N1 WCWUWLWSXQKLBN-MRXNPFEDSA-N 0.000 claims description 2
- KAWBBMVMSIXVFC-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-phenoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCOC=2C=CC=CC=2)=N1 KAWBBMVMSIXVFC-QGZVFWFLSA-N 0.000 claims description 2
- VOKDBHSMDJNRSR-GOSISDBHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-phenylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)=N1 VOKDBHSMDJNRSR-GOSISDBHSA-N 0.000 claims description 2
- WELWTYKOXICFEL-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-piperidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN2CCCCC2)=N1 WELWTYKOXICFEL-QGZVFWFLSA-N 0.000 claims description 2
- CHFDRNXBGJILHY-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-pyrrolidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN2CCCC2)=N1 CHFDRNXBGJILHY-MRXNPFEDSA-N 0.000 claims description 2
- LEBSANLCLDTCKV-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(3-methylbutyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC(C)C)=N1 LEBSANLCLDTCKV-OAHLLOKOSA-N 0.000 claims description 2
- OVDBVSIILYEALU-LJQANCHMSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(3-phenylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCC=2C=CC=CC=2)=N1 OVDBVSIILYEALU-LJQANCHMSA-N 0.000 claims description 2
- CSHPZBZXTBWTLG-HXUWFJFHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(4-phenylbutyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCCC=2C=CC=CC=2)=N1 CSHPZBZXTBWTLG-HXUWFJFHSA-N 0.000 claims description 2
- BICIEPIKVJHMTI-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(pyridin-3-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=NC=CC=2)=N1 BICIEPIKVJHMTI-MRXNPFEDSA-N 0.000 claims description 2
- NTGXPHPQEZHKLB-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(pyridin-4-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CN=CC=2)=N1 NTGXPHPQEZHKLB-MRXNPFEDSA-N 0.000 claims description 2
- XTVVIPBRJVOUNT-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2SC=CC=2)=N1 XTVVIPBRJVOUNT-CQSZACIVSA-N 0.000 claims description 2
- PSVDPKSTMNHSBS-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[(5-methylfuran-2-yl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2OC(C)=CC=2)=N1 PSVDPKSTMNHSBS-OAHLLOKOSA-N 0.000 claims description 2
- ZAUMXNJFGFSWBY-PYUWXLGESA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC2N(CCC2)C)=N1 ZAUMXNJFGFSWBY-PYUWXLGESA-N 0.000 claims description 2
- DAJCMVOMEZYTHT-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[3-(2-oxopyrrolidin-1-yl)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCN2C(CCC2)=O)=N1 DAJCMVOMEZYTHT-MRXNPFEDSA-N 0.000 claims description 2
- PZUBCNYUFQIMFT-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=C(C=CC=2)C(F)(F)F)=N1 PZUBCNYUFQIMFT-QGZVFWFLSA-N 0.000 claims description 2
- IUZOEOJVUFMQQK-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[[4-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=N1 IUZOEOJVUFMQQK-QGZVFWFLSA-N 0.000 claims description 2
- HRYZMGIHWGHZFY-LJQANCHMSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-nonylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCCCCCCCC)=CC(NC=2N=C(N[C@H](CC)CO)C(Br)=CN=2)=C1 HRYZMGIHWGHZFY-LJQANCHMSA-N 0.000 claims description 2
- CUYPKHHYFHWVGZ-GOSISDBHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-octylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCCCCCCC)=CC(NC=2N=C(N[C@H](CC)CO)C(Br)=CN=2)=C1 CUYPKHHYFHWVGZ-GOSISDBHSA-N 0.000 claims description 2
- GNMPHDLJXUNMST-SNVBAGLBSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(F)(=O)=O)=N1 GNMPHDLJXUNMST-SNVBAGLBSA-N 0.000 claims description 2
- ZWRAIRQTWVNPEU-CYBMUJFWSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-methoxyethyl)-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCOC)=N1 ZWRAIRQTWVNPEU-CYBMUJFWSA-N 0.000 claims description 2
- XWIQIMJNKSRVIY-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(cyclohexylmethyl)-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC2CCCCC2)=N1 XWIQIMJNKSRVIY-QGZVFWFLSA-N 0.000 claims description 2
- WIZNZHHHZHNUED-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(furan-2-ylmethyl)-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2OC=CC=2)=N1 WIZNZHHHZHNUED-CQSZACIVSA-N 0.000 claims description 2
- ASODTPRJACMKOC-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(2-methoxyphenyl)methyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C(=CC=CC=2)OC)=N1 ASODTPRJACMKOC-QGZVFWFLSA-N 0.000 claims description 2
- UCPPHFPDYPTIGC-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(3-fluorophenyl)methyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=C(F)C=CC=2)=N1 UCPPHFPDYPTIGC-QGZVFWFLSA-N 0.000 claims description 2
- CUHRYIWKILBNEK-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-fluorophenyl)methyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CC(F)=CC=2)=N1 CUHRYIWKILBNEK-QGZVFWFLSA-N 0.000 claims description 2
- HEEXRWNVOCHSKJ-GOSISDBHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-chlorophenyl)ethyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC=2C=CC(Cl)=CC=2)=N1 HEEXRWNVOCHSKJ-GOSISDBHSA-N 0.000 claims description 2
- JBRACZXUTCMBGG-GOSISDBHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC=2C=CC(OC)=CC=2)=N1 JBRACZXUTCMBGG-GOSISDBHSA-N 0.000 claims description 2
- ZSSOAXOUKRUDLQ-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN(C)C)=N1 ZSSOAXOUKRUDLQ-CQSZACIVSA-N 0.000 claims description 2
- NMEMOQCDOKTFDX-GOSISDBHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-[di(propan-2-yl)amino]ethyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN(C(C)C)C(C)C)=N1 NMEMOQCDOKTFDX-GOSISDBHSA-N 0.000 claims description 2
- KGEVWSPBOZNJDG-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(dimethylamino)propyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCN(C)C)=N1 KGEVWSPBOZNJDG-OAHLLOKOSA-N 0.000 claims description 2
- VXDVNQWKMOMECD-GFCCVEGCSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-cyclopropyl-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NC2CC2)=N1 VXDVNQWKMOMECD-GFCCVEGCSA-N 0.000 claims description 2
- JHNAAZGCISYTLS-HXUWFJFHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-decyl-2-methylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCCCCCCCCC)=CC(NC=2N=C(N[C@H](CC)CO)C(Br)=CN=2)=C1 JHNAAZGCISYTLS-HXUWFJFHSA-N 0.000 claims description 2
- QBNCIMDBZKJYJY-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-heptyl-2-methylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCCCCCC)=CC(NC=2N=C(N[C@H](CC)CO)C(Br)=CN=2)=C1 QBNCIMDBZKJYJY-QGZVFWFLSA-N 0.000 claims description 2
- MDLCRTCAGLJYTQ-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-hexyl-2-methylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCCCCC)=CC(NC=2N=C(N[C@H](CC)CO)C(Br)=CN=2)=C1 MDLCRTCAGLJYTQ-MRXNPFEDSA-N 0.000 claims description 2
- UZACHZKCPVCRPX-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-morpholin-4-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN2CCOCC2)=N1 UZACHZKCPVCRPX-OAHLLOKOSA-N 0.000 claims description 2
- MMXKUKKKEBEZME-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-phenylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC=2C=CC=CC=2)=N1 MMXKUKKKEBEZME-MRXNPFEDSA-N 0.000 claims description 2
- RAMVJNHDITVKPQ-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(3-methylbutyl)benzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCC(C)C)=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 RAMVJNHDITVKPQ-CQSZACIVSA-N 0.000 claims description 2
- MGGGDGAPYCYHCK-GOSISDBHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(4-phenylbutyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCCC=2C=CC=CC=2)=N1 MGGGDGAPYCYHCK-GOSISDBHSA-N 0.000 claims description 2
- WSRQHUQCQMQOAO-CYBMUJFWSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2SC=CC=2)=N1 WSRQHUQCQMQOAO-CYBMUJFWSA-N 0.000 claims description 2
- KUJVLMIOVUPWLQ-CYBMUJFWSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[(5-methylfuran-2-yl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2OC(C)=CC=2)=N1 KUJVLMIOVUPWLQ-CYBMUJFWSA-N 0.000 claims description 2
- LYBOWECFDWDSBO-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[3-(2-oxopyrrolidin-1-yl)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCN2C(CCC2)=O)=N1 LYBOWECFDWDSBO-OAHLLOKOSA-N 0.000 claims description 2
- TYKYVNGEZLPOIP-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=C(C=CC=2)C(F)(F)F)=N1 TYKYVNGEZLPOIP-CQSZACIVSA-N 0.000 claims description 2
- NWYSHTULYODZLP-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[[4-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=N1 NWYSHTULYODZLP-CQSZACIVSA-N 0.000 claims description 2
- LHNALFLUSPFRFI-SECBINFHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(F)(=O)=O)=N1 LHNALFLUSPFRFI-SECBINFHSA-N 0.000 claims description 2
- LQWGKFRWBCQQNL-GFCCVEGCSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-methoxyethyl)-2-methylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCOC)=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 LQWGKFRWBCQQNL-GFCCVEGCSA-N 0.000 claims description 2
- GTSDKLCPGKWKNV-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-imidazol-1-ylpropyl)-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCN2C=NC=C2)=N1 GTSDKLCPGKWKNV-OAHLLOKOSA-N 0.000 claims description 2
- PUBMJHHLKSAMDQ-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(cyclohexylmethyl)-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC2CCCCC2)=N1 PUBMJHHLKSAMDQ-OAHLLOKOSA-N 0.000 claims description 2
- QAJITLOKYBDAKN-CYBMUJFWSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(furan-2-ylmethyl)-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2OC=CC=2)=N1 QAJITLOKYBDAKN-CYBMUJFWSA-N 0.000 claims description 2
- BTZVXASAHBNVFY-KLAILNCOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-cyanocyclohexyl)methyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC2CCC(CC2)C#N)=N1 BTZVXASAHBNVFY-KLAILNCOSA-N 0.000 claims description 2
- FZDLEUQBKRLLMJ-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-chlorophenyl)ethyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC=2C=CC(Cl)=CC=2)=N1 FZDLEUQBKRLLMJ-OAHLLOKOSA-N 0.000 claims description 2
- CTYZROHZHGPNDL-CYBMUJFWSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(dimethylamino)ethyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN(C)C)=N1 CTYZROHZHGPNDL-CYBMUJFWSA-N 0.000 claims description 2
- BBSCSWBFPZYQCW-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-[di(propan-2-yl)amino]ethyl]-2-methylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCN(C(C)C)C(C)C)=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 BBSCSWBFPZYQCW-QGZVFWFLSA-N 0.000 claims description 2
- DIZCNGLAEAQTFI-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(dimethylamino)propyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCN(C)C)=N1 DIZCNGLAEAQTFI-CQSZACIVSA-N 0.000 claims description 2
- NJQLKHCHRKBOFF-LLVKDONJSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-cyclopropyl-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NC2CC2)=N1 NJQLKHCHRKBOFF-LLVKDONJSA-N 0.000 claims description 2
- KSHGLZPYSXZAPV-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-hexyl-2-methylbenzenesulfonamide Chemical compound C1=C(C)C(S(=O)(=O)NCCCCCC)=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 KSHGLZPYSXZAPV-OAHLLOKOSA-N 0.000 claims description 2
- WWABYTQOYXNSQU-UHFFFAOYSA-N 5-bromo-2-n-(4-morpholin-4-ylsulfonylphenyl)-4-n-prop-2-ynylpyrimidine-2,4-diamine Chemical compound N1=C(NCC#C)C(Br)=CN=C1NC1=CC=C(S(=O)(=O)N2CCOCC2)C=C1 WWABYTQOYXNSQU-UHFFFAOYSA-N 0.000 claims description 2
- AHLFRQTVSBOXIE-UHFFFAOYSA-N 5-bromo-4-n-prop-2-ynyl-2-n-[3-(trifluoromethylsulfonyl)phenyl]pyrimidine-2,4-diamine Chemical compound FC(F)(F)S(=O)(=O)C1=CC=CC(NC=2N=C(NCC#C)C(Br)=CN=2)=C1 AHLFRQTVSBOXIE-UHFFFAOYSA-N 0.000 claims description 2
- JOIORRUUZNTGDY-UHFFFAOYSA-N 6-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]-n-(1,3-dihydroxypropan-2-yl)hexanamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCCCCC(=O)NC(CO)CO)=N1 JOIORRUUZNTGDY-UHFFFAOYSA-N 0.000 claims description 2
- JGDHGKUWDDZRII-UHFFFAOYSA-N 6-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]hexanoic acid Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCCCCC(O)=O)=N1 JGDHGKUWDDZRII-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- HXWVARUJJXRLFD-HNNXBMFYSA-N [(2r)-2-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]-3-methylbutyl] acetate Chemical compound C1=C(Br)C(N[C@@H](COC(C)=O)C(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 HXWVARUJJXRLFD-HNNXBMFYSA-N 0.000 claims description 2
- NQLLJCWSEDXJGP-IBGZPJMESA-N [(2r)-2-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]-3-methylbutyl] n-(3,4,5-trimethoxyphenyl)carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)OC[C@H](NC=2C(=CN=C(NC=3C=CC(=CC=3)S(N)(=O)=O)N=2)Br)C(C)C)=C1 NQLLJCWSEDXJGP-IBGZPJMESA-N 0.000 claims description 2
- DVEMUNMMHWICPE-IBGZPJMESA-N [(2r)-2-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]-3-methylbutyl] n-phenylcarbamate Chemical compound C([C@@H](C(C)C)NC=1C(=CN=C(NC=2C=CC(=CC=2)S(N)(=O)=O)N=1)Br)OC(=O)NC1=CC=CC=C1 DVEMUNMMHWICPE-IBGZPJMESA-N 0.000 claims description 2
- MEPFFDPMFNUOSD-UHFFFAOYSA-N [3-acetyloxy-2-[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]oxypropyl] acetate Chemical compound C1=C(Br)C(OC(COC(C)=O)COC(=O)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 MEPFFDPMFNUOSD-UHFFFAOYSA-N 0.000 claims description 2
- XXBTYXOWBDMMQN-UHFFFAOYSA-N [4-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]cyclohexyl] n-butylcarbamate Chemical compound C1CC(OC(=O)NCCCC)CCC1NC1=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C1Br XXBTYXOWBDMMQN-UHFFFAOYSA-N 0.000 claims description 2
- FJZDVAQIQBWNJC-UHFFFAOYSA-N [[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]methyl-methoxyphosphinic acid Chemical compound C1=C(Br)C(NCP(O)(=O)OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 FJZDVAQIQBWNJC-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- MWRQKPVXCYLOED-UHFFFAOYSA-N benzyl 5-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]pentanoate Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCCCC(=O)OCC=2C=CC=CC=2)=N1 MWRQKPVXCYLOED-UHFFFAOYSA-N 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- ZZBCEDDMQQHNLP-UHFFFAOYSA-N ethyl 4-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]butanoate Chemical compound C1=C(Br)C(NCCCC(=O)OCC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 ZZBCEDDMQQHNLP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- IZENRYJZRXUJHC-OAHLLOKOSA-N methyl (2r)-2-[[5-bromo-2-[4-(2-hydroxyethylsulfamoyl)anilino]pyrimidin-4-yl]amino]-3-methylbutanoate Chemical compound C1=C(Br)C(N[C@@H](C(=O)OC)C(C)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCO)=N1 IZENRYJZRXUJHC-OAHLLOKOSA-N 0.000 claims description 2
- VAENHQILJYHGQK-WYMLVPIESA-N methyl (e)-6-[[5-chloro-2-[4-(2-hydroxyethylsulfamoyl)anilino]pyrimidin-4-yl]amino]-3-methylhex-2-en-4-ynoate Chemical compound C1=C(Cl)C(NCC#CC(/C)=C/C(=O)OC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCO)=N1 VAENHQILJYHGQK-WYMLVPIESA-N 0.000 claims description 2
- SJWFPJZXWGKMEU-UHFFFAOYSA-N methyl 2-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]-3-hydroxypropanoate Chemical compound C1=C(Br)C(NC(CO)C(=O)OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 SJWFPJZXWGKMEU-UHFFFAOYSA-N 0.000 claims description 2
- SDOJPUMBQBDAQS-UHFFFAOYSA-N methyl 2-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]butanoate Chemical compound C1=C(Br)C(NC(CC)C(=O)OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 SDOJPUMBQBDAQS-UHFFFAOYSA-N 0.000 claims description 2
- CVWHZCDRMJQOBC-UHFFFAOYSA-N methyl 4-[3-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]propanoylamino]butanoate Chemical compound C1=C(Br)C(NCCC(=O)NCCCC(=O)OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 CVWHZCDRMJQOBC-UHFFFAOYSA-N 0.000 claims description 2
- BPDQTICFFSLEBY-UHFFFAOYSA-N methyl 4-[6-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]hexanoylamino]butanoate Chemical compound C1=C(Br)C(NCCCCCC(=O)NCCCC(=O)OC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 BPDQTICFFSLEBY-UHFFFAOYSA-N 0.000 claims description 2
- QRVBZWQEQOXGKP-UHFFFAOYSA-N methyl 4-[[5-bromo-2-[4-(2-hydroxyethylsulfamoyl)anilino]pyrimidin-4-yl]amino]butanoate Chemical compound C1=C(Br)C(NCCCC(=O)OC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCO)=N1 QRVBZWQEQOXGKP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 4
- 241001024304 Mino Species 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- YNVRKQALFIIIRZ-UHFFFAOYSA-N 4-[(4-morpholin-4-ylpyrimidin-2-yl)amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=CC(N2CCOCC2)=N1 YNVRKQALFIIIRZ-UHFFFAOYSA-N 0.000 claims 1
- IBTCCVNYIPUVRC-UHFFFAOYSA-N 4-[[5-bromo-4-(thiophen-2-ylmethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC=2SC=CC=2)=N1 IBTCCVNYIPUVRC-UHFFFAOYSA-N 0.000 claims 1
- OUXRNUPTKPCVAM-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-piperidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN2CCCCC2)=N1 OUXRNUPTKPCVAM-OAHLLOKOSA-N 0.000 claims 1
- LXIXVTKNXULCQQ-CQSZACIVSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-pyrrolidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCN2CCCC2)=N1 LXIXVTKNXULCQQ-CQSZACIVSA-N 0.000 claims 1
- GSQRVWWDZPUURH-GFCCVEGCSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2SC=CC=2)=N1 GSQRVWWDZPUURH-GFCCVEGCSA-N 0.000 claims 1
- VBPYEQIXWPOOCU-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(3-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=C(F)C=CC=2)=N1 VBPYEQIXWPOOCU-CYBMUJFWSA-N 0.000 claims 1
- YGVSYUFPVBDBIX-IURRXHLWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC2N(CCC2)C)=N1 YGVSYUFPVBDBIX-IURRXHLWSA-N 0.000 claims 1
- ZTGMVKFRZXONFQ-OAHLLOKOSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-methoxyphenyl)ethyl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1CCNS(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(Br)C(N[C@H](C)CO)=N1 ZTGMVKFRZXONFQ-OAHLLOKOSA-N 0.000 claims 1
- KFFUNORGDJUGDY-GOSISDBHSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[(4-methylphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CC(C)=CC=2)=N1 KFFUNORGDJUGDY-GOSISDBHSA-N 0.000 claims 1
- BSLVEIYIAPPGSP-UHFFFAOYSA-N 5-bromo-2-n-[4-[2-(diethylamino)ethylsulfonyl]phenyl]-4-n-prop-2-ynylpyrimidine-2,4-diamine Chemical compound C1=CC(S(=O)(=O)CCN(CC)CC)=CC=C1NC1=NC=C(Br)C(NCC#C)=N1 BSLVEIYIAPPGSP-UHFFFAOYSA-N 0.000 claims 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 claims 1
- GEBAUYJDXWCBIZ-MERQFXBCSA-N NS(=O)(=O)c1ccc(Nc2ncc(I)c(NCC#C)n2)cc1.CSCC[C@@H](CO)Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)ncc1Br Chemical compound NS(=O)(=O)c1ccc(Nc2ncc(I)c(NCC#C)n2)cc1.CSCC[C@@H](CO)Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)ncc1Br GEBAUYJDXWCBIZ-MERQFXBCSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 29
- 108091007914 CDKs Proteins 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 19
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 230000022131 cell cycle Effects 0.000 description 17
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 16
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 102000016736 Cyclin Human genes 0.000 description 9
- 108050006400 Cyclin Proteins 0.000 description 9
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 9
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 101100273648 Mus musculus Ccna2 gene Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 6
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 101100327242 Drosophila melanogaster CycE gene Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 4
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101100112680 Ostreococcus tauri CycD gene Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000006369 cell cycle progression Effects 0.000 description 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 230000020172 G2/M transition checkpoint Effects 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 229960001456 adenosine triphosphate Drugs 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 102000007588 cdc25 Phosphatases Human genes 0.000 description 3
- 108010046616 cdc25 Phosphatases Proteins 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 230000022983 regulation of cell cycle Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101100059444 Mus musculus Ccnb1 gene Proteins 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 108010072268 cyclin-dependent kinase-activating kinase Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- CUGDYSSBTWBKII-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(dimethylamino)hexane-1,2,3,4,5-pentol Chemical class CN(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CUGDYSSBTWBKII-LXGUWJNJSA-N 0.000 description 1
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical class CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 description 1
- XGLICGVXAPVYBI-ZETCQYMHSA-N (2s)-2-[[5-bromo-2-(4-sulfamoylanilino)pyrimidin-4-yl]amino]propanamide Chemical compound C1=C(Br)C(N[C@@H](C)C(N)=O)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 XGLICGVXAPVYBI-ZETCQYMHSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RNHVJBJVOGMYMW-UHFFFAOYSA-N 1,3-dimethyl-1-propylurea Chemical compound CCCN(C)C(=O)NC RNHVJBJVOGMYMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VLUHDALZYKXLTA-UHFFFAOYSA-N 1-[4-[(5-bromo-4-prop-2-ynoxypyrimidin-2-yl)amino]phenoxy]-3-(4-phenylpiperazin-1-yl)propan-2-ol Chemical compound C1CN(C=2C=CC=CC=2)CCN1CC(O)COC(C=C1)=CC=C1NC1=NC=C(Br)C(OCC#C)=N1 VLUHDALZYKXLTA-UHFFFAOYSA-N 0.000 description 1
- SPIWTTJEIQYNPK-UHFFFAOYSA-N 1-[[1,3-bis(methylamino)-2,4-dihydropyrimidin-2-yl]oxy]propan-2-ol Chemical class CNN1CC=CN(NC)C1OCC(C)O SPIWTTJEIQYNPK-UHFFFAOYSA-N 0.000 description 1
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- JQLOELYADIUZLD-UHFFFAOYSA-N 2-bromo-1,1-diethoxybutane Chemical compound CCOC(OCC)C(Br)CC JQLOELYADIUZLD-UHFFFAOYSA-N 0.000 description 1
- ZSMDMXGZKLLHGL-UHFFFAOYSA-N 2-chloro-5-fluoro-n-prop-2-ynylpyrimidin-4-amine Chemical compound FC1=CN=C(Cl)N=C1NCC#C ZSMDMXGZKLLHGL-UHFFFAOYSA-N 0.000 description 1
- ZZJGPMAXOXVLGM-UHFFFAOYSA-N 2-chloro-n-prop-2-ynylpyrimidin-4-amine Chemical compound ClC1=NC=CC(NCC#C)=N1 ZZJGPMAXOXVLGM-UHFFFAOYSA-N 0.000 description 1
- XQMKRPIZJHEKSG-INIZCTEOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(1,3-dihydroxypropan-2-yl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C(C)C)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NC(CO)CO)=N1 XQMKRPIZJHEKSG-INIZCTEOSA-N 0.000 description 1
- WMVKSRVLBYMNNR-GFCCVEGCSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCOC)=N1 WMVKSRVLBYMNNR-GFCCVEGCSA-N 0.000 description 1
- ZHRIYMCBQBKDHN-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCN2CCOCC2)=N1 ZHRIYMCBQBKDHN-OAHLLOKOSA-N 0.000 description 1
- CVNAOWSLMKCPDR-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-piperidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCN2CCCCC2)=N1 CVNAOWSLMKCPDR-MRXNPFEDSA-N 0.000 description 1
- WEEXJQUWKDSMQN-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-imidazol-1-ylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCN2C=NC=C2)=N1 WEEXJQUWKDSMQN-OAHLLOKOSA-N 0.000 description 1
- QBMQJPSFFULETH-SNVBAGLBSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-methylsulfanyl-1h-1,2,4-triazol-5-yl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NC=2NN=C(SC)N=2)=N1 QBMQJPSFFULETH-SNVBAGLBSA-N 0.000 description 1
- DSXTVCKGNOCFHH-GOSISDBHSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-phenylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCC=2C=CC=CC=2)=N1 DSXTVCKGNOCFHH-GOSISDBHSA-N 0.000 description 1
- NTTYBZPCDJEMGL-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(cyclohexylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC2CCCCC2)=N1 NTTYBZPCDJEMGL-MRXNPFEDSA-N 0.000 description 1
- XNCPLDQMRCGQLJ-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(furan-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2OC=CC=2)=N1 XNCPLDQMRCGQLJ-CYBMUJFWSA-N 0.000 description 1
- RWMLEQMESBSDMD-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(pyridin-4-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CN=CC=2)=N1 RWMLEQMESBSDMD-OAHLLOKOSA-N 0.000 description 1
- SLAQTACRMFNDIX-CYBMUJFWSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(thiophen-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2SC=CC=2)=N1 SLAQTACRMFNDIX-CYBMUJFWSA-N 0.000 description 1
- AGKAZHMKZRTJOQ-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(3-fluorophenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=C(F)C=CC=2)=N1 AGKAZHMKZRTJOQ-MRXNPFEDSA-N 0.000 description 1
- OMQITYLLWBUKKU-CQSZACIVSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(5-methylfuran-2-yl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2OC(C)=CC=2)=N1 OMQITYLLWBUKKU-CQSZACIVSA-N 0.000 description 1
- RKVDLZVPSHAYPI-LDCVWXEPSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCC2N(CCC2)C)=N1 RKVDLZVPSHAYPI-LDCVWXEPSA-N 0.000 description 1
- FTNVAOSKGMGKSL-QGZVFWFLSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-chlorophenyl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCC=2C=CC(Cl)=CC=2)=N1 FTNVAOSKGMGKSL-QGZVFWFLSA-N 0.000 description 1
- PPKBRPTUSPUDQR-QGZVFWFLSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-[di(propan-2-yl)amino]ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCN(C(C)C)C(C)C)=N1 PPKBRPTUSPUDQR-QGZVFWFLSA-N 0.000 description 1
- ORBIQXHHKZROQS-OAHLLOKOSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[3-(2-oxopyrrolidin-1-yl)propyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCCN2C(CCC2)=O)=N1 ORBIQXHHKZROQS-OAHLLOKOSA-N 0.000 description 1
- JNLSCERXOUBHGD-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[3-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=C(C=CC=2)C(F)(F)F)=N1 JNLSCERXOUBHGD-MRXNPFEDSA-N 0.000 description 1
- UAKAXDMMFAGEHM-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[[4-(trifluoromethyl)phenyl]methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=N1 UAKAXDMMFAGEHM-MRXNPFEDSA-N 0.000 description 1
- XLBCJSGIMQHZEH-LLVKDONJSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound COCCNS(=O)(=O)C1=CC=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 XLBCJSGIMQHZEH-LLVKDONJSA-N 0.000 description 1
- AUSPUCCQZAVOPM-MRXNPFEDSA-N 3-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-[di(propan-2-yl)amino]ethyl]benzenesulfonamide Chemical compound CC(C)N(C(C)C)CCNS(=O)(=O)C1=CC=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=C1 AUSPUCCQZAVOPM-MRXNPFEDSA-N 0.000 description 1
- VKRFUGHXKNNIJO-UHFFFAOYSA-N 4,4,4-trifluorobutan-1-ol Chemical compound OCCCC(F)(F)F VKRFUGHXKNNIJO-UHFFFAOYSA-N 0.000 description 1
- ODJCIHKBMUREOC-UHFFFAOYSA-N 4-(difluoromethylsulfanyl)aniline Chemical compound NC1=CC=C(SC(F)F)C=C1 ODJCIHKBMUREOC-UHFFFAOYSA-N 0.000 description 1
- SWJSXYKJQHZHTP-UHFFFAOYSA-N 4-(difluoromethylsulfanyl)aniline;hydrochloride Chemical compound Cl.NC1=CC=C(SC(F)F)C=C1 SWJSXYKJQHZHTP-UHFFFAOYSA-N 0.000 description 1
- VYZCYFWOCSNLDS-UHFFFAOYSA-N 4-[[5-bromo-4-(3-hydroxybutan-2-ylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(NC(C)C(O)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 VYZCYFWOCSNLDS-UHFFFAOYSA-N 0.000 description 1
- AGAVDGOMGVNRTE-UHFFFAOYSA-N 4-[[5-bromo-4-(cyclohexylmethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC2CCCCC2)=N1 AGAVDGOMGVNRTE-UHFFFAOYSA-N 0.000 description 1
- SVHRGOHQMWLVJZ-UHFFFAOYSA-N 4-[[5-bromo-4-(pyridin-4-ylmethylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCC=2C=CN=CC=2)=N1 SVHRGOHQMWLVJZ-UHFFFAOYSA-N 0.000 description 1
- RWMBSHSFSDPDNN-UHFFFAOYSA-N 4-[[5-bromo-4-[(4-hydroxycyclohexyl)amino]pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCO)=CC=C1NC1=NC=C(Br)C(NC2CCC(O)CC2)=N1 RWMBSHSFSDPDNN-UHFFFAOYSA-N 0.000 description 1
- WVCXHMNXASLWIV-UHFFFAOYSA-N 4-[[5-bromo-4-[2-(2-oxo-1h-imidazol-3-yl)ethylamino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(Br)C(NCCN2C(NC=C2)=O)=N1 WVCXHMNXASLWIV-UHFFFAOYSA-N 0.000 description 1
- XXRVXBGHUKJSIE-GFCCVEGCSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxy-4-methylpentan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC(C)C)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 XXRVXBGHUKJSIE-GFCCVEGCSA-N 0.000 description 1
- RPCBQIYZEZPTPF-GOSISDBHSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3-phenylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCC=2C=CC=CC=2)=N1 RPCBQIYZEZPTPF-GOSISDBHSA-N 0.000 description 1
- JNOAGNVWSYXSPQ-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(furan-2-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2OC=CC=2)=N1 JNOAGNVWSYXSPQ-CYBMUJFWSA-N 0.000 description 1
- LLRIYDPKZNCKIW-QGZVFWFLSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-chlorophenyl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC=2C=CC(Cl)=CC=2)=N1 LLRIYDPKZNCKIW-QGZVFWFLSA-N 0.000 description 1
- BZZHQAZRENPBLF-QGZVFWFLSA-N 4-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-methoxyphenyl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCC=2C=CC(OC)=CC=2)=N1 BZZHQAZRENPBLF-QGZVFWFLSA-N 0.000 description 1
- LYKOLNKZXOWCFK-CYBMUJFWSA-N 4-[[5-bromo-4-[[(2s)-1-hydroxy-3-methylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonyl fluoride Chemical compound C1=C(Br)C(N[C@H](CO)C(C)C)=NC(NC=2C=CC(=CC=2)S(F)(=O)=O)=N1 LYKOLNKZXOWCFK-CYBMUJFWSA-N 0.000 description 1
- NLLQUEKHQAIVQU-NSHDSACASA-N 4-[[5-bromo-4-[[(2s)-1-hydroxy-4-methylsulfanylbutan-2-yl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@H](CO)CCSC)=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=N1 NLLQUEKHQAIVQU-NSHDSACASA-N 0.000 description 1
- UUEUZISITWLJBZ-UHFFFAOYSA-N 4-[[5-bromo-4-[[4-[2-(dimethylamino)ethylamino]cyclohexyl]amino]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1CC(NCCN(C)C)CCC1NC1=NC(NC=2C=CC(=CC=2)S(N)(=O)=O)=NC=C1Br UUEUZISITWLJBZ-UHFFFAOYSA-N 0.000 description 1
- FJUGTPKOPRPWFQ-UHFFFAOYSA-N 4-[[5-iodo-4-(prop-2-ynylamino)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=NC=C(I)C(NCC#C)=N1 FJUGTPKOPRPWFQ-UHFFFAOYSA-N 0.000 description 1
- WIFPJDJJFUSIFP-UHFFFAOYSA-N 4-aminobutane-1,2,3-triol Chemical compound NCC(O)C(O)CO WIFPJDJJFUSIFP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- FGDGJJNJEUYMFK-UHFFFAOYSA-N 4-n,6-n-diphenylpyrimidine-4,6-diamine Chemical class C=1C(NC=2C=CC=CC=2)=NC=NC=1NC1=CC=CC=C1 FGDGJJNJEUYMFK-UHFFFAOYSA-N 0.000 description 1
- PSBFJCJIKCXCMO-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[2-(4-sulfamoylphenyl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC=2C=CC(=CC=2)S(N)(=O)=O)=N1 PSBFJCJIKCXCMO-QGZVFWFLSA-N 0.000 description 1
- ADKORQSOLXNILO-XMMPIXPASA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-(3,3-diphenylpropyl)-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 ADKORQSOLXNILO-XMMPIXPASA-N 0.000 description 1
- ZJZZVXBDVMXSJN-DAWZGUTISA-N 5-[[5-bromo-4-[[(2r)-1-hydroxybutan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-cyanocyclohexyl)methyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)CC)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC2CCC(CC2)C#N)=N1 ZJZZVXBDVMXSJN-DAWZGUTISA-N 0.000 description 1
- CGPSZEURQFOQBR-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-phenoxyethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCOC=2C=CC=CC=2)=N1 CGPSZEURQFOQBR-MRXNPFEDSA-N 0.000 description 1
- QBBLKECBLORKCL-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(2-pyrrolidin-1-ylethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCN2CCCC2)=N1 QBBLKECBLORKCL-OAHLLOKOSA-N 0.000 description 1
- NTVISAJIAZPDTC-QGZVFWFLSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(3-phenylpropyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCCC=2C=CC=CC=2)=N1 NTVISAJIAZPDTC-QGZVFWFLSA-N 0.000 description 1
- ZWDNLJHYDZKZSO-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(pyridin-3-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=NC=CC=2)=N1 ZWDNLJHYDZKZSO-CQSZACIVSA-N 0.000 description 1
- MIQUAKWQUBUMRP-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-(pyridin-4-ylmethyl)benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CN=CC=2)=N1 MIQUAKWQUBUMRP-CQSZACIVSA-N 0.000 description 1
- FVUSJYPBVZKLJP-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[(4-methylphenyl)methyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CC(C)=CC=2)=N1 FVUSJYPBVZKLJP-MRXNPFEDSA-N 0.000 description 1
- SZXMCRLJQZBFGY-LDCVWXEPSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[2-(1-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC2N(CCC2)C)=N1 SZXMCRLJQZBFGY-LDCVWXEPSA-N 0.000 description 1
- UFXONPNVMBXORI-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-2-methyl-n-[2-(4-sulfamoylphenyl)ethyl]benzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCCC=2C=CC(=CC=2)S(N)(=O)=O)=N1 UFXONPNVMBXORI-OAHLLOKOSA-N 0.000 description 1
- UTPQOVOJOJHIQS-OAHLLOKOSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(2-methoxyphenyl)methyl]-2-methylbenzenesulfonamide Chemical compound COC1=CC=CC=C1CNS(=O)(=O)C1=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=CC=C1C UTPQOVOJOJHIQS-OAHLLOKOSA-N 0.000 description 1
- PRAWLWNFIZPWMT-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(3-fluorophenyl)methyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=C(F)C=CC=2)=N1 PRAWLWNFIZPWMT-CQSZACIVSA-N 0.000 description 1
- ROIXALYMOQIAKO-CQSZACIVSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[(4-fluorophenyl)methyl]-2-methylbenzenesulfonamide Chemical compound C1=C(Br)C(N[C@@H](CO)C)=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)NCC=2C=CC(F)=CC=2)=N1 ROIXALYMOQIAKO-CQSZACIVSA-N 0.000 description 1
- LEKDCGCGHXTBFQ-MRXNPFEDSA-N 5-[[5-bromo-4-[[(2r)-1-hydroxypropan-2-yl]amino]pyrimidin-2-yl]amino]-n-[2-(4-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1CCNS(=O)(=O)C1=CC(NC=2N=C(N[C@H](C)CO)C(Br)=CN=2)=CC=C1C LEKDCGCGHXTBFQ-MRXNPFEDSA-N 0.000 description 1
- QPQVAWHFCNQCEX-UHFFFAOYSA-N 5-bromo-2,4-bis(4,4,4-trifluorobutoxy)pyrimidine Chemical compound FC(F)(F)CCCOC1=NC=C(Br)C(OCCCC(F)(F)F)=N1 QPQVAWHFCNQCEX-UHFFFAOYSA-N 0.000 description 1
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 1
- UUTAOLFWFKZORC-UHFFFAOYSA-N 5-bromo-2-chloro-4-(4,4,4-trifluorobutoxy)pyrimidine Chemical compound FC(F)(F)CCCOC1=NC(Cl)=NC=C1Br UUTAOLFWFKZORC-UHFFFAOYSA-N 0.000 description 1
- UCJCBQDVERWXCJ-UHFFFAOYSA-N 5-bromo-2-n-[4-(difluoromethylsulfanyl)phenyl]-4-n-prop-2-ynylpyrimidine-2,4-diamine Chemical compound C1=CC(SC(F)F)=CC=C1NC1=NC=C(Br)C(NCC#C)=N1 UCJCBQDVERWXCJ-UHFFFAOYSA-N 0.000 description 1
- HEKCAWDMCHLTOK-UHFFFAOYSA-N 5-bromo-n-[3-(oxiran-2-ylmethoxy)phenyl]-2-prop-2-ynoxy-1h-pyrimidin-2-amine Chemical compound N1=CC(Br)=CNC1(OCC#C)NC1=CC=CC(OCC2OC2)=C1 HEKCAWDMCHLTOK-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- FPVUCBMBMUHRDX-XMMPIXPASA-N [4-hydroxy-3-(3-methylbut-2-enyl)phenyl]methyl (2r)-4-hydroxy-3-(4-hydroxyphenyl)-2-methyl-5-oxofuran-2-carboxylate Chemical compound C1=C(O)C(CC=C(C)C)=CC(COC(=O)[C@@]2(C)C(=C(O)C(=O)O2)C=2C=CC(O)=CC=2)=C1 FPVUCBMBMUHRDX-XMMPIXPASA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000008059 anilinopyrimidines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- RTWCHRMHGXBETA-UHFFFAOYSA-N prop-1-yn-1-amine Chemical compound CC#CN RTWCHRMHGXBETA-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- HMZIGHBQOOGZAK-UHFFFAOYSA-N pyrimidine-2-sulfonyl fluoride Chemical class FS(=O)(=O)C1=NC=CC=N1 HMZIGHBQOOGZAK-UHFFFAOYSA-N 0.000 description 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical class N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Description
Den foreliggende oppfinnelse angår pyrimidinderivater, deres fremstilling og deres anvendelse for fremstilling av medikamenter for behandling av forskjellige sykdommer.
CDK-familien (syklinavhengig kinase) er en enzymfamilie som spiller en viktig rolle ved reguleringen av cellesyklusen og dermed utgjør et spesielt interessant objekt for utvikling av små inhiberende molekyler. Selektive inhibitorer av CDK-familien kan anvendes for behandling av kreft eller andre sykdommer som forårsakes av forstyrrelser av celleproliferasjonen.
Pyrimidiner og deres analoger er allerede beskrevet som virkestoffer, eksempelvis 2-anilinopyrimidiner som fungicider (DE 4029650) eller substituerte pyrimidinderivater for behandling av nevrologiske eller nevrodegenerative sykdommer
(WO 99/19305). Som CDK-inhibitorer er de forskjelligste pyrimidinderivater beskrevet, som f.eks. bis(anilino)pyrimidinderivater (WO 00/12486), 2-amino-4-substituerte pyrimidiner
(WO 01/14375), puriner (WO 99/02162), 5-cyanpyrimidiner (WO 02/04429), anilinopyrimidiner (WO 00/12486) og 2-hydroksy-3-N,N-dimetylaminopropoksypyrimidiner (WO 00/39101).
Oppgaven som ligger bak den foreliggende oppfinnelse,
har vært å fremstille forbindelser som oppviser bedre egenskaper enn de allerede kjente inhibitorer. De her beskrevne substanser er mer virksomme, da de oppviser inhiberende virkning allerede i det nanomolare område og således atskiller seg fra andre, allerede kjente CDK-inhibitorer, som f.eks. olomoucin og roscovitin.
Oppfinnelsen angår forbindelser som er kjennetegnet ved generell formel I,
hvori
R<1> betegner halogen,
R<2> betegner -CH (CH3) - (CH2) n-R5, -CH- (CH2OH) 2, -(CH2)nR<7>, -CH(C3H7)-(CH2)n-R<5>, -CH(C2H5)-(CH2)n-R<5>, -CH2-CN, -CH(CH3)COCH3, -CH(CH3)-C(OH) (CH3)2, -CH (CH (OH) CH3) OCH3, -CH(C2H5)CO-R<5>, C2-C4-alkynyl, - (CH2) n-COR<5>, - (CH2) n-CO-Ci-C6-alkyl, -(CH2)n-C(OH) (CH3)-fenyl, -CH (CH3)-C (CH3)-R<5>, -CH(CH3)-C(CH3) (C2H5)-R<5>, -CH (OCH3) -CH2-R<5>, -CH2-CH (OH)-R<5>, -CH (OCH3) -CHR5-CH3, -CH (CH3)-CH (OH)-CH2-CH=CH2, -CH(C2H5)-CH(OH) - (CH2)n-CH3, -CH(CH3)-CH(OH)-(CH2)n-CH3, -CH(CH3)-CH(OH)-CH(CH3)2, (CH2OAC)2, -(CH2)„-R<6>, - (CH2) „- (CF2) n-CF3, -CH(CH2)n-R<5>)2, -CH(CH3)-CO-NH2f -CH (CH2OH) -fenyl, -CH (CH2OH) -CH (OH) - (CH2) nR5, -CH (CH2OH) -CH (OH) -f enyl, -CH(CH2OH) -C2H4-R5, - (CH2) n-CsC-C (CH3) =CH-COR5, -CH(Ph)-(CH2)n-R<5>, -(CH2)n-COR<5>, -(CH2)nP03(R<5>)2f - (CH2) n-COR5, -CH ( (CH2) nOR5) CO-R<5>, - (CH2) nCONHCH ( (CH2) nR<5>) 2, - (CH2) nNH-COR<5>, -CH (CH2) nR5- (CH2) nC3-Cio-sykloalkyl, - (CH2) n-C3-Ci0-sykloalkyl, C3-Ci0-sykloalkyl; Ci-C6-alkyl, C3-Cio-syklo-alkyl, - (CH2)n-0-(CH2)n-R5, eller - (CH2) n-NR3R4 som eventuelt er substituert på ett eller flere steder, lik eller forskjellig med hydroksy, Ci-C6-alkyl eller gruppen -COONH(CH2)nCH3 eller -NR<3>R<4>, -CH (C3H7) - (CH2) n-OC (0) - (CH2) n-CH3, -(CH2)n-R<5>, -C(CH3)2-(CH2)n-R<5>, -C (CH2) n (CH3) - (CH2) nR<5>, -C(CH2)n- (CH2)nR5, -CH(t-butyl)-(CH2)n-R<5>, -CCH3(C3H7)-(CH2)nR<5>, -CH(C3H7)-(CH2)n-R<5>r -CH (C3H7)-COR5, -CH(C3H7)-(CH2) n-OC (0) -NH-Ph, -CH ( (CH2) n (C3H7) ) - (CH2) nR<5>, -CH(C3H7)-(CH2)n-OC(0)-NH-Ph(OR<5>)3, -NR<3>R<4>, -NH-(CH2) n-NR<3>R<4>, R<5-> (CH2) n-C*H-CH (R<5>) - (CH2) n-R5, - (CH2) n-CO-NH- (CH2) n-CO-R5, -OC(0)NH-Ci-C6-alkyl eller - (CH2) n-CO-NH-(CH2) n-CH-( (CH2)nR5)2,
eller betegner C3-Cio~sykloalkyl, som er substituert med gruppen
eller betegner gruppen X betegner oksygen eller gruppen -NH-, N (Ci-C3-alkyl) eller
R<2> betegner gruppen
eller
X og R<2> danner sammen en gruppe
A betegner -S02-C2H4-OH, -S02CF3, -S02- (CH2)n-N-R<3>R4,
-S02-NR<3>R<4> eller -S02R<7>,
B betegner hydrogen, hydroksy eller Ci-C3-alkyl,
R<3> og R<4>, i hvert tilfelle uavhengig av hverandre, betegner hydrogen, fenyl, benzyloksy, Ci-Ci2-alkyl, Ci-C6-alkoksy, C2-C4-alkenyloksy, C3-C6-sykloalkyl, hydroksy, hydroksy-Ci-C6-alkyl, dihydroksy-Ci-C6-alkyl, heteroaryl, heterosyklo-C3-Ci0-alkyl, heteroaryl-Ci-C3-alkyl, C3-C6-sykloalkyl-Ci-C3-alkyl som eventuelt er substituert med cyano, eller
betegner Ci-C6~alkyl som eventuelt er substituert på ett eller flere steder, lik eller forskjellig med fenyl, pyridyl, fenyloksy, C3-C6-sykloalkyl, Ci-C6-alkyl eller Ci-C6~alkoksy, hvorved fenylgruppen i seg selv kan være substituert på ett eller flere steder, lik eller forskjellig med halogen, trifluormetyl, d-C6-alkyl, C1-C6-alkoksy eller med gruppen -S02NR<3>R<4>,
eller betegner gruppen - (CH2) nNR3R4, -CNHNH2 eller
-NR3R<4> eller betegner
som eventuelt kan være substituert med Ci-C6-alkyl,
R<5> betegner hydroksy, fenyl, Ci-CValkyl, C3-C6-sykloalkyl,
benzoksy, Ci-C6-alkyltio eller Ci-C6-alkoksy,
R<6> betegner gruppen
R<7> betegner halogen, hydroksy, fenyl, Ci-C6-alkyl,
-(CH2)nOH, -NR3R4 eller gruppen
R<8>, R9 og R1<0> betegner hydrogen, hydroksy, Ci-C6-alkyl eller
betegner gruppen -(CH2) n-COOH, og
n betegner 0-6,
så vel som diastereomerer, enantiomerer og salter derav.
Dersom forbindelsene inneholder en sur funksjon, er de fysiologisk forlikelige salter av organiske og uorganiske baser egnet som salter, som f.eks. de godt oppløselige alkalimetall-og jordalkalimetallsalter, samt salter av N-metylglukamin, di-metylglukamin, etylglukamin, lysin, 1,6-heksadiamin, etanolamin, glukosamin, sarkosin, serinol, tris-hydroksy-metyl-amino-metan, aminopropandiol, Sovak-base og l-amino-2,3,4-butantriol.
Dersom forbindelsene inneholder en basisk funksjon, er de fysiologisk forlikelige salter av organiske og uorganiske syrer egnet, som f.eks. salter av saltsyre, svovelsyre, fosforsyre, sitronsyre, vinsyre og andre.
Særlig foretrukne forbindelser er valgt fra: 5-brom-N2- [4- (2-dietylaitiino-etansulfonyl) -fenyl] -N4-prop-2-ynyl-pyrimidin-2,4-diamin,
N2-(3-benzensulfonyl-fenyl)-5-brom-N4-prop-2-ynyl-pyrimidin-2,4-diamin,
5-brom-N2-[4-(morfolin-4-sulfonyl)-fenyl]-N4-prop-2-ynyl-pyrimidin-2,4-diamin,
4-[5-fluor-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[4-((R)-l-hydroksymetyl-2-metyl-propylamino)-5-jod-pyrimidin-2-ylamino]-benzensulfonamid,
4-(5-fluor-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonamid,
4-{5-brom-4-[2-(2-okso-2,3-dihydroimidazol-l-yl)-etylamino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-[5-brom-4-(2,2,3,3,3-pentafluor-propoksy)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[[5-brom-4-(1,3-bisacetoksy-2-propyloksy)-2-pyrimidinyl]-amino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l-hydroksymetyl-etoksy)-pyrimidin-2-ylamino]-benzensulfonamid,
(S)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propionamid,
5-brom-N4-prop-2-ynyl-N2-(3-trifluormetansulfonyl-fenyl)-pyrimidin-2,4-diamin,
3-(5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzen-sulf onamid,
3- (5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-N-butyl-benzensulfonamid,
2-[3-(5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonyl]-etanol,
4- (5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzen-sulf onamid,
4-(5-klor-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzen-sulf onamid,
2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-smørsyre-metylester,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
2-{5-brom-2-[3-(2-hydroksy-etansulfonyl)-fenylamino] - pyrimidin-4-ylamino}-propan-1,3-diol,
4-[5-brom-4-(2-hydroksy-l-hydroksymetyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(syklopropylmetyl-amino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, 4-[5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
2-{3-[5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonyl}-etanol,
2-{3-[5-brom-4-(2-morfolin-4-yl-etylamino)-pyrimidin-2-ylamino]-benzensulfonyl}-etanol,
4-[5-brom-4-(2-morfolin-4-yl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4,4,4-trifluor-butoksy)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-etoksy-l-etoksymetyl-etoksy)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-smørsyre,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, (R)-2-{5-brom-2-[3-(2-hydroksy-etansulfonyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-butan-l-ol,
4-[5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-((R)-2-hydroksy-l-fenyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-metyl-benzensulfonamid,
4- [5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N,N-dimetyl-benzensulfonamid,
5- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-pentansyre-benzylester,
6- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre-metylester,
4-(5-jod-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzen-sulf onamid
4-[5-brom-4-((S)-l-hydroksymetyl-3-metylsulfanyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((IS,2S)-2-hydroksy-l-hydroksymetyl-2-fenyl-etylamino) -pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-2-okso-tetrahydrofuran-3-ylamino)-pyrimidin-2 -ylamino] -benzensulfonamid,
4-[5-brom-4-((S)-l-hydroksymetyl-2,2-dimetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-{3-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propionylamino}-smørsyre-metylester, 4-(4-morfolin-4-yl-pyrimidin-2-ylamino)-benzensulfonamid, 6-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre,
4-(5-brom-4-sykloheksylamino-pyrimidin-2-ylamino)-benzensulfonamid,
4-{6-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksanoylamino}-smørsyre-metylester, 6-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre-metylester,
4-[5-brom-4-( (IR,2S)-2,3-dihydroksy-l-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-((R)-2-sykloheksyl-l-hydroksymetyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
6-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre-(2-hydroksy-l-hydroksymetyl-etyl) -amid, 4-[5-brom-4-( (S)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4-hydroksy-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-{4-[(adamantan-l-ylmetyl)-amino]-5-brom-pyrimidin-2-ylamino}-benzensulfonamid,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-metyl-benzensulfonamid, (R)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-smørsyre,
4-(5-brom-4-sykloheksylamino-pyrimidin-2-ylamino)-N-(2-hydroksyetyl)-benzensulfonamid,
4-[5-brom-4-(2,2,3,3,4,4,4-heptafluor-butylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, 4-[5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, fenylkarbaminsyre-(R)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butylester,
(R)-2-{5-brom-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-smørsyre,
(R)-2-{5-brom-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-smørsyre-metylester, 4-(5-klor-4-prop-2-ynylamino-pyrimidin-2-ylamino)-N-(2-hydroksyetyl)-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l,1-dimetyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-((S)-l-hydroksymetyl-3-metyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4- (tetrahydro-pyran-4-yloksy)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4- ( (IS,2S)-2-hydroksy-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
butylkarbaminsyre-4-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-sykloheksylester,
(R)-2-[5-brom-2-(4-metansulfonyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butan-l-ol,
(R)-2-{5-brom-2-[4-(morfolin-4-sulfonyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-butan-l-ol,
4-[5-brom-4-(4-dimetylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4-dimetylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4-piperidin-l-yl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-3-hydroksy-benzensulfonamid, 4-[5-brom-4-(4-syklopropylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
(R)-2-[5-brom-2-(3-metansulfonyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butan-l-ol,
4-{5-brom-4-[2-(2-etoksy-etoksy)-etoksy]-pyrimidin-2-ylamino}-benzensulfonamid,
4-{5-brom-4-[4-(2-dimetylamino-etylamino)-sykloheksylamino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-{5-brom-4-[4-(2-pyrrolidin-l-yl-etylamino)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[4-(4-hydroksy-piperidin-l-yl)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-smørsyre-metylester,
4-{5-brom-4-[4-(3-hydroksy-pyrrolidin-l-yl)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[4-(3-hydroksy-pyrrolidin-l-yl)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-3-metyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-{5-brom-4-[2-(l-metyl-pyrrolidin-2-yl)-etylamino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-[5-brom-4-(piperidin-4-yloksy)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(3-dimetylamino-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
eddiksyre-(R)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butylester,
4-[5-brom-4-(4-hydroksy-sykloheksylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, (3,4,5-trimetoksyfenyl)-karbaminsyre-(R)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butylester,
4-(5-brom-4-sykloheptylamino-pyrimidin-2-ylamino)-benzensulfonamid,
4-[5-brom-4-((R)-l-hydroksymetyl-2,2-dimetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4-okso-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
(E)-6-{5-klor-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-heks-2-en-4-ynsyre- metylester, 4-[5-brom-4-(1-hydroksymetyl-syklopentylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[4-(bisyklo[2.2.1]hept-2-ylamino)-5-brom-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-morfolin-4-yl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-morfolin-4-yl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-({5-brom-4-[(R)-(2-hydroksy-l-metyletyl)amino]pyrimidin-2-yljamino)benzensulfonamid, 4-[5-brom-4-(2,2,3,3,3-pentafluor-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-hydroksy-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(1-etynyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(3-hydroksy-l-fenyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, (+)-4-[5-brom-4-(2-metyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, (-)-4-[5-brom-4-(2-metyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-{5-brom-4-[4-(2-hydroksy-l-hydroksymetyl-etylamino)-sykloheksylamino]-pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[4-(2-hydroksy-l-hydroksymetyl-etylamino)-sykloheksylamino]-pyrimidin-2-ylamino}-benzensulfonamid, (R)-2-[5-brom-2-(4-trifluormetansulfonyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butan-l-ol,
4-[5-brom-4-(4-syklopropylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4-syklopropylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4- [5-brom-4-{tetrahydrotiofen-3-ylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-hydroksy-propionsyre-metylester,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-pyrimidin-2-yl-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-tiazol-2-yl-benzensulfonamid, 4-[5-brom-4-(4-hydroksy-butylamino)-pyrimidin-2-ylamino]-N-metyl-benzensulfonamid,
4-{5-brom-4-[2-(3H-imidazol-4-yl)-etylamino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-[5-brom-4-(1-etyl-l-hydroksymetyl-propylamino)-pyrimidin-2- ylamino]-benzensulfonamid,
4-[5-brom-4-(1-hydroksymetyl-l,2-dimetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4-metyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-{5-brom-4-[ (S)-(tetrahydrofuran-3-yl)amino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-[5-brom-4-(sykloheksylmetyl-amino)-pyrimidin-2-ylamino]-benzensulfonamid,
3- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propionsyre,
4- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-smørsyre-etylester,
{3-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propyl}-fosfonsyre-dietylester,
4-{5-brom-4-[(3-pyridin-3-yl-isoksazol-4-ylmetyl)-amino]-pyrimidin-2-ylamino}-benzensulfonamid,
{[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-metyl}-fosfonsyre-dimetylester,
{[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-metyl}-fosfonsyre-monometylester,
4-{5-brom-4-[(pyridin-4-ylmetyl)-amino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-{5-brom-4-t (tiofen-2-ylmetyl)-amino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-{5-brom-4-[(pyridin-2-ylmetyl)-amino]-pyrimidin-2-ylamino}-benzensulfonamid,
4-[5-brom-4-(4-fluorbenzylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(4-metoksy-benzylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
{3-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propyl}-fosfonsyre,
4-[5-brom-4-(2-hydroksyetylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(1-fenyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
N-allyloksy-4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 3-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(5-hydroksy-pentyl)-benzensulfonamid, 3-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksy-l-hydroksymetyl-etyl) - benzensulfonamid,
3- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(3-hydroksy-propyl)-benzensulfonamid, N-benzyloksy-4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksy-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-syklopropylmetyl-benzensulfonamid,
4- [5-brom-4- ( (R) -l-hydr'6ksymetyl-2-metyl-propylamino) - pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(5-hydroksy-pentyl)-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(tetrahydrofuran-2-ylmetyl)-benzensulfonamid,
4-[5-brom-4- ( (S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-hydroksy-benzensulfonamid, 4-[5-brom-4-((S)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksy-l-hydroksymetyl-etyl)-benzensulfonamid,
4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(3-hydroksy-propyl)-benzensulfonamid, 4- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-hydroksy-benzensulfonamid, 5- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-benzensulfonamid, 3- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-etoksy-benzensulfonamid, N-allyloksy-3-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4- (5-brom-4-morfolin-4-yl-pyrimidin-2-ylamino)-benzensulfonamid,
7-[(5-brom-4-{[(R)-2-hydroksy-l-metyletyl]amino}pyrimidin-2-yl)amino]-3,4-dihydro-2H-l,2-benzotiazin-l,1-dioksid, 4-[5-brom-4-(2-hydroksy-2-fenyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l,2-dimetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l,2-dimetyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-okso-2-fenyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-(5-brom-4-sek-butylamino-pyrimidin-2-ylamino)-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l-metyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4- (3,3-dimetyl-2-okso-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l-metyl-3-fenyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-br om-4-(2-hydroksy-l-metyl-pent-4-enylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l-metyl-pentylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(l-metyl-2-okso-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l,3-dimetyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[4-((IR,2R)-2-benzyloksy-syklopentylamino)-5-brom-pyrimidin-2-ylamino]-benzensulfonamid,
4-[4-((IS,2S)-2-benzyloksy-syklopentylamino)-5-brom-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(l-etyl-2-hydroksy-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(l-etyl-2-hydroksy-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-2-fenyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-3,3-dimetyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksyimino-l-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-(5-brom-4-{2-[(E)-metoksyimino]-1-metyl-propylamino}-pyrimidin-2-ylamino)-benzensulfonamid,
4-(5-brom-4-{2-[(E)-tert-butoksyimino]-1-metyl-propylamino}-pyrimidin-2-ylamino)-benzensulfonamid,
[2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-1- metyl-prop-(E)-ylidenaminooksy]-eddiksyre, 4-[5-brom-4-(2-syklopropylamino-l-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
4-[5-brom-4-(2-hydroksy-l-metoksymetyl-etylamino)-pyrimidin-2- ylamino]-benzensulfonamid,
4- [5-brom-4-(2-hydroksy-l-metoksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
5- [5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-sykloheksylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-fenyl-butyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3,3-difenyl-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-2-metyl-benzensulfonamid, 5- [5-brom-4- ( (R) -l-hydroksymetyl--propylamino) -pyrimidin-2-ylamino]-N-3-imidazol-l-yl-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-trifluormetyl-benzyl)-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-heptyl-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-oktyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-nonyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-decyl-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-trifluormetyl-benzyl)-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-fenyl-propyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid,
5-[5-brom-4-( (R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-metyl-butyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-heksyl-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-syklopropyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-fenetyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-tiofen-2-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-metoksyfenyl)-etyl]-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-3-ylmetyl-benzensulfonamid, 5-[5-brom-4-{(R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-4-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-fenoksy-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-[2-(4-sulfamoyl-fenyl)-etyl]-benzensulfonamid,
5- [5-brom-4- ( (R) -l-hydroksymetyl^-propylamino) -pyrimidin-2-ylamino]-2-metyl-N-(4-metyl-benzyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-sykloheksylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-fenyl-butyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-trifluormetyl-benzyl)-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-trifluormetyl-benzyl)-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-fenyl-propyl)-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-metyl-butyl)-benzensulfonamid, 5-[5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-heksyl-2-metyl-benzensulfonamid,
5-[5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-2-metyl-benzensulfonamid,
5-[5-brom-4-( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-syklopropyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-fenetyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylaminp]-2-metyl-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-tiofen-2-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-metoksyfenyl)-etyl]-2-metyl-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-vlaminol-2-metvl-N-(2-DiDeridin-l-vl-etvl}-benzensulfnnamid.
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino] -2-metyl-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-3-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-4-ylmetyl-benzensulfonamid, 5-[5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-fenoksy-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-[2-(4-sulfamoyl-fenyl)-etyl]-benzensulfonamid,
5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-metyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-sykloheksylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fenyl-propyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid,
3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-benzensulfonamid,
3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-fenetyl-benzensulfonamid,
3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 3- [5-brom-4- ( (R) -l-hydroksymetyl-^propylamino) -pyrimidin-2-ylamino]-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid,
3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-3-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-4-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-fenoksy-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-metyl-benzyl)-benzensulfonamid,
3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid,
3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid,
3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-fenetyl-benzensulfonamid,
3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 3-[5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-morfolin-4-yl-etyl) -benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid,
3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid,
3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-pyridin-3-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-pyridin-4-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-fenoksy-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-metyl-benzyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid,
4- [5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid,
3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid,
5- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-benzensulfonylfluorid,
3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid,
5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-benzensulfonylfluorid,
3-[5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 3- [5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 4- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid,
4-[5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-sykloheksyImetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-fenyl-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N- (3-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-fenyl-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid,
4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-syklopropyl-benzensulfonamid,
4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-fenetyl-benzensulfonamid,
4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-benzensulfonamid,
4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-metoksyfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid,
4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-pyridin-3-yImetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-pyridin-4-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-fenoksy-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-metyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-sykloheksyImetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-benzensulfonamid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fenyl-propyl)-benzensulfonamid, 4-[5-brom-4- ( (R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-syklopropyl-benzensulfonamid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-fenetyl-benzensulfonamid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3,4-dimetoksy-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-metoksyfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N- (2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N- (2-piperidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-benzensulfonamid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid,
4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-3-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-4-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-fenoksy-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-metyl-benzyl)-benzensulfonamid eller 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid.
Forbindelsene ifølge oppfinnelsen inhiberer i det vesentlige syklinavhengige kinaser, hvilket også forklarer deres virkning mot f.eks. kreft, som f.eks. faste tumorer og leukemi, autoimmunsykdommer som psoriasis, alopesi og multippel sklerose, kjemoterapeutika-frembrakt alopesi og mukositt, kardiovaskulære sykdommer, som f.eks. stenose, arteriosklerose og restenose, infeksiøse sykdommer, som f.eks. trypanosom, toksoplasma eller plasmodium, frembrakt gjennom encellede parasitter eller gjennom sopp, nefrologiske sykdommer, som f.eks. glomerulonefritt, kroniske nevrodegenerative sykdommer, som f.eks. Huntingtons sykdom, amyotrof lateralsklerose, Parkinsons sykdom, AIDS-demens og Alzheimers sykdom, akutte nevrodegenerative sykdommer, som f.eks. hjerneiskemi og nerveskader, virusinfeksjoner, som f.eks. cytomegalovirusinfeksjoner, herpes, hepatitt B og C og HIV-sykdommer.
Den eukaryote celledelingssyklus sikrer duplikasjonen av genomet og dets fordeling på dattercellene, idet den gjennom-løper en koordinert og regulert rekkefølge av hendelser. Cellesyklusen inndeles i fire på hverandre følgende faser: fasen Gl representerer tiden forut for DNA-replikasjonen, da cellen vokser og er mottakelig for eksterne stimuli. I fasen S repli-kerer cellen sitt DNA, og i fasen G2 forbereder den seg på inntredenen i mitosen. I mitosen (fase M) blir det replikerte DNA delt og celledelingen fullført.
De syklinavhengige kinaser (CDK-er), en familie av serin-/treoninkinaser, hvis medlemmer er avhengige av binding av et syklin (Cyc) som regulerende underenhet for å aktiveres, driver cellene gjennom cellesyklusen. Forskjellige CDK/Cyc-par er aktive i de ulike faser av cellesyklusen. CDK/Cyc-par som har betydning for den grunnleggende funksjon av cellesyklusen, er f.eks. CDK4(6)/CycD, CDK2/CycE, CDK2/CycA, CDKl/CycA og CDKl/CycB. Noen medlemmer av CDK-enzymfamilien er i besittelse av en regulerende funksjon, idet de påvirker aktiviteten av de ovennevnte cellesyklus-CDK-er, mens andre medlemmer av CDK-enzymf amlien ikke kan tilordnes noen bestemt funksjon. Ett av disse, CDK5, utmerker seg ved at det har en regulatorisk underenhet (p35) som avviker fra syklinene, og at dets aktivitet er på sitt høyeste i hjernen.
Inntredenen i cellesyklusen og gjennomløpingen av "restriksjonspunktene", som markerer en celles uavhengighet av ytterligere vekstsignaler for avslutning av den begynnende celledeling, kontrolleres gjennom aktiviteten av CDK4(6)/CycD-og CDK2/CycE-kompleksene. Det vesentlige substrat for disse CDK-komplekser er retinoblastomproteinet (Rb), produktet av retino-blastomtumorsuppressorgenet. Rb er et transkripsjonelt ko-repressorprotein. I tillegg til andre og i stor utstrekning ikke forståtte mekanismer binder og inaktiverer Rb transkripsjons-faktorer av typen E2F og danner transkripsjonene repressorkomplekser med Histon-deacetylaser (HDAC), Zhang, H.S. et al.
(2000). Utgangen fra Gl-fasen og S-fasen av cellesyklusen reguleres av repressorkomplekser inneholdende HDAC-Rb-hSWI/SNF og Rb-hSWI/SNF. Cell, 101, 79-89. Ved fosforylering av Rb ved hjelp av CDK-er blir bundne E2F-transkripsjonsfaktorer satt fri, og disse fører til transkripsjonen aktivering av gener, hvis produkter er nødvendige for DNA-syntesen og progresjonen gjennom S-fasen. I tillegg avstedkommer Rb-fosforyleringen oppløsning av Rb-HDAC-kompleksene, hvorved ytterligere gener blir aktivert. Fosforyleringen av Rb ved hjelp av CDK-er blir å sidestille med en overskridelse av "restriksjonspunktet". For progresjonen gjennom S-fasen og avslutning av denne er aktiviteten av CDK2/CycE- og CDK2/CycA-kompleksene nødvendig. Eksempelvis blir aktiviteten av transkripsjonsfaktorene av E2F-typen utsjaltet ved fosforylering ved hjelp av CDK2/CycA så snart cellene er kommet inn i S-fasen. Etter fullstendig replikasjon av DNA-molekylet styrer CDK1 i kompleks med CycA eller CycB inntredenen og gjennomløpingen av fasene G2 og M(Abb. 1). I overensstemmelse med den overordentlig store betydning av celledelingssyklusen blir gjennomløpingen av syklusen strengt regulert og kontrollert. Enzymene som er nødvendige for progresjonen gjennom syklusen, må aktiveres på det riktige tids-punkt, og må igjen utsjaltes så snart den angjeldende fase er gjennomløpt. Tilsvarende kontrollpunkter ("checkpoints") stanser progresjonen gjennom cellesyklusen dersom DNA-skader påvises, eller dersom DNA-replikasjonen eller oppbyggingen av spindel-apparatet ikke er sluttført. Aktiviteten av CDK-ene kontrolleres direkte ved hjelp av forskjellige mekanismer, som f.eks. syntese og nedbygging av syklinene, dannelse av komplekser av CDK-ene med de tilsvarende sykliner, fosforylering og defosforylering av regulatoriske treonin- og tyrosinrester, og binding av naturlig inhibitoriske proteiner. Mens CDK-enes proteinmengde i en proli-ferativ celle er relativt konstant, oscillerer mengden av de enkelte sykliner under gjennomløpingen av syklusen. Således blir f.eks. eksprimeringen av CycD under den tidlige Gl-fase stimu-lert ved hjelp av vekstfaktorer, og eksprimeringen av CycE frem-kalles ved aktivering av transkripsjonsfaktorene av E2F-typen etter overskridelse av "restriksjonspunktet". Syklinene selv nedbygges ved ubiquitin-formidlet proteolyse. Aktiverende og inaktiverende fosforyleringer regulerer aktiviteten av CDK-ene. Eksempelvis fosforylerer CDK-aktiverende kinaser (CAK-er) Thrl60/161 i CDKl, mens familien av Weel/Mytl-kinaser inaktiverer CDK1 ved fosforylering av Thrl4 og Tyrl5. Disse inaktiverende fosforyleringer kan så igjen oppheves ved hjelp av cdc25-fosfataser. Av stor betydning er reguleringen av aktiviteten av CDK/Cyc-kompleksene ved hjelp av to familier av naturlig forekommende CDK-inhibitorproteiner (CKI-er), protein-produktene fra p21-genfamilien (p21, p27, p57) og pl6-gen-familien (pl5, pl6, pl8, pl9). Medlemmer av p21-familien binder seg til syklinkomplekser av CDK-er 1, 2, 4, 6, men inhiberer kun komplekser som inneholder CDKl eller CDK2. Medlemmer av pl6-familien er spesifikke inhibitorer av CDK4- og CDK6-kompleksene. Ovenfor denne komplekse direkte regulering av aktiviteten av CDK-ene ligger platået for kontrollpunktregulering. Kontrollpunkter gjør det mulig for cellen å følge det ordnede forløp av de enkelte faser under cellesyklusen. De viktigste kontrollpunkter ligger ved overgangen fra Gl til S og fra G2 til M. Gl-kontrollpunktet sikrer at cellen ikke påbegynner noen DNA-syntese dersom den ikke er tilsvarende ernært, dersom den sam-virker korrekt med andre celler eller med substratet, og dersom dens DNA er intakt. G2/M-kontrollpunktet sikrer fullstendig replikasjon av DNA-molekylet og oppbyggingen av den mitotiske spiral, før cellen trer inn i mitosen. Gl-kontrollpunktet aktiveres av p53-tumorsuppressorgenets genprodukt. p53 aktiveres etter påvisning av forandringer i metabolismen eller i cellens genomiske integritet og kan utløse en stansing enten av cellesyklusprogresjonen eller apoptose. I dette spiller den transkripsjonene aktivering av eksprimeringen av CDK-inhibitor-proteinet p21 ved hjelp av p53 en avgjørende rolle. En annen gren av Gl-kontrollpunktet omfatter aktiveringen av ATM- og Chkl-kinasene etter DNA-beskadigelse som følge av ultrafiolett lys eller ioniserende stråling og sluttelig fosforylering og påfølgende proteolytisk nedbygging av cdc25A-fosfatasen (Mailand, N. et al. (2000). Rapid destruction of human cdc25A in response to DNA damage, Science, 288, 1425-1429). Dette resul-terer i en stansing av cellesyklusen, da den inhibitoriske fosforylering av CDK-ene ikke fjernes. Etter aktivering av G2/M-kontrollpunktet som følge av beskadigelse av DNA-molekylet vil begge mekanismer på vanlig måte bidra til at progresjonen gjennom cellesyklusen stoppes. Opphør av reguleringen av cellesyklusen og opphør av kontrollpunktets funksjon er karakteristisk for tumorceller. CDK-Rb-signalveien er i mer enn 90 % av humane tumorceller rammet av mutasjoner. Disse mutasjoner, som til slutt fører til inaktiverende fosforylering av RB, innebærer overeksprimering av D- og E-sykliner gjennom genamplifikasjon eller kromosomale translokasjoner, inaktiverende mutasjoner eller deletering av CDK-inhibitorer av pl6-typen, samt forhøyet (p27) eller nedsatt (CycD) proteinnedbygging. Den andre gruppe av gener, som rammes av mutasjoner i tumorceller, koder for komponenter av kontroll-punktene. Således er p53, som er essensielt for Gl- og G2/M-kontrollpunktene, det hyppigst muterte gen i humane tumorer (ca. 50 %). I tumorceller som eksprimerer p53 uten mutasjon, blir det ofte inaktivert på grunn av en sterkt forhøyet proteindegrader-ing. På tilsvarende måte rammes genene i andre nødvendige proteiner for kontrollpunktenes funksjonering av mutasjoner, f.eks. ATM (inaktiverende mutasjoner) eller cdc25-fosfataser (overeksprimering). Overbevisende eksperimentelle data tyder på at CDK2/Cyc-komplekser spiller en avgjørende rolle under cellesyklusprogresjonen: (1) Så vel dominant-negative former av CDK2 som den transkripsjonene represjon av CDK2-eksprimeringen ved antisenseoligonukleotider avstedkommer en stans i cellesyklusprogresjonen. (2) Inaktiveringen av CycA-genet hos mus er dødelig. (3) Forstyrrelse av CDK2/CycA-kompleksets funksjon i celler forårsaket av cellepermeable peptider førte til tumor-celleselektiv apoptose (Chen, Y.N.P. et al. (1999). Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists, Proe. Nati. Acad. Sei. USA, 96, 4325-4329). Det er ikke bare ved kreftsykdommer at endringer i cellesykluskontrollen spiller en rolle. Cellesyklusen aktiveres av en rekke vira, så vel av transformerende som av ikke-transformerende sådanne, for å muliggjøre en formering av viraene i vertscellen. Den uønskede inntreden i cellesyklusen av normalt postmitotiske celler settes i sammenheng med forskjellige nevrodegenerative sykdommer. Mekanismene ved cellesyklusreguleringen, endringene av disse ved sykdommer og en rekke forsøk på utvikling av inhibitorer av cellesyklusprogresjonen, og spesielt av CDK-ene, er allerede blitt utførlig sammenfattet i flere publi-kasjoner (Sielecki, T.M. et al. (2000), "Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation", J. Med. Chem. 43, 1-18; Fry, D.W. & Garrett, M.D. (2000), "Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer", Curr. Opin. Oncol. Endo. Metab. Invest. Drugs, 2, 40-59; Rosiania, G.R. & Chang, Y.T. (2000), "Targeting hyper-proliferative disorders with cyclin dependent kinase inhibitors", Exp. Opin. Ther. Patents, 10, 215-230; Meijer, L. et al.
(1999), "Properties and potential applications of chemical inhibitors of cyclin-dependent kinases", Pharmacol. Ther., 82, 279-284; Senderowicz, A.M. & Sausville, E.A. (2000), "Preclini-cal and clinical development of cyclin-dependent kinase modulators", J. Nati. Cancer Inst., 92, 376-387).
For anvendelse av forbindelsene ifølge oppfinnelsen som legemidler bringes disse i form av et farmasøytisk preparat som i tillegg til virkestoffet inneholder for enteral eller parenteral administrering egnede farmasøytiske, organiske eller uorganiske, inerte bærermaterialer, som f.eks. vann, gelatin, gummi arabicum, laktose, stivelse, magnesiumstearat, talkum, planteoljer, polyalkylenglykoler osv. De farmasøytiske preparater kan foreligge i fast form, f.eks. som tabletter, drasjeer, stikkpiller eller kapsler eller i væskeform, f.eks. som opp-løsninger, suspensjoner eller emulsjoner. Eventuelt inneholder de i tillegg hjelpestoffer som konserveringsmidler, stabili-seringsmidler, fuktemidler eller emulgeringsmidler, salter for å endre det osmotiske trykk eller buffere. Disse farmasøytiske preparater er også gjenstand for den foreliggende oppfinnelse.
For parenteral administrering egner seg spesielt injeksjonsoppløsninger eller -suspensjoner, spesielt vandige oppløsninger av de aktive forbindelser i polyhydroksyetoksylert ricinusolj e.
Som bærersystemer kan det også benyttes grenseflate-aktive hjelpestoffer, som f.eks. salter av gallesyrer eller animalske eller vegetabilske fosfolipider, men også blandinger av slike samt liposomer eller deres bestanddeler anvendes.
For oral administrering er spesielt tabletter, drasjeer eller kapsler med talkum og/eller hydrokarbonbærer eller -binde-middel, som f.eks. laktose, maisstivelse eller potetstivelse, vel egnet. Preparatet kan også administreres i flytende form, f.eks. som en saft som eventuelt er tilsatt et søtningsstoff.
Også de enterale, parenterale og orale anvendelser er gjenstand for den foreliggende oppfinnelse.
Dosen av virkestoffet kan variere alt etter admini-streringsmetode, pasientens alder og vekt, arten og graden av sykdommen som skal behandles, og lignende faktorer. Den daglige dose vil være 0,5-1000 mg, fortrinnsvis 50-200 mg, idet denne dose kan gis som en enkeltdose eller fordelt på to eller flere dagsdoser.
Gjenstand for den foreliggende oppfinnelse er likeledes anvendelsen av forbindelsene med den generelle formel I for fremstilling av et legemiddel for behandling av kreft, auto-immun sykdommer, kardiovaskulære sykdommer, kjemoterapeutika-frembrakt alopesi og mukositt, infeksiøse sykdommer, hefro-logiske sykdommer, kroniske og akutte nevrodegenerative sykdommer, virusinfeksjoner, idet det med kreft skal forstås tumorer og leukemi, med autoimmunsykdommer menes psoriasis, alopesi og multippel sklerose, med kardiovaskulære sykdommer menes stenose, arteriosklerose og restenose, med infeksiøse sykdommer menes sykdommer frembrakt av encellede parasitter, med nefrologiske sykdommer menes glomerulonefritt, med kroniske nevrodegenerative sykdommer menes Huntingtons sykdom, amyotrof lateralsklerose, Parkinsons sykdom, AIDS-demens og Alzheimers sykdom, med akutte nevrodegenerative sykdommer menes hjerneiskemi og nerveskader, og med virusinfeksjoner menes cytomegalovirusinfeksjoner, herpes, hepatitt B eller C og HIV-sykdommer.
Gjenstand for oppfinnelsen er også legemidler for behandling av de ovenfor omtalte sykdommer, som inneholder minst én forbindelse med den generelle formel I, samt legemidler med egnede tilsetnings- og bærermaterialer.
Forbindelsene ifølge oppfinnelsen med den generelle formel I er blant annet fremragende inhibitorer for syklin-avhengige kinaser som f.eks. CDKl, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 og CDK9, og glykogen-syntase-kinasene (GSK-3(3) .
I den utstrekning fremstillingen av utgangsforbin-delsene ikke er beskrevet, er disse kjente forbindelser eller analoge med kjente forbindelser, eller de lar seg fremstille etter her beskrevne fremgangsmåter. Det er også mulig å utføre alle de her beskrevne omsetninger i parallelle reaktorer eller ved hjelp av kombinatoriske arbeidsteknikker. Isomerblandingene kan separeres etter vanlige metoder, som f.eks. krystallisasjon, kromatografi eller saltdannelse, i enantiomerene eller E/Z-isomerene. Fremstillingen av salter foretas på vanlig måte, idet en oppløsning av forbindelsen med formel I omsettes med den ekvivalente mengde eller et overskudd av en base eller syre som eventuelt foreligger i oppløsning, og utfellingen fraskilles eller oppløsningen opparbeides på vanlig måte.
Fremstilling av forbindelsene ifølge oppfinnelsen
De etterfølgende eksempler illustrerer fremstillingen av forbindelsene ifølge oppfinnelsen, uten at de skal anses å begrense omfanget av de krevde forbindelser. Forbindelsene ifølge oppfinnelsen med den generelle formel I lar seg fremstille etter det følgende generelle fremstillingsskjema:
Eksempel 1
Fremstilling av 5- brom- N2-( 4- difluormetyltiofenyl)- N4- 2- propyn-yl- 2, 4- pyrimidindiamin ( i henhold til fremstillingsskjema 1)
( forbindelse 23)
245 mg (1 mmol) 2-klor-4-2-propynylaminopyrimidin opp-løses i 2 ml acetonitril, og det tilsettes dertil en suspensjon av 4-(difluormetyltio)-anilinhydroklorid [fremstilt ut fra 352 rna (2 mmol) 4-(difluormetvltio)-anilin. 1 ml acetonitril oa
0,5 ml vandig HC1 (4 M i dioksan)] ved romtemperatur. Deretter kokes reaksjonsblandingen med tilbakeløpskjøling natten over under N2-atmosfære. Etter avkjøling filtreres blandingen, og den frafiltrerte faste fase vaskes med H20 og tørkes. Det kan for-ventes et utbytte på 328 mg (85 %) av produktet.
6H 8,25 (s, 1 H) utbytte: 85 %
2C 7,86 (d, 2 H)
H 7,51 (d, 2 H)
7,38 (t, 56,8 Hz, 1 H) smeltepunkt: > 235 °C
4C 4,18 (m, 2 H)
H 3,16 (sb, 1 H)
10,24 (sb, 1 H)
NH 8,17 (sb, 1 H)
Eksempel 2
Fremstilling av 5- Brom- N-( 3-( oksiranylmetoksy) fenyl)- 2-( 2-propynyloksy)- 2- pyrimidinamin ( forbindelse 51) etter fremstillingsskjema 2
1,55 g (4,9 mmol) av forbindelse 20 oppløses i 5,5 ml epi-bromhydrin, og det tilsettes dertil 1,38 g K2C03 og 65 mg tetra-butylammoniumbromid. Reaksjonsblandingen omrøres i 1 time ved 100 °C under nitrogenatmosfære. Etter tilsetning av etylacetat oppsamles den resulterende utfelling, og denne omkrystalliseres fra etanol. Produktet fås i en mengde på 1,15 g (utbytte 62 %) som et hvitt pulver.
6H 8,45 (s, 1 H)
2CH 7.47 (s, 1H)
7,32 (d, 1H) utbytte: 62 % 7,20 (t, 1 H)
6,40 (d, 1 H) smeltepunkt: 173 °C 4,32 (dd,l H)
3,82 (dd,l H)
3,3-3,4 (m, 1 H)
2,87 (t, 1 H)
2,72 (dd,l H)
4CH 5,13 (d, 2 H)
3,67 (t, 1 H)
NH 9,84 (sb, 1 H)
Forbindelse 40 fremstilles på tilsvarende måte som angitt i eksempel 2.
6-H 8,36 (s, 1 H) kromatografi:
2CH 7,60 (d, 1H) H/EA 1:3 0,5 % TEA
6,91 (d, 1H)
4,28 (dd, 1 H)
3,79 (dd, 1 H) utbytte: 38 % 3,31 (m, 1 H)
2,84 (dd, 1 H) smeltepunkt: 140-141 °C 2,70 (dd, 1 H)
4CH 5,07 (d, 12 H)
3,65 (t, 1 H)
NH 9,65 (sb, 1 H)
OH
Eksempel 3
Fremstilling av 1-( 4-(( 5- brom- 4-( 2- propynyloksy)- pyrimidin- 2-yl)- amino) fenoksy)- 3-( 4- fenylpiperazin- l- yl)- 2- propanol
( forbindelse 41)
Til en oppløsning av 19 mg (0,05 mM) av forbindelse 51 i N,N'-dimetylpropylurea (DMPU) tilsettes 0,2 ml av en 0,5 M 4-fenylpiperazinoppløsning i DMPU. Reaksjonsblandingen holdes i 18 timer ved en temperatur på 80 °C. Etter avkjøling tilsettes 3,5 ml tert.-butylmetyleter, og den organiske fase ekstraheres fem ganger med 1,5 ml H2O og inndampes deretter i vakuum. Residuet kromatograferes på 1,7 g (15 uM) "Lichrosphere Si60"
(gradient: diklormetan/heksan 1:1 til DCM og deretter diklormetan/metanol fra 99:1 til 93:7). Produktet-oppnås i en mengde på 17 mg (utbytte 64 %).
På tilsvarende måte fremstilles også de følgende forbindelser:
De følgende forbindelser ble fremstilt på tilsvarende måte som de beskrevne eksempler.
De følgende forbindelser ble fremstilt analogt med de beskrevne syntesemetoder ifølge skjema 1 eller 2. Alle NMR-spektre ble målt i det angitte oppløsningsmiddel eller i DMSO.
Forbindelsene nr. 159, 160, 161, 163, 167, 168, 170, 174, 175, 191, 192, 203 og 204 som er merket <*>), kan fremstilles etter den fremgangsmåtevariant som er beskrevet i eksempel nr. 295.
Eksempel 258
Fremstilling av 4-( 5- brom- 4- morfolin- 4- ylpyrimidin- 2- ylamino)-fenylsulfonamid
Til 202 mg (0,60 mmol) av forbindelsen ifølge eksempel 122 settes 1 ml vann og 0,2 g (1,2 mmol) brom, og blandingen omrøres ved romtemperatur. Etter 24 timer tilsettes på ny 0,2 g (1,2 mmol) brom, og blandingen omrøres i ytterligere 24 timer ved romtemperatur. Oppløsningsmidlet avdampes i vakuum, og residuet renses kromatografisk ("Flashmaster II", DCM/MeOH 7:3). Det fås 17 mg (0,04 mmol; 7 %) av produktet som et hvitt, fast stoff.
Analogt med fremgangsmåten for fremstilling av mellomprodukter ifølge eksempel 6.0 ble også de følgende forbindelser fremstilt:
I henhold til den etterfølgende fremstillingsvariant ble også de følgende forbindelser syntetisert:
30 mg (0, 0678 mmol)' av forbindelse 277 oppløses i 1 ml iietanol/tetrahydrofuran 1:1. Etter tilsetning av ca. 10 mg natriumborhydrid omrøres blandingen i 2 timer. Deretter stoppes reaksjonen under kjøling med ca. 3-4 dråper iseddik, og det foretas inndamping. Råproduktet tas deretter opp i en liten nengde vann, hvoretter det foretas frafiltrering, ettervasking med acetonitril og tørking i vakuum ved 60 °C. Det fås 21 mg (70 % av det teoretiske) av den ønskede forbindelse.
Eksempel 290
Fremstilling av oksimeter- pyrimidinforbindelsene med den generelle formel I
Fremstillingen av oksimeteren foretas i henhold til det følgende generelle reaksjonsskjema:
hvor R<8> og R<9> har de betydninger som er angitt for den generelle formel I. Fremstilling av forbindelsen ifølge eksempel 290 50 mg (0,12 mmol) av forbindelse 282, 34 mg hydroksyl-ammoniumklorid og 150 mg pulverisert KOH kokes med tilbakeløps-kjøling i 2 timer i 2 ml etanol. Deretter helles blandingen over i isvann, og det foretas surgjøring med iseddik, ekstraksjon tre ganger med diklormetan/isopropanol 4:1, tørking med magnesiumsulfat og inndamping. Residuet oppslemmes i acetonitril, hvoretter det foretas frafiltrering og tørking ved 60 °C. Det fås 28 mg (54 % av det teoretiske) av den ønskede forbindelse.
På tilsvarende måte ble også de følgende forbindelser fremstilt:
Eksempel 294 Reduktiv aminering 50 mg (0,12 mmol) av forbindelse 282 og 7,5 mg (0,132 mmol) syklopropylamin oppløses i 2 ml 1,2-dikloretan. Etter tilsetning av 9,1 mg (0,144 mmol) natriumcyanborhydrid omrøres blandingen i 12 timer. Det foretas deretter fortynning med diklormetan/isopropanol 4:1, vasking to ganger med vann, tørking med magnesiumsulfat og inndamping. Residuet kromatograferes over silikagel med diklormetan/metanol 95:5. Det fås 18 mg (33 % av det teoretiske) av den ønskede forbindelse.
På tilsvarende måte fremstilles også forbindelsene nr. 159, 160, 161, 163, 167, 168, 170, 174, 175, 191, 192, 203 og 204.
Eksempler 295 og 296
På tilsvarende måte som i eksempel 1 fremstilles de følgende to forbindelser: Fremstilling av sulfonamidene med den generelle formel I
0,2 mmol sulfonsyrefluorid anbringes i synteseenheten i en reaktor. Det tilsettes 1,0 ml oppløsningsmiddel, fortrinnsvis 2-butanol. I tur og orden tilsettes med en pipette 0,2 ml (0,2 mmol) DMAP - oppløst i et oppløsningsmiddel som f.eks. DMSO eller 2-butanol - og 0,2 ml (0,2 mmol) av aminet, oppløst i 2-butanol. Reaksjonsblandingen omrøres deretter i 20 timer ved 80 °C. Etter endt reaksjon tas råproduktet ut med en pipette, og reaktoren ettervaskes med 1,0 ml THF. Oppløsningen av råproduktet inndampes deretter og renses ved HPLC.
De etterfølgende forbindelser ble fremstilt:
<*>) fremstilt etter fremgangsmåten beskrevet under Sulfonamider.
Fremstilling av pyrimidin- sulfonylfluorider med den generelle formel I
Fremstillingen av pyrimidin-sulfonsyrefluoridene foretas analogt med fremstillingen av sulfonsyreamidene.
På tilsvarende måte som forbindelsene ifølge de ovenfor beskrevne eksempler ble også de følgende paraforbindelser fremstilt:
Separasjon av diastereomerblandinger av forbindelser ifølge oppfinnelsen Separasjon av diastereomerblandingen av forbindelsen ifølge eksempel 274
Diastereomerblandingen ble separert i de to korrespon-derende racemater (A og B) ved HPLC:
Betingelser:
Kolonne: Kromasil C18 (5 um) 150 x 4,6 mm Elueringsmiddel: 25 % acetonitril/vann med 1 ml NH3/I Strømningsmengde: 1,0 ml/min
Påvisning: PDA 300 nm
Retensjonstider: racemat A - 11,6 min
racemat B - 12,4 min
Hvert av racematene A og B ble separert ved kiral HPLC i henhold til det nedenstående.
Betingelser:
Kolonne: Chiralpak AD (10 \ xm) 250 x 4, 6 mm Elueringsmiddel: heksan/etanol 80:20
Strømningsmengde: 1,0 ml/min
Påvisning: PDA 300 nm
Retensjonstider: enantiomer Al - 16,6 min enantiomer A2 - 19,6 min enantiomer Bl - 16,0 min enantiomer B2 - 17,8 min Fremstilling av de fortrinnsvis benyttede mellomprodukter for syntesen av forbindelsene ifølge oppfinnelsen med den generelle formel I
Eksempel 1. 0
Fremstilling av N-( 2- klor- 5- fluor- 4- pyrimidinyl)- N- 2- propynylamin
11,1 g (66 mmol) 2,4-diklor-5-fluorpyrimidin oppløses i 60 ml acetonitril, og det tilsettes dertil 10,2 ml (73 mmol) trietylamin og 6,0 ml (86 mmol) propynylamin. Reaksjonsblandingen omrøres ved romtemperatur natten over og helles deretter over i vann. Blandingen ekstraheres med etylacetat, de sammenslåtte organiske faser tørkes over MgSG-2, og oppløsnings-midlet avdampes under et middels vakuum. Etter omkrystallisering av det tilbakeblivende materiale med diisopropyleter/heksan fås 10,6 g (utbytte: 87 % av det teoretiske) av produktet.
5-H 8,18 (3,3 Hz, 1 H) oppløsningsmiddel: DMSO
4CH 4,14 (dd, 2 H) utbytte: 87 %
3,20 (t, 1 H) smeltepunkt: 96 °C
NH 8,65 (tb, 1 H)
De nedenfor beskrevne 4-(diaminosykloheksyl)derivater syntetiseres via reduktive amineringer av det beskrevne keto-derivat og bruk av triacetoksyborhydrid (Abdel-Magid, Carson, Harris, Maryanoff, Sha, J. Org. Chem., 1996, 61, 3849). Keto-derivatet fås ved TPAP-oksidasjon (Griffith, Ley, Aldrichimica Acta, 1990, 23, 13) av den tilsvarende alkohol.
Analogt med denne fremgangsmåte fremstilles også de følgende mellomprodukter:
Eksempel 2. 0
Fremstilling av 5- brom- 2- klor- 4-( 4, 4, 4- trifluorbutoksy) pyrimidin
3,19 g (14 mmol) 5-brom-2,4-diklorpyrimidin blandes med 8,06 g (63 mmol) 4,4,4-trifluorbutanol, og 0,74 ml (8,4 mmol) trifluormetansulfonsyre tilsettes langsomt. Reaksjonsblandingen omrøres ved romtemperatur natten over og helles deretter over i vann. Blandingen ekstraheres med etylacetat, de sammenslåtte organiske faser tørkes over MgS02, og oppløsningsmidlet avdampes under et undertrykk. Produktet er alltid forurenset med varierende mengder 2,4-bisalkoksypyrimidin. Derfor renses residuet ved gradientkromatografi med silikagel som bærermateriale (elueringsmiddel: heksan og heksan/etylacetat i forholdet 9:1). Denne fremgangsmåte gir et utbytte på 1,7 0 g (38 %) og gir likeledes 1,93 g (34 %) 5-brom-2,4-bis-(4, 4, 4-trifluorbutoksy) - pyrimidin (utgangsmateriale).
5-CH 8,74 (s, 1 H) kromatografi: fra H til H/EA 9:1 4 C 4,48 (t, 2 H) utbytte: 38 %
H 2,00 (mc, 2 H) smeltepunkt: 66,5-67,5 °C
2,44 (mc, 2 H)
5C
H
På analog måte fremstilles også de følgende forbindelser:
Analogt med. fremgangsmåteeksemplene 1 og 2 fremstilles også de følgende mellomprodukter:
Eksempel 3. 0 Fremstilling av aminene
4,5 g (20 mmol) 2-brombutyraldehyddietylacetal
(Fa. Pfaltz-Bauer) og 5,2 g (80 mmol) natriumazid omrøres i 5 døgn i 15 ml DMF ved 100 °C. Blandingen helles så over i kald, fortynnet natriumhydrogenkarbonatoppløsning. Det foretas ekstraksjon tre ganger med eter, og den organiske fase tørkes med magnesiumsulfat og inndampes. Utbytte av råprodukt: 1,87 g (50 % av det teoretiske). 936 mg av råproduktet oppløses i 50 ml metanol. Det tilsettes palladium på karbon (10 %-ig), og blandingen omrøres i 12 timer under H2-atmosfære. Etter frafiltrering av katalysatoren og inndamping blir det tilbake 457 mg (57 % av det teoretiske) av det ønskede amin.
Eksempel 4. 0
Fremstilling av de frie aldehydene
148 mg (0,5 mmol) av mellomproduktforbindelsen 1.18 oppløses i 1 ml iseddik. Ved romtemperatur tilsettes 0,5 ml 1 N saltsyre, og blandingen omrøres i 12 timer. For opparbeidelse helles blandingen over i isvann og nøytraliseres forsiktig med pulverisert natriumhydrogenkarbonat. Det foretas så ekstraksjon med eddikester tre ganger, hvoretter den organiske fase tørkes med magnesiumsulfat og inndampes. Som råprodukt fås 104 mg (83 %) av det teoretiske av aldehydet av forbindelse 4.0. Råproduktet kan anvendes videre uten ytterligere rensing. Eksempel 5. 0 Fremstilling av ketonene 100 mg (0,356 mmol) av forbindelse 6.0 og 126 mg N-metylmorfolin-N-oksid oppløses i 5 ml diklormetan, og oppløs-ningen omrøres i 10 minutter med pulverisert molsikt (4 Å). Det tilsettes 6 mg tetrapropylammoniumperruthenat, og blandingen omrøres i 4 timer ved romtemperatur. Etter inndamping foretas kromatografering over silikagel (heksan/eddikester 4:1 > 2:1). Utbytte: 75 mg (76 % av det teoretiske) av ketonet av forbindelse 5.0.
Eksempel 6. 0
Fremstilling av alkoholene
265 mg (1 mmol) av forbindelse 4.2 oppløses i 20 ml tetrahydrofuran. Under kjøling i et isbad tilsettes porsjonsvis 5 ekvivalenter metylmagnesiumbromid (en 3-molar oppløsning i eter). Blandingen omrøres deretter i 3 timer ved romtemperatur, hvoretter reaksjonen stoppes under kjøling med vann. Deretter tilsettes ammoniumkloridoppløsning, og det foretas ekstraksjon tre ganger med eddikester. Den organiske fase tørkes med magnesiumsulfat og inndampes. Ved flashkromatografering (heksan/eddikester 2:1) fås 213 mg (76 % av det teoretiske) av alkoholen av forbindelse 6.0.
ESI: MH<+> 282 (100 %), 276 (5 %).
På analog måte fremstilles også de følgende mellomprodukter:
Gjenstand for den foreliggende oppfinnelse er således også forbindelser med den generelle formel Ia
hvor D betegner halogen, og X, R<1> og R<2> har de betydninger som er angitt for den generelle formel (I).
Særlig verdifulle er slike mellomprodukter med den generelle formel Ia hvor D betegner klor, og X, R<1> og R<2> har de betydninger som er angitt for den generelle formel (I).
Gjenstand for den foreliggende oppfinnelse er også slike forbindelser som faller inn under beskyttelsesområdet for DE 4029650, og hvis virkning ligger i det fungicide område, men som ikke er beskrevet som CDK-inhibitorer, og hvis anvendelse for behandling av kreft ikke er beskrevet.
I de etterfølgende eksempler beskrives den biologiske virkning av forbindelsene ifølge oppfinnelsen, uten at oppfinnelsen skal anses å begrenses av disse eksempler.
Eksempel 1
CDK2/ CycE- kinase- prøve
Rekombinante CDK2- og CycE-GST-fusjonsproteiner, renset fra baculovirus-infiserte insektceller (Sf9), ble oppnådd fra dr. Dieter Marmé, Klinikk fur Tumorbiologie, Freiburg. Histon HIS, som ble benyttet som kinasesubstrat, ble innkjøpt fra Fa. Sigma.
CDK2/CycE (50 ng/målepunkt) ble inkubert i 15 minutter ved 22 °C i nærvær av forskjellige konsentrasjoner av test-substanser (0 uM, samt konsentrasjoner innenfor området 0,01-100 uM) i testbuffer [50 mM Tris/HCl, pH 8,0; 10 mM MgCl2,
0,1 mM Na-ortovanadat, 1,0 mM ditiotreitol, 0,5 uM adenosin-trisfosfat (ATP), 10 ug/målepunkt Histon HIS, 0,2 uCi/målepunkt <33>P-gamma ATP, 0,05 % NP40, 12,5 % dimetylsulfoksid]. Reaksjonen ble stoppet ved tilsetning av EDTA-oppløsning (250 mM, pH 8,0;
14 jul /målepunkt) .
Av hver reaksjonssats ble 10 u.1 påført på P30-filter-strimler (Fa. Wallac), og ikke-innbygget <33>P-ATP ble fjernet ved vasking av filterstrimlene tre <q>an<g>er, hver gang i 10 minutter, i 0,5 %-ig fosforsyre. Etter tørking av filterstrimlene i 1 time ved 70 °C ble filterstrimlene dekket med scintillator-strimler (MeltiLex™ A, Fa. Wallac) og innbrent i 1 time ved 90 °C. Mengden av innbygget <33>P (substratfosforylering) ble bestemt ved scintillasjonsmåling i et gamma-strålingsmåleapparat (Wallac).
Eksempel 2
Proliferasjonstest
Dyrkede humane tumorceller (som angitt) ble lagt ut i en tykkelse av 5000 celler/målepunkt i en 96-hulls multititer-plate i 200 ul av det tilsvarende vekstmedium. Etter 24 timer ble cellene på én plate (nullpunktplate) farget (s.u.) med krystallfiolett, mens mediet på de andre platene ble erstattet med friskt dyrkningsmedium (200 ul), til hvilket testsubstansene var blitt tilsatt i ulike konsentrasjoner (0 uM, samt konsentrasjoner i området 0,01-30 uM; sluttkonsentrasjonen av oppløs-ningsmidlet dimetylsulfoksid var 0,5 %). Cellene ble inkubert i 4 døgn i nærvær av testsubstansene. Celleproliferasjonen ble bestemt ved farging av cellene med krystallfiolett. Cellene ble fiksert i 15 minutter ved romtemperatur ved tilsetning av 20 ul/målepunkt av en 11 %-ig glutaraldehydoppløsning. Etter vasking av de fikserte celler tre ganger med vann ble platene tørket ved romtemperatur. Cellene ble farget ved tilsetning av 100 ul/målepunkt av en 0,1 %-ig oppløsning av krystallfiolett (pH-verdien innstilt på pH 3 ved tilsetning av eddiksyre). Etter vasking av de fargede celler tre ganger med vann ble platene tørket ved romtemperatur. Fargestoffet ble oppløst ved tilsetning av 100 ul/målepunkt av en 10 %-ig eddiksyreoppløsning. Ekstinksjonen ble bestemt fotometrisk ved en bølgelengde på
595 nm. Den prosentuelle endring av celleveksten ble beregnet ved normalisering av måleverdien til nullpunktplatens ekstink-sjonsverdi (= 0 %) og ekstinksjonen av de ubehandlede (0 uM) celler (=» 100 %) .
Resultatene som ble oppnådd i eksempler 1 og 2, er gitt i den følgende tabell.
Påvisning av overlegenheten av forbindelsene ifølge oppfinnelsen overfor de kjente forbindelser
For påvisning av overlegenheten av forbindelsene ifølge oppfinnelsen overfor de kjente forbindelser ble forbindelsene ifølge oppfinnelsen sammenlignet med kjente referanseforbindel-ser og kjente forbindelser med lignende struktur ved enzymtesten. Resultatene er gitt i den følgende tabell.
Av resultatene i tabellen kan det sluttes at forbindelsene ifølge oppfinnelsen oppviser tydelig høyere aktivitet, så vel ved enzymtesten. som også ved celletesten på enzymer og i MCF-7-celler, enn forbindelsene som tilhører den kjente teknikk. Følgelig er forbindelsene ifølge oppfinnelsen de kjente forbindelser langt overlegne.
Claims (9)
1. Forbindelser,
karakterisert ved generell formel I,
hvori
R<1> betegner halogen,
R<2> betegner -CH (CH3) - (CH2) n"R<5>, -CH-(CH2OH) 2, -(CH2)nR<7>, -CH(C3H7)-(CH2)n-R5, -CH(C2H5)-(CH2)n-R5, -CH2-CN, -CH(CH3)COCH3, -CH(CH3)-C(OH) (CH3)2, -CH (CH (OH) CH3) OCH3, -CH(C2H5)CO-R<5>, C2-C4-alkynyl, - (CH2) n"COR<5>, - (CH2) n-C0-Ci-C6-alkyl, - (CH2)n-C(OH) (CH3)-fenyl, -CH (CH3)-C (CH3)-R<5>, -CH(CH3)-C (CH3) (C2H5)-R<5>, -CH (OCH3)-CH2-R<5>, -CH2-CH (OH) -R<5>, -CH(OCH3)-CHR<5->CH3, -CH (CH3)-CH (OH)-CH2-CH=CH2, -CH(C2H5)-CH(OH) - (CH2)n-CH3, -CH(CH3)-CH(OH)-(CH2)n-CH3, -CH(CH3)-CH(OH)-CH(CH3)2, (CH2OAC)2, -(CH2)n-R<6>, - (CH2) n- (CF2) n-CF3, -CH(CH2)n-R<5>)2, -CH(CH3)-CO-NH2, -CH (CH2OH)-fenyl, -CH (CH2OH) -CH (OH) - (CH2)nR5, -CH (CH2OH) -CH (OH) -fenyl, -CH(CH2OH)-C2H4-R<5>, - (CH2) n-C=C-C (CH3) =CH-COR5, -CH(Ph)-(CH2)n-R<5>, -(CH2) n-COR5, -(CH2)nP03(R5)2, - (CH2) n-COR<5>, -CH ( (CH2) nOR5) CO-R5, - (CH2) nCONHCH ( (CH2) nR<5>) 2, - (CH2) nNH-COR<5>, -CH(CH2)nR<5->(CH2)nC3-Cio-sykloalkyl, - (CH2) n-C3-Ci0-sykloalkyl, C3-Ci0-sykloalkyl; Ci-C6~alkyl, C3-Ci0-syklo-alkyl, - (CH2)n-0-(CH2)n-R5, eller - (CH2) n-NR<3>R<4> som eventuelt er substituert på ett eller flere steder, lik eller forskjellig med hydroksy, Ci-C6~alkyl eller gruppen -COONH(CH2)nCH3 eller -NR<3>R<4>, -CH (C3H7) - (CH2) n-0C (0) - (CH2) n-CH3, -(CH2)n-R<5>, -C(CH3)2-(CH2)n-R<5>, -C (CH2) n (CH3) - (CH2) nR<5>, -C(CH2)n-(CH2)nR<5>, -CH(t-butyl)-(CH2)n-R<5>, -CCH3(C3H7)-(CH2)nR<5>, -CH(C3H7)-(CH2)„-R<5>, -CH (C3H7)-COR5, -CH(C3H7)-(CH2) n-OC (0) -NH-Ph, -CH ( (CH2) n (C3H7) ) - (CH2) nR<5>, -CH(C3H7)-(CH2)n-OC(0)-NH-Ph(OR<5>)3, -NR<3>R<4>, -NH-(CH2)n-NR<3>R<4>, R<5->(CH2)n-C<*>H-CH(R<5>)-(CH2)n-R<5>, - (CH2) n-CO-NH-(CH2) n-CO-R<5>, -OC(0)NH-Ci-C6-alkyl eller - (CH2) n-CO-NH-(CH2) n-CH-( (CH2)nR5)2,
eller betegner C3-Ci0-sykloalkyl, som er substituert med gruppen
X betegner oksygen eller gruppen -NH-, N (Ci-C3-alkyl) eller R<2> betegner gruppen
eller
X og R<2> danner sammen en gruppe
A betegner -S02-C2H4-OH, -S02CF3, -S02-(CH2) n-N-R3R4, -S02-NR3R<4> eller -S02R<7>,
B betegner hydrogen, hydroksy eller Ci~C3-alkyl,
R<3> og R<4>, i hvert tilfelle uavhengig av hverandre, betegner
hydrogen, fenyl, benzyloksy, Ci-Ci2-alkyl, Ci-C6~alkoksy, C2-C4-alkenyloksy, C3-C6-sykloalkyl, hydroksy, hydroksy-Ci-C6~alkyl, dihydroksy-Ci-C6-alkyl, heteroaryl, heterosyklo-C3-Ci0-alkyl, heteroaryl-Ci-C3-alkyl, C3-C6-sykloalkyl-Ci-C3-alkyl som eventuelt er substituert med cyano, eller betegner Ci-C6-alkyl som eventuelt er substituert på ett eller flere steder, lik eller forskjellig med fenyl, pyridyl, fenyloksy, C3-C6-sykloalkyl, Ci-C6-alkyl eller Ci-C6-alkoksy, hvorved fenylgruppen i seg selv kan være substituert på ett eller flere steder, lik eller forskjellig med halogen, trifluormetyl, Ci-C6~alkyl, C1-C6-alkoksy eller med gruppen -SC>2NR<3>R<4>,
eller betegner gruppen - (CH2)nNR3R4, -CNHNH2 eller -NR3R4 eller betegner
som eventuelt kan være substituert med Ci-C6~alkyl,
R<5> betegner hydroksy, fenyl, Ci-C6-alkyl, C3-C6-sykloalkyl,
benzoksy, Ci-C6-alkyltio eller Ci-C6~alkoksy,
R<6> betegner gruppen
R<7> betegner halogen, hydroksy, fenyl, Ci-C6~alkyl, -(CH2)nOH, -NR3R4 eller gruppen
R<8>, R<9> og R<10> betegner hydrogen, hydroksy, Ci-C6-alkyl eller
betegner gruppen - (CH2) n-COOH, og
n betegner 0-6,
så vel som diastereomerer, enantiomerer og salter derav.
2. Pyrimidinderivat av formel (I) ifølge krav 1, karakterisert ved at det er valgt fra: 5-brom-N2-[4-(2-dietylamino-etansulfonyl)-fenyl]-N4-prop-2-ynyl-pyrimidin-2,4-diamin, N2-(3-benzensulfonyl-fenyl)-5-brom-N4-prop-2-ynyl-pyrimidin-2,4-diamin, 5-brom-N2-[4-(morfolin-4-sulfonyl)-fenyl]-N4-prop-2-ynyl-pyrimidin-2,4-diamin, 4-[5-fluor-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[4-((R)-l-hydroksymetyl-2-metyl-propylamino)-5-jod-pyrimidin-2-ylamino]-benzensulfonamid, 4-(5-fluor-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonamid, 4-{5-brom-4-[2-(2-okso-2,3-dihydroimidazol-l-yl)-etylamino]-pyrimidin-2-ylamino}-benzensulfonamid, 4-[5-brom-4-(2,2,3,3,3-pentafluor-propoksy)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[[5-brom-4-(1,3-bisacetoksy-2-propyloksy)-2-pyri-midinyl]amino]-benzensulfonamid, 4- [5-brom-4- (2-hydroksy-l-hydroksymetyl-etoksy)-pyrimidin-2- ylamino]-benzensulfonamid, (S)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propionamid, 5- brom-N4-prop-2-ynyl-N2-(3-trifluormetansulfonyl-fenyl)-pyrimidin-2,4-diamin, 3- (5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonamid, 3- (5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-N-butyl-benzensulfonamid, 2-[3-(5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonyl]-etanol, 4- (5-brom-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonamid, 4-(5-klor-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonamid, 2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-smørsyre-metylester, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 2-{5-brom-2-[3-(2-hydroksy-etansulfonyl)-fenylamino]-pyrimidin-4-ylamino}-propan-1,3-diol, 4-[5-brom-4-(2-hydroksy-l-hydroksymetyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(syklopropylmetyl-amino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, 4-[5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 2-{3-[5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonyl}-etanol, 2-{3-[5-brom-4-(2-morfolin-4-yl-etylamino)-pyrimidin-2-ylamino]-benzensulfonyl}-etanol, 4-[5-brom-4-(2-morfolin-4-yl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4,4,4-trifluor-butoksy)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-etoksy-l-etoksymetyl-etoksy)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-smørsyre, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, (R)-2-{5-brom-2-[3-(2-hydroksy-etansulfonyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-butan-l-ol, 4-[5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4- ( (R)-2-hydroksy-l-fenyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4- ( (S)-2-metoksy-l-métyl-etylamino)-pyrimidin-2-ylamino]-N-metyl-benzensulfonamid, 4- [5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N,N-dimetyl-benzensulfonamid, 5- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-pentansyre-benzylester, 6- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre-metylester, 4-(5-jod-4-prop-2-ynylamino-pyrimidin-2-ylamino)-benzensulfonamid 4-[5-brom-4-((S)-l-hydroksymetyl-3-metylsulfanyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4- ( (1S,2S)-2-hydroksy-l-hydroksymetyl-2-fenyl-etylamino) -pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-2-okso-tetrahydrofuran-3-ylamino)-pyrimidin-2 -ylamino] -benzensulfonamid, 4-[5-brom-4-( (S)-l-hydroksymetyl-2,2-dimetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-{3-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propionylamino}-smørsyre-metylester, 4-(4-morfolin-4-yl-pyrimidin-2-ylamino)-benzensulfonamid, 6-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre, 4-(5-brom-4-sykloheksylamino-pyrimidin-2-ylamino)-benzensulfonamid, 4-{6-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksanoylamino}-smørsyre-metylester, 6-[5-brom-2- (4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre-metylester, 4-[5-brom-4-((IR,2S)-2,3-dihydroksy-l-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-2-sykloheksyl-l-hydroksymetyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 6-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-heksansyre-(2-hydroksy-l-hydroksymetyl-etyl)-amid, 4-[5-brom-4-( (S)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-hydroksy-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-{4-[(adamantan-l-ylmetyl)-amino]-5-brom-pyrimidin-2-ylamino}-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-metyl-benzensulfonamid, (R)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-smørsyre, 4-(5-brom-4-sykloheksylamino-pyrimidin-2-ylamino)-N-(2-hydroksyetyl)-benzensulfonamid, 4-[5-brom-4-(2,2,3,3,4,4,4-heptafluor-butylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, 4-[5-brom-4-((S)-2-metoksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, fenylkarbaminsyre-(R)-2-[5-brom-2-(4-sulfamoyl-fenyl-amino) -pyrimidin-4-ylamino]-3-metyl-butylester, (R)-2-{5-brom-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-smørsyre, (R)-2-{5-brom-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-smørsyre-metylester, 4-(5-klor-4-prop-2-ynylamino-pyrimidin-2-ylamino)-N-(2-hydroksyetyl)-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l,1-dimetyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((S)-l-hydroksymetyl-3-metyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(tetrahydro-pyran-4-yloksy)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((IS,2S)-2-hydroksy-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, butylkarbaminsyre-4-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-sykloheksylester, (R)-2-[5-brom-2-(4-metansulfonyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butan-l-ol, (R)-2-{5-brom-2-[4-(morfolin-4-sulfonyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-butan-l-ol, 4-[5-brom-4-(4-dimetylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4- (4-dimetylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4- [5-brom-4- (4-piperidin-l-yl-s'ykloheksylamino) -pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-3-hydroksy-benzensulfonamid, 4-[5-brom-4-(4-syklopropylamino-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, (R)-2-[5-brom-2-(3-metansulfonyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butan-l-ol, 4-{5-brom-4-[2-(2-etoksy-etoksy)-etoksy]-pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[4-(2-dimetylamino-etylamino)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4- [4-(2-pyrrolidin-l-yl-etylamino)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[4-(4-hydroksy-piperidin-l-yl)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-smørsyre-metylester, 4-{5-brom-4-[4-(3-hydroksy-pyrrolidin-l-yl)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[4-(3-hydroksy-pyrrolidin-l-yl)-sykloheksyl-amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-[5-brom-4- ( (R)-l-hydroksymetyl-3-metyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-{5-brom-4-[2-(l-metyl-pyrrolidin-2-yl)-etylamino]-pyrimidin-2-ylamino}-benzensulfonamid, 4-[5-brom-4-(piperidin-4-yloksy)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(3-dimetylamino-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, eddiksyre-(R)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butylester, 4-[5-brom-4-(4-hydroksy-sykloheksylamino)-pyrimidin-2-ylamino]-N-(2-hydroksyetyl)-benzensulfonamid, (3,4,5-trimetoksyfenyl)-karbaminsyre-(R)-2-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butylester, 4-(5-brom-4-sykloheptylamino-pyrimidin-2-ylamino)-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2,2-dimetyl-propylamino) - pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-okso-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, (E)-6-{5-klor-2-[4-(2-hydroksyetylsulfamoyl)-fenylamino]-pyrimidin-4-ylamino}-3-metyl-heks-2-en-4-ynsyre-metylester, 4-[5-brom-4-(1-hydroksymetyl-syklopentylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[4-(bisyklo[2.2.1]hept-2-ylamino)-5-brom-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-morfolin-4-yl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-morfolin-4-yl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-({5-brom-4-[(R)-(2-hydroksy-l-metyletyl)amino]pyrimidin-2-yl}amino)benzensulfonamid, 4-[5-brom-4-(2,2,3,3,3-pentafluor-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-hydroksy-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(1-etynyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(3-hydroksy-l-fenyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, (+)-4-[5-brom-4-(2-metyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, (-)-4-[5-brom-4-(2-metyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-{5-brom-4-[4-(2-hydroksy-l-hydroksymetyl-etylamino)-sykloheksylamino]-pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[4-(2-hydroksy-l-hydroksymetyl-etylamino)-sykloheksylamino]-pyrimidin-2-ylamino}-benzensulfonamid, (R)-2-[5-brom-2-(4-trifluormetansulfonyl-fenylamino)-pyrimidin-4-ylamino]-3-metyl-butan-l-ol, 4-[5-brom-4-(4-syklopropylamino-sykloheksylamino)-pyrimidin-2 -ylamino] -benzensulfonamid, 4-[5-brom-4-(4-syklopropylamino-sykloheksylamino)-pyrimidin-2 -ylamino] -benzensulfonamid, 4-[5-brom-4-(tetrahydrotiofen-3-ylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 2- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]- 3- hydroksy-propionsyre-metylester, 4- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-pyrimidin-2-yl-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-tiazol-2-yl-benzensulfonamid, 4-[5-brom-4-(4-hydroksy-butylamino)-pyrimidin-2-ylamino]-N-metyl-benzensulfonamid, 4-{5-brom-4-[2-(3H-imidazol-4-yl)-etylamino]-pyrimidin-2-ylamino)-benzensulfonamid, 4-[5-brom-4-(1-etyl-l-hydroksymetyl-propylamino)-pyrimidin-2 -ylamino] -benzensulfonamid, 4-[5-brom-4-(1-hydroksymetyl-l, 2-dimetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-metyl-sykloheksylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-{5-brom-4-[(S)-(tetrahydrofuran-3-yl)amino]-pyrimidin-2-ylamino}-benzensulfonamid, 4-[5-brom-4-(sykloheksylmetyl-amino)-pyrimidin-2-ylamino]-benzensulfonamid, 3- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-propionsyre, 4- [5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-smørsyre-etylester, {3-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-yl-amino]-propyl}-fosfonsyre-dietylester, 4-{5-brom-4-[(3-pyridin-3-yl-isoksazol-4-ylmetyl)-amino]-pyrimidin-2-ylamino}-benzensulfonamid, {[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-metyl}-fosfonsyre-dimetylester, {[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-ylamino]-metyl}-fosfonsyre-monometylester, 4- {5-brom-4- [ (pyridin-4-ylmetyl") -amino] -pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[(tiofen-2-ylmetyl)-amino]-pyrimidin-2-ylamino}-benzensulfonamid, 4-{5-brom-4-[(pyridin-2-ylmetyl)-amino]-pyrimidin-2-ylamino}-benzensulfonamid, 4-[5-brom-4-(4-fluorbenzylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(4-metoksy-benzylamino)-pyrimidin-2-ylamino]-benzensulfonamid, {3-[5-brom-2-(4-sulfamoyl-fenylamino)-pyrimidin-4-yl-amino]-propyl}-fosfonsyre, 4-[5-brom-4-(2-hydroksyetylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(1-fenyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, N-allyloksy-4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 3-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(5-hydroksy-pentyl)-benzensulfonamid, 3-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino] -N- (2-hydroksy-l-hydroksyitietyl-etyl) - benzensulfonamid, 3- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(3-hydroksy-propyl)-benzensulfonamid, N-benzyloksy-4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksy-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-syklopropylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(5-hydroksy-pentyl)-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(tetrahydrofuran-2-ylmetyl)-benzensulfonamid, 4-[5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-hydroksy-benzensulfonamid, 4-[5-brom-4-((S)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(2-hydroksy-l-hydroksymetyl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-(3-hydroksy-propyl)-benzensulfonamid, 4- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-hydroksy-benzensulfonamid, 5- [5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-benzensulfonamid, 3-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-N-etoksy-benzensulfonamid, N-allyloksy-3-[5-brom-4-((R)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-(5-brom-4-morfolin-4-yl-pyrimidin-2-ylamino)-benzensulfonamid, 7-[(5-brom-4-{[(R)-2-hydroksy-l-metyletyl]amino}pyrimidin-2-yl)amino]-3,4-dihydro-2H-l,2-benzotiazin-l,1-dioksid, 4-[5-brom-4-(2-hydroksy-2-fenyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l,2-dimetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l,2-dimetyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4- (2-okso-2-fenyl-etylamino)-pyrimidin-2-yl-amino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4- [5-brom-4- (2-hydroksy-l-metyl'-propylamino) -pyrimidin-2-ylamino]-benzensulfonamid, 4-(5-brom-4-sek-butylamino-pyrimidin-2-ylamino)-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l-metyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(3,3-dimetyl-2-okso-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l-metyl-3-fenyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l-metyl-pent-4-enylamino)-pyrimidin-2 -ylamino] -benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l-metyl-pentylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(l-metyl-2-okso-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l,3-dimetyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[4-((IR,2R)-2-benzyloksy-syklopentylamino)-5-brom-pyrimidin-2-ylamino]-benzensulfonamid, 4-[4-{(IS,2S)-2-benzyloksy-syklopentylamino)-5-brom-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(l-etyl-2-hydroksy-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(l-etyl-2-hydroksy-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-2-fenyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-3,3-dimetyl-butylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksyimino-l-metyl-propylamino)-pyrimidin-2 -ylamino] -benzensulfonamid, 4-(5-brom-4-{2-[(E)-metoksyimino]-1-metyl-propylamino}-pyrimidin-2-ylamino)-benzensulfonamid, 4-(5-brom-4-{2-[(E)-tert-butoksyimino]-1-metyl-propylamino} -pyrimidin-2-ylamino) -benzensulfonamid, [2-[5-brom-2-(4-sulfamoyl-fenylåmino)-pyrimidin-4-ylamino]-1-metyl-prop-(E)-ylidenaminooksy]-eddiksyre, 4-[5-brom-4-(2-syklopropylamino-l-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4-[5-brom-4-(2-hydroksy-l-metoksymetyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 4- [5-brom-4-(2-hydroksy-l-metoksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 5- [5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-sykloheksylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-fenyl-butyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3,3-difenyl-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-3-imidazol-l-yl-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-heptyl-2-metyl-benzensulfonamid, 5-[5-brom-4- ( (R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-oktyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-nonyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-decyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-fenyl-propyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino] -2-metyl-N- [3- (2-okso-p'yrrolidin-l-yl) -propyl] - benzensulfonamid, 5-[5-brom-4- ( (R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-metyl-butyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2- ylamino]-N-heksyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2- ylamino]-N- (3-dimetylamino-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4- ( (R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-syklopropyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-fenetyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-tiofen-2-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-metoksyfenyl)-etyl]-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-3-yImetyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N- (4-fluorbenzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-4-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-fenoksy-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-[2-(4-sulfamoyl-fenyl)-etyl]-benzensulfonamid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-metyl-benzyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-sykloheksylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-fenyl-butyl)-benzensulfonamid, 5-[5-brom-4-( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-fenyl-propyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(3-metyl-butyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-heksyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-syklopropyl-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-fenetyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-tiofen-2-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino] -N- [2- (4-metoksyf enyl") -etyl] -2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-3-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N- (4-fluorbenzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-pyridin-4-ylmetyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-(2-fenoksy-etyl)-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-2-metyl-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-2-metyl-N-[2-(4-sulfamoyl-fenyl)-etyl]-benzensulfonamid, 5-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-2-metyl-N-(4-metyl-benzyl)-benzensulfonamid, 3- [5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-sykloheksylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fenyl-propyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-fenetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-3-ylmetyl-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N- (4-fluorbenzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-4-ylmetyl-behzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N- (2-fenoksy-etyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-metyl-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(2-dimetylamino-etyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(3-imidazol-l-yl-propyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 3- [5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-furan-2-ylmetyl-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(3-dimetylamino-propyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 3- [5-brom-4- ( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-fenetyl-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 3- [5-brom-4-( (R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 3- [5-brom-4- ( (R) -2-hydroksy-l-m'etyl-etylamino) -pyrimidin-2- ylamino]-N-(2-metoksy-etyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(3-fluorbenzyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-pyridin-3-ylmetyl-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(4-fluorbenzyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-pyridin-4-ylmetyl-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(2-fenoksy-etyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 3-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(4-metyl-benzyl)-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid, 4- [5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonamid, 3- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 5- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2- ylamino]-2-metyl-benzensulfonylfluorid, 3- [5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 5-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-2-metyl-benzensulfonylfluorid, 3-[5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 3- [5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 4- [5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 4-[5-brom-4-((S)-l-hydroksymetyl-2-metyl-propylamino)-pyrimidin-2-ylamino]-benzensulfonylfluorid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-sykloheksylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-fenyl-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-imidazol-l-yl-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-fenyl-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-syklopropyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-fenetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(4-metoksyfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-pyridin-3-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-pyridin-4-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-fenoksy-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(4-metyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-2-hydroksy-l-metyl-etylamino)-pyrimidin-2-ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-sykloheksyImetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-dimetylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino] -N- (3-imidazol-l-yl-pro'pyl) -benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-furan-2-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-trifluormetyl-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fenyl-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[3-(2-okso-pyrrolidin-l-yl)-propyl]-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-metyl-butyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-dimetylamino-propyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-diisopropylamino-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-syklopropyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-cyano-sykloheksylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-fenetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3,4-dimetoksy-benzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-klorfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metyl-furan-2-ylmetyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-morfolin-4-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-tiofen-2-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(4-metoksyfenyl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-pyrrolidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-piperidin-l-yl-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(3-fluorbenzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-[2-(l-metyl-pyrrolidin-2-yl)-etyl]-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-3-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-fluorbenzyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-pyridin-4-ylmetyl-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-fenoksy-etyl)-benzensulfonamid, 4-[5-brom-4-((R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(2-metoksy-benzyl)-benzensulfonamid, 4-[5-brom-4- ( (R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(4-metyl-benzyl)-benzensulfonamid eller 4-[5-brom-4- ( (R)-1-hydroksymetyl-propylamino)-pyrimidin-2-ylamino]-N-(5-metylsulfanyl-lH-[1,2,4]triazol-3-yl)-benzensulfonamid.
3. Forbindelse,
karakterisert ved generell formel Ia
hvori D betegner halogen, og X, R<1> og R<2> har de•betydninger som er angitt i generell formel (I), for anvendelse som et mellom-produkt for fremstilling av forbindelsen av generell formel I.
4. Forbindelser av generell formel Ia ifølge krav 4, karakterisert ved at D betegner klor, og X,
R<1> og R2 har de betydninger som er angitt i den generelle formel I.
5. Anvendelse av forbindelsene av generell formel I ifølge krav 1 eller 2, for fremstilling av et farmasøytisk middel for behandling av kreft, autoimmune sykdommer, kjemoterapimiddel-fremkalt alopeci og mukositt, kardiovaskulære sykdommer, infeksiøse sykdommer, nefrologiske sykdommer, kroniske og akutte nevrodegenerative sykdommer og virale infeksjoner.
6. Anvendelse ifølge krav 5, hvori kreft er definert som faste tumorer og leukemi; autoimmune sykdommer er definert som psoriasis, alopeci og multippel sklerose; kardiovaskulære sykdommer er definert som stenoser, arterioskleroser og restenoser; infeksiøse sykdommer er definert som sykdommer som forårsakes av unicellulære parasitter; nefrologiske sykdommer er definert som glomerulonefritt; kroniske, nevrodegenerative sykdommer er definert som Huntingtons sykdom, amyotrofisk lateralsklerose, Parkinsons sykdom, AIDS-demens og Alzheimers sykdom; akutte, nevrodegenerative sykdommer er definert som iskemi av hjernen og nevrotraumer; og virale infeksjoner er definert som cytomegaliske infeksjoner, herpes, hepatitt B og C og HIV-sykdommer.
7. Farmasøytiske midler,
karakterisert ved at de inneholder minst én forbindelse ifølge krav 1 eller 2.
8. Farmasøytisk middel ifølge krav 7, for behandling av kreft, autoimmune sykdommer, kardiovaskulære sykdommer, infeksiøse sykdommer, nefrologiske sykdommer, nevrodegenerative sykdommer og virale infeksjoner.
9. Forbindelser av generell formel I som definert i krav 1 eller 2, formulert med egnede formuleringssubstanser og bærere.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10127581A DE10127581A1 (de) | 2001-05-29 | 2001-05-29 | CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
DE10212098A DE10212098A1 (de) | 2002-03-11 | 2002-03-11 | CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
PCT/EP2002/005669 WO2002096888A1 (de) | 2001-05-29 | 2002-05-23 | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20035298D0 NO20035298D0 (no) | 2003-11-28 |
NO327129B1 true NO327129B1 (no) | 2009-04-27 |
Family
ID=26009483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035298A NO327129B1 (no) | 2001-05-29 | 2003-11-28 | CDK-inhiberende pyrimider, farmasoytiske preparater,og deres anvendelse for fremstilling av legemidler |
Country Status (23)
Country | Link |
---|---|
US (3) | US7235561B2 (no) |
EP (1) | EP1392662B1 (no) |
JP (1) | JP4291135B2 (no) |
KR (1) | KR100874791B1 (no) |
CN (1) | CN100480242C (no) |
AR (1) | AR036035A1 (no) |
AT (1) | ATE420077T1 (no) |
AU (1) | AU2002312933B2 (no) |
BR (1) | BR0209774A (no) |
CA (1) | CA2449118A1 (no) |
CO (1) | CO5540316A2 (no) |
DE (1) | DE50213202D1 (no) |
ES (1) | ES2320204T3 (no) |
HR (1) | HRP20031081A2 (no) |
IL (1) | IL159120A0 (no) |
ME (1) | MEP13408A (no) |
MX (1) | MXPA03010810A (no) |
NO (1) | NO327129B1 (no) |
NZ (1) | NZ529654A (no) |
PL (1) | PL367130A1 (no) |
RS (1) | RS94703A (no) |
RU (1) | RU2330024C2 (no) |
WO (1) | WO2002096888A1 (no) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002312933B2 (en) * | 2001-05-29 | 2007-12-06 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
EP1406875B1 (en) * | 2001-06-26 | 2013-07-31 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
EP2090571B1 (de) | 2001-10-17 | 2012-05-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
WO2003055489A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
ATE451104T1 (de) | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US7504410B2 (en) * | 2002-11-28 | 2009-03-17 | Schering Aktiengesellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
PL379330A1 (pl) | 2002-12-20 | 2006-08-21 | Pfizer Products Inc. | Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1590334B1 (en) | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
CN1849318B (zh) | 2003-07-30 | 2011-10-12 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法 |
EP1663242B1 (en) * | 2003-08-07 | 2011-04-27 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP1694652A1 (en) | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
EP1809614B1 (en) * | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
WO2005111024A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
MXPA06013164A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
BRPI0510963A (pt) | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | derivados pirimidina para o tratamento do crescimento anormal de células |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
US7534780B2 (en) * | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
US20050277625A1 (en) * | 2004-05-21 | 2005-12-15 | Ralf Wyrwa | Estriol and estetrol prodrugs |
JP2008505910A (ja) | 2004-07-08 | 2008-02-28 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Pkc−シータのインヒビターとして有用なピリミジン誘導体 |
PL382308A1 (pl) | 2004-08-25 | 2007-08-20 | Targegen, Inc. | Związki heterocykliczne i sposoby stosowania |
JP2008514571A (ja) * | 2004-09-29 | 2008-05-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換2−置換アニリノピリミジン類、それらの製造および薬剤としての使用 |
WO2006044457A1 (en) * | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
CA2584295C (en) | 2004-11-24 | 2014-08-26 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
WO2006064251A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
CA2594477C (en) | 2005-01-21 | 2016-07-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
MX2007011500A (es) * | 2005-03-16 | 2007-11-21 | Targegen Inc | Compuestos pirimidina y metodos de uso. |
EP1705177A1 (en) * | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
EP1883302A4 (en) * | 2005-05-03 | 2009-05-20 | Rigel Pharmaceuticals Inc | JAK KINASE HEMMER AND ITS USE |
KR101312225B1 (ko) | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Jak 경로의 억제를 위한 조성물 및 방법 |
JP2008543775A (ja) * | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | 眼の障害を治療するための方法および組成物 |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
MX2008001428A (es) * | 2005-07-30 | 2008-04-04 | Astrazeneca Ab | Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos. |
WO2007038387A2 (en) * | 2005-09-23 | 2007-04-05 | Yale University | Compounds and methods for the treatment of viruses and cancer |
DE102005048072A1 (de) * | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
WO2007036732A1 (en) * | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
US20070110751A1 (en) * | 2005-10-25 | 2007-05-17 | Maclellan Robb | Compositions and methods for reducing infarct size |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
BR122021011787B1 (pt) * | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
US20070149508A1 (en) * | 2005-11-02 | 2007-06-28 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
US7705009B2 (en) * | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
US20070123500A1 (en) * | 2005-11-29 | 2007-05-31 | Gerd Mueller | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds |
US20070197488A1 (en) * | 2005-11-29 | 2007-08-23 | Olaf Peters | Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds |
US20070135375A1 (en) * | 2005-11-30 | 2007-06-14 | Ralf Wyrwa | Sulfamoyl sulfonate prodrugs |
US20070135399A1 (en) * | 2005-11-30 | 2007-06-14 | Ralf Wyrwa | Heteroaromatic sulphonamide prodrugs |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
DE102006001161A1 (de) * | 2006-01-06 | 2007-07-12 | Qiagen Gmbh | Verfahren zum Nachweis von Cytosin-Methylierungen |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
PE20080068A1 (es) * | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
RU2008152195A (ru) * | 2006-06-15 | 2010-07-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа |
AU2007257701A1 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-aminoalkyleneaminopyrimidines |
EP1878726A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2684874B1 (en) | 2006-10-23 | 2017-05-17 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors |
EP1939185A1 (de) * | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
EP2109605B1 (en) | 2006-12-22 | 2013-02-20 | Boehringer Ingelheim International GmbH | 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer |
DE102007010801A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
WO2008129380A1 (en) * | 2007-04-18 | 2008-10-30 | Pfizer Products Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
WO2008140421A2 (en) * | 2007-05-15 | 2008-11-20 | S*Bio Pte Ltd | Heterocycloalkyl substituted pyrimidine derivatives |
KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
US20090030005A1 (en) * | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
WO2009089277A2 (en) * | 2008-01-08 | 2009-07-16 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
CA2723185A1 (en) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
TW201020245A (en) * | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
JP5644499B2 (ja) * | 2008-09-01 | 2014-12-24 | アステラス製薬株式会社 | 2,4−ジアミノピリミジン化合物 |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
EP2179993A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP2179992A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP2179991A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
DE102009001438A1 (de) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
DE102009015070A1 (de) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
US8466155B2 (en) | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
DE102010014427A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
DE102010014426A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
CA2798578C (en) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Novel pyrimidine derivatives |
EA201291220A1 (ru) | 2010-06-04 | 2013-07-30 | Ф.Хоффманн-Ля Рош Аг | Производные аминопиримидина в качестве модуляторов lrrk2 |
CA2812744A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
RS59106B1 (sr) | 2010-11-10 | 2019-09-30 | Genentech Inc | Derivati pirazol aminopirimidina kao lrrk2 modulatori |
EP2646448B1 (en) | 2010-11-29 | 2017-08-30 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
EP2782579B1 (en) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
EP3121174A1 (en) * | 2011-11-29 | 2017-01-25 | F. Hoffmann-La Roche AG | 2-(phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
MX2014011240A (es) | 2012-03-21 | 2014-10-15 | Bayer Ip Gmbh | Uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r, 2r)-2-hidroxi-1-metilpro pil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfoximida para el tratamiento de tumores especificos. |
EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
WO2014106606A1 (en) * | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
ES2702951T3 (es) * | 2014-04-04 | 2019-03-06 | Syros Pharmaceuticals Inc | Inhibidores de quinasas dependientes de ciclina 7 (cdk7) |
JP7041515B2 (ja) | 2015-01-08 | 2022-03-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞 |
CN108721307B (zh) * | 2018-03-20 | 2021-01-15 | 重庆医科大学 | Cdk2激酶抑制剂在制备乙型肝炎治疗药物中的应用 |
FI3902547T3 (fi) | 2018-12-28 | 2023-12-05 | Deciphera Pharmaceuticals Llc | Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa |
EP3947368A4 (en) | 2019-04-04 | 2023-01-04 | Dana-Farber Cancer Institute, Inc. | CDK2/5 DEGRADING AGENTS AND ASSOCIATED USES |
CA3132656A1 (en) | 2019-04-30 | 2020-11-05 | Instituto De Medicina Molecular Joao Lobo Antunes | Rank pathway inhibitors in combination with cdk inhibitors |
CN111138417B (zh) * | 2019-12-18 | 2021-03-23 | 浙江工业大学 | 一种三氮唑修饰的5-氟-2,4-嘧啶二胺类化合物及其应用 |
CN112110863A (zh) * | 2020-08-27 | 2020-12-22 | 中山大学 | 一种磺酰氟类化合物、其制备方法以及通过其制备磺酰胺类化合物的方法 |
EP4251613A1 (en) * | 2020-11-27 | 2023-10-04 | Allorion Therapeutics Inc. | Aminoheteroaryl kinase inhibitors |
CN114105887B (zh) * | 2021-09-16 | 2023-12-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
WO2023226920A1 (en) * | 2022-05-27 | 2023-11-30 | Anrui Biomedical Technology (Guangzhou) Co.,Ltd. | Aminoheteroaryl kinase inhibitors |
CN115304550A (zh) * | 2022-07-25 | 2022-11-08 | 南通大学 | 哌嗪苯基氨基取代的嘧啶氨基酸衍生物及制备方法与应用 |
CN115304551A (zh) * | 2022-07-25 | 2022-11-08 | 南通大学 | 2-((4-吗啉苯基)氨基)嘧啶氨基酸衍生物及其制备方法与应用 |
CN115232076A (zh) * | 2022-07-25 | 2022-10-25 | 南通大学 | 苯氨基取代的嘧啶氨基酸衍生物及其制备方法与应用 |
WO2024059010A1 (en) * | 2022-09-13 | 2024-03-21 | Genesis Therapeutics, Inc. | Compounds for treating cancer |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3947467A (en) | 1973-08-02 | 1976-03-30 | Eli Lilly And Company | 3-(5-Nitro-2-imidazolyl) pyrazoles |
FR2257272B1 (no) | 1974-01-15 | 1978-08-25 | Pharmascience Labo | |
DE2413935A1 (de) | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
US4193926A (en) | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
DE2541855A1 (de) | 1975-09-18 | 1977-03-31 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone ii |
EP0006298B1 (en) | 1978-06-15 | 1982-03-31 | Imperial Chemical Industries Plc | Anti-inflammatory 1-phenyl-2-aminoethanol derivatives, pharmaceutical compositions thereof for topical use, and processes for their manufacture |
EP0112707B1 (en) | 1982-12-23 | 1987-11-04 | Smith Kline & French Laboratories Limited | Aminopyrimidinone derivatives as histamine h1-antagonists |
DE3581570D1 (de) | 1984-06-25 | 1991-03-07 | Ciba Geigy Ag | Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel. |
JPH0629263B2 (ja) * | 1985-10-30 | 1994-04-20 | クミアイ化学工業株式会社 | ピリミジン誘導体および農園芸用殺菌剤 |
US4876252A (en) | 1986-01-13 | 1989-10-24 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
US4788195A (en) | 1986-01-13 | 1988-11-29 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
HU215433B (hu) | 1986-04-29 | 2000-05-28 | Pfizer Inc. | Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására |
US5128358A (en) | 1988-01-19 | 1992-07-07 | Pfizer Inc. | Aryl substituted nitrogen heterocyclic antidepressants |
US4792561A (en) | 1986-05-29 | 1988-12-20 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors |
US4921862A (en) | 1986-05-29 | 1990-05-01 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors |
CN1030415A (zh) | 1987-02-20 | 1989-01-18 | 山之内制药株式会社 | 饱和的杂环碳酰胺衍生物和它的制备方法 |
US5274002A (en) | 1987-04-14 | 1993-12-28 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
US4971959A (en) | 1987-04-14 | 1990-11-20 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
ES2054867T3 (es) * | 1987-09-28 | 1994-08-16 | Ciba Geigy Ag | Plaguicidas y pesticidas. |
US4973690A (en) | 1988-04-12 | 1990-11-27 | Ciba-Geigy Corporation | Novel ureas |
US4966622A (en) | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
US4897396A (en) | 1988-06-03 | 1990-01-30 | Ciba-Geigy Corporation | 2-phenylamino pyrimidine derivatives and their uses as microbicides |
DE59009351D1 (de) | 1989-04-17 | 1995-08-03 | Byk Gulden Lomberg Chem Fab | Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel. |
US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
JPH03127790A (ja) * | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
US5164078A (en) * | 1989-12-28 | 1992-11-17 | Chevron Research And Technology Company | Process for removal of calcium from a hydrocarbon feedstock |
DE4003919A1 (de) | 1990-02-09 | 1991-08-14 | Basf Ag | Heteroarylalkene, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung |
GB9007762D0 (en) | 1990-04-05 | 1990-06-06 | Beecham Group Plc | Novel compounds |
WO1991016892A1 (en) | 1990-04-27 | 1991-11-14 | Rorer International (Holdings), Inc. | Styryl compounds which inhibit egf receptor protein tyrosine kinase |
ZW9091A1 (en) | 1990-07-10 | 1992-04-29 | Smithkline Beecham Corp | Oxamides |
US5124455A (en) | 1990-08-08 | 1992-06-23 | American Home Products Corporation | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents |
DE4029650A1 (de) * | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
CA2091989A1 (en) | 1990-09-28 | 1992-03-29 | Roderick Alan Porter | Phenylpyridinol derivatives as medicaments |
JPH06501941A (ja) | 1990-10-16 | 1994-03-03 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | アリールピリダジノン |
IE913855A1 (en) | 1990-11-06 | 1992-05-22 | Smithkline Beecham Corp | Imidazolidinone compounds |
GB9027055D0 (en) | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
US5698711A (en) | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
US5449676A (en) | 1991-04-26 | 1995-09-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridazines |
PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
EP0540165A1 (en) | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
DE4136921A1 (de) | 1991-11-11 | 1993-05-13 | Knoll Ag | Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure |
US5385963A (en) * | 1992-01-30 | 1995-01-31 | Gencorp Inc. | Unsaturated polyester-modified flexible copolymers for use in sheet molding compositions |
US5326898A (en) | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
EP0633775B1 (en) | 1992-04-02 | 2000-05-31 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB9212673D0 (en) | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
GB9212693D0 (en) | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
IL106517A0 (en) | 1992-07-28 | 1994-08-26 | Rhone Poulenc Rorer Ltd | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group |
GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
KR950704228A (ko) | 1992-12-02 | 1995-11-17 | 알렌 제이. 스피겔 | 선택적 포스포디에스테르가수분해효소 iv형(pde_iv) 저해제로서의 카테콜 디에테르(catecol diethers as selective pde_iv inhibitors) |
ATE154887T1 (de) | 1992-12-07 | 1997-07-15 | Blangy Gerard De | Verfahren und anlage zur behandlung und verwertung von abfallstoffen durch veränderung dieser in wiederverwertbare, nicht verunreinigte materialien |
DE69327254T2 (de) | 1992-12-17 | 2000-03-30 | Pfizer | Substituierte pyrazole als crf antagonisten |
US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
TW263495B (no) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
US5612340A (en) | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
ATE325113T1 (de) | 1993-10-01 | 2006-06-15 | Novartis Pharma Gmbh | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
PT672041E (pt) | 1993-10-01 | 2002-04-29 | Novartis Ag | Derivados da piridina farmacologicamente activos e processos para a sua preparacao |
PL314605A1 (en) | 1993-11-26 | 1996-09-16 | Pfizer | Isoxazolin compounds as anti-inflammatory agents |
GB9326173D0 (en) | 1993-12-22 | 1994-02-23 | Celltech Ltd | Chemical compounds and process |
ATE260911T1 (de) | 1993-12-22 | 2004-03-15 | Celltech R&D Ltd | Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe |
GB9326600D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
EP0764153A1 (en) | 1994-06-06 | 1997-03-26 | Pfizer Inc. | Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity |
US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
DE69532817T2 (de) | 1994-11-10 | 2005-01-13 | Millenium Pharmaceuticals, Inc., Cambridge | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
CA2182946A1 (en) | 1994-12-23 | 1996-07-04 | Raymond John Owens | Human phosphodiesterase type ivc, and its production and use |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
JPH11512390A (ja) | 1995-09-01 | 1999-10-26 | シグナル ファーマシューティカルズ,インコーポレイテッド | ピリミジンカルボキシレートおよび関連化合物ならびに炎症状態を処置するための方法 |
CZ98998A3 (cs) | 1995-10-02 | 1998-10-14 | F. Hoffmann-La Roche Ag | Deriváty pyrimidinu jako antagonisty 5HT2C receptoru |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526243D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526246D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
US5785354A (en) * | 1996-05-06 | 1998-07-28 | Temtec, Inc. | Self-expiring identification band |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9806739D0 (en) * | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
AU2002312933B2 (en) * | 2001-05-29 | 2007-12-06 | Schering Ag | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
EP2090571B1 (de) | 2001-10-17 | 2012-05-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7504410B2 (en) * | 2002-11-28 | 2009-03-17 | Schering Aktiengesellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2002
- 2002-05-23 AU AU2002312933A patent/AU2002312933B2/en not_active Ceased
- 2002-05-23 RU RU2003136080/04A patent/RU2330024C2/ru active
- 2002-05-23 MX MXPA03010810A patent/MXPA03010810A/es active IP Right Grant
- 2002-05-23 ME MEP-134/08A patent/MEP13408A/xx unknown
- 2002-05-23 PL PL02367130A patent/PL367130A1/xx not_active Application Discontinuation
- 2002-05-23 IL IL15912002A patent/IL159120A0/xx unknown
- 2002-05-23 ES ES02738100T patent/ES2320204T3/es not_active Expired - Lifetime
- 2002-05-23 AT AT02738100T patent/ATE420077T1/de not_active IP Right Cessation
- 2002-05-23 CA CA002449118A patent/CA2449118A1/en not_active Abandoned
- 2002-05-23 BR BR0209774-5A patent/BR0209774A/pt not_active IP Right Cessation
- 2002-05-23 WO PCT/EP2002/005669 patent/WO2002096888A1/de active Application Filing
- 2002-05-23 KR KR1020037015597A patent/KR100874791B1/ko not_active IP Right Cessation
- 2002-05-23 DE DE50213202T patent/DE50213202D1/de not_active Expired - Lifetime
- 2002-05-23 CN CNB02814886XA patent/CN100480242C/zh not_active Expired - Fee Related
- 2002-05-23 RS YUP-947/03A patent/RS94703A/sr unknown
- 2002-05-23 JP JP2003500067A patent/JP4291135B2/ja not_active Expired - Fee Related
- 2002-05-23 NZ NZ529654A patent/NZ529654A/en unknown
- 2002-05-23 EP EP02738100A patent/EP1392662B1/de not_active Expired - Lifetime
- 2002-05-29 AR ARP020102001A patent/AR036035A1/es unknown
- 2002-05-29 US US10/156,759 patent/US7235561B2/en not_active Expired - Fee Related
-
2003
- 2003-11-28 NO NO20035298A patent/NO327129B1/no not_active IP Right Cessation
- 2003-12-23 HR HR20031081A patent/HRP20031081A2/hr not_active Application Discontinuation
- 2003-12-26 CO CO03112613A patent/CO5540316A2/es not_active Application Discontinuation
-
2004
- 2004-05-11 US US10/842,419 patent/US7291624B2/en not_active Expired - Fee Related
-
2007
- 2007-06-26 US US11/819,307 patent/US7598260B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2320204T3 (es) | 2009-05-20 |
US20040224966A1 (en) | 2004-11-11 |
US7291624B2 (en) | 2007-11-06 |
CN100480242C (zh) | 2009-04-22 |
JP2004535414A (ja) | 2004-11-25 |
CA2449118A1 (en) | 2002-12-05 |
MEP13408A (en) | 2010-06-10 |
EP1392662B1 (de) | 2009-01-07 |
IL159120A0 (en) | 2004-05-12 |
CO5540316A2 (es) | 2005-07-29 |
NO20035298D0 (no) | 2003-11-28 |
BR0209774A (pt) | 2004-06-01 |
KR20040030645A (ko) | 2004-04-09 |
DE50213202D1 (de) | 2009-02-26 |
AR036035A1 (es) | 2004-08-04 |
ATE420077T1 (de) | 2009-01-15 |
CN1633419A (zh) | 2005-06-29 |
HRP20031081A2 (en) | 2005-10-31 |
MXPA03010810A (es) | 2004-03-22 |
EP1392662A1 (de) | 2004-03-03 |
US20080039447A1 (en) | 2008-02-14 |
RU2003136080A (ru) | 2005-05-20 |
US7598260B2 (en) | 2009-10-06 |
NZ529654A (en) | 2005-12-23 |
RU2330024C2 (ru) | 2008-07-27 |
JP4291135B2 (ja) | 2009-07-08 |
RS94703A (en) | 2007-02-05 |
AU2002312933B2 (en) | 2007-12-06 |
WO2002096888A1 (de) | 2002-12-05 |
US20040102630A1 (en) | 2004-05-27 |
PL367130A1 (en) | 2005-02-21 |
KR100874791B1 (ko) | 2008-12-18 |
US7235561B2 (en) | 2007-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO327129B1 (no) | CDK-inhiberende pyrimider, farmasoytiske preparater,og deres anvendelse for fremstilling av legemidler | |
US7338958B2 (en) | Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | |
US7943629B2 (en) | Sulphimides as protein kinase inhibitors | |
Lücking et al. | The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R, 2R)‐2‐hydroxy‐1‐methylpropyl] oxy}‐5‐(trifluoromethyl) pyrimidin‐2‐yl] amino} phenyl) sulfoximide (BAY 1000394) for the Treatment of Cancer | |
US7825128B2 (en) | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | |
US7456191B2 (en) | N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents | |
US20040209895A1 (en) | Macrocyclic pyrimidines, their production and use as pharmaceutical agents | |
US20080167330A1 (en) | Carbamoylsulphoximides as protein kinase inhibitors | |
AU2003288198A1 (en) | CHK-,PDK- and AKT-inhibitory pyrimidines, their production and use as pharmaceutical agents | |
US20060111378A1 (en) | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | |
CA2581454A1 (en) | Novel pyrimidine compounds, process for their preparation and compositions containing them | |
ZA200309824B (en) | CDK inhibiting pyrimidines, production thereof and their use as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |